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Exploring attitudes towards dietary modification and nutritional supplementation in 
people with and without age-related macular degeneration 
Rebekah Stevens. Doctor of Philosophy. July 2015 
Age-related macular degeneration (AMD) is the leading cause for visual impairment and 
blindness registration in the developed world. Due to the large amounts of conflicting AMD 
research on the role of nutrition and antioxidant intake, it is difficult for patients and 
practitioners to determine which measures can be taken to slow down the disease progression.  
The aim of this research was to determine the beliefs and knowledge that patients with AMD 
have about nutrition, to identify whether their condition is preventing them from eating a healthy 
diet, and to discover what their diet consists of.  
For the initial study, 158 participants with AMD (mean age 79 ± 7.8 years) and 50 participants 
without AMD (mean age 67 ± 8 years) were recruited from the Macular Society helpline, or 
from optometric practice. Participants had a 25 minute telephone interview where a 36-
question survey was completed. The survey elicited demographic information, and questions 
covered the knowledge that participants had on nutrition and their current diet. 
 
The results from this survey uncovered three major findings: 1) 100% of AMD participants felt 
that they do not have enough information and support from eye-care practitioners regarding 
nutrition, 2) AMD patients are confused over, and display a lack of knowledge of, which foods 
are beneficial for eye health and when and what nutritional supplements to take, evidenced by 
65% of participants not taking the correct dosage 3) AMD patients are not eating enough 
nutrients that would be beneficial for their condition - consuming an average of 1.4mg of lutein 
and zeaxanthin rather than the recommended 10mg. 
 
A clinical decision-making aid was created as an intervention based upon these findings. The 
aim of the aid was to help eye-care practitioners give the correct nutritional advice to their 
patients. Founded on the AREDS 2 inclusion and exclusion criteria, practitioners are able to 
identify which patients could benefit from a nutritional supplement, and which patients could 
benefit from dietary modification. An evaluation of the aid with 72 qualified eye-care 
practitioners exhibited a statistically significant increase in confidence after using the aid for 
two weeks. An evaluation using 51 student optometrists showed a statistically significant 
increase in confidence and a statistically significant increase in appropriate management of 
patients after using the aid. 
 
This project has elicited findings that are significant for AMD patient education. It is hoped that 
through these studies, patients will receive consistent advice about the risk factors for AMD, 
the link between AMD and nutrition, and the importance of maintaining a healthy, well-
balanced diet. 
 
Keywords: age-related macular degeneration, diet, flowchart, nutrition, survey.  
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Chapter One 
Background and literature review 
 
1.1 Introduction to age-related macular degeneration  
Loss of vision can be one of the most feared complications of aging 1-4. For many older people, 
good vision represents life, autonomy and being active whereas poor vision is associated with 
depression, fear and loss of activity 3. 
Age-related macular degeneration (AMD) is a multifactorial degenerative condition affecting the 
central area of the retina. It is the leading cause of visual impairment and blindness registration 
in the developed world 5. A rapidly aging population has raised the priority of reducing the risk 
for age related eye diseases that impair sight and quality of life. As there are currently 9.7 
million people aged 65 and older in the UK and by 2020 one in five UK citizens will be aged 65 
or older (approximately 12 million people) 6,  it is imperative that more is learnt about AMD and 
more is done to help those with the condition. 
Aetiology 
Central vision, high resolution and fine detail are possible due a critical area of the retina 
known as the macula. The macula is approximately 5mm in diameter and is central in the 
retina. The retina consists of two layers, the inner neurosensory retina, and the outer retinal 
pigment epithelium (RPE) cell layer. The RPE is separated from the outer vascular layer known 
as the choroid, by Bruch’s membrane, an atypical basement membrane. The choroid consists 
of an internal network of capillaries (choriocapillaris) adjacent to Bruch’s membrane, and an 
external large vessel layer. The retina derives its blood supply from the choroid, as well as an 
intra-retinal capillary network. Bipolar and ganglion cells help transmit signals to photoreceptor 
cells, and at the macula they are displaced laterally - this displacement ensures minimal 
interference with signalling. The fovea, forming the macular centre, is a depression in the inner 
retinal surface (approximately 1.5mm in diameter) that is thinner and concave in cross-section 
and contains the highest concentrations of cone photoreceptors 7 (please see Figure 1.1).  
Age-related macular degeneration is a disease of the outer retina: the damage or loss of 
photoreceptors, a breakdown of the retinal pigment epithelium (RPE), Bruch’s membrane and 
the choriocapillaris. Much of the damage and/or loss of this area occur in individuals over the 
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age of 50, hence providing the condition with its name. However, the disease is multifactorial in 
which multiple genetic and environmental factors are involved.  
 
 
                                  
Figure 1.1. Cross-sectional pathological changes occurring in the macula in (a) Normal macula, (b) Dry AMD and 
(c) Wet AMD. Copied from 8 
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The exact reason for the damage in the outer retina of the macula is still a matter for debate 
and on-going research. There are also a number of modifiable and non-modifiable risk factors 
that have been associated with AMD, increasing age and smoking being the two principal 
influences.  
1.2 Progression and Classifications of AMD 
The International Classification and Grading System for Age-related Maculopathy (ARM) was 
introduced in 1995 to standardise classification 9, and has been tested for accuracy 10. ARM 
refers to: 
• Large soft drusen that can be distinct or indistinct 
• Pigmentary abnormalities of the retinal pigment epithelium (RPE) and the retina: either 
hyperpigmentation in the outer choroid and/or retina, or hypopigmentation of the RPE. 
                  
Figure 1.2 ARM, showing soft indistinct drusen across the entire retina.  Image from IRI – Illinois Retina Institute. 
 
Age-related macular degeneration (AMD) is the classification used in later stages of the 
condition. It includes all the clinical signs found in ARM, plus a progression into one of the 
following forms: 
14 
 
 
 
• ‘Dry’ – also known as non-exudative AMD. Manifestations: drusen and sharp, 
demarcated round/ oval areas of hypopigmentation in the RPE that are at least 175 µm 
in diameter. Geographic atrophy is advanced dry AMD – focal RPE atrophy leading to 
loss of the RPE and photoreceptors. 
•  ‘Wet’ – also known as neovascular/ disciform/ exudative AMD. Manifestations: 
neovascular membranes (either sub-retinal or sub-RPE), pigment epithelium 
detachments, sub-retinal haemorrhages, hard exudates and fibrous scarring of the 
macular. 
In 2013, Ferris et al. 11 proposed a five stage classification of AMD which achieved consensus 
among many macular specialists: Stage  (1) no apparent ageing changes 
(2) normal ageing changes, known as ‘drupelets’ (small drusen ≤ 63 μm) 
  (3) early AMD– medium-sized drusen 125 ≤μm  
(4) intermediate AMD – large drusen and pigmentary (hyper or hypo) anomalies 
(5) late AMD – geographic atrophy and/or neovascularisation. 
The largest recent clinical trial of supplements for AMD – the Age Related Eye Disease Study 
(AREDS) 12– classified AMD using the following system: 
Category 1: No AMD. No drusen, or a few small drusen (≤ 63 μm in diameter) 
Category 2: Early stage AMD. Any or all of the following: multiple small drusen or a few 
intermediate drusen (63 – 124 μm in diameter) in one or both eyes, or RPE abnormalities. 
Category 3: Intermediate AMD. Any or all of the following : extensive intermediate drusen and 
at least one large drusen (≥ 125 μm in diameter) in one or both eyes, or geographic atrophy 
not involving the centre of the fovea. 
Category 4: Advanced AMD. Geographic atrophy (GA)  involving the fovea or abnormal and 
fragile blood vessels under the retina (neovascular form). 
The AREDS studies are discussed in length in the sections ‘Clinical Intervention of other 
Nutrients’ and ‘Lutein and zeaxanthin: a review of evidence’. 
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Figure 1.3 . Wet AMD, with large sub-retinal haemorrhages over the entire macula area.  Image from CNIB (Seeing 
Through Vision Loss). 
 
1.3 Diagnosis and treatment  
Formal diagnosis in the UK occurs via an ophthalmologist after a referral from either an 
optometrist or the patient’s GP. Often, after the initial diagnosis, the patient will receive some 
written material regarding the disease during their visit to an ophthalmology department. The 
decision then rests with the ophthalmologist as to whether the patient requires any treatment 
such as anti-vascular endothelial growth factor therapy (e.g., Lucentis®) or surgery/laser work 
for ‘wet’ AMD conditions, low vision services or placement upon a sight impairment register. If 
the AMD is early or ‘dry’ type, the patient will have very little contact with any vision 
professionals for some years – if at all – unless the AMD changes to a ‘wet’ type. Patients are 
advised to have a yearly eye examination with an optometrist who will monitor the condition, 
but is often unable to provide physical or psychological help without referral 13. 
1.4 Prevalence 
UK prevalence: 
The UK has an ageing population - the proportion of the population aged 65 and over has 
increased over the past 30 years, and this change is projected to continue. This is partly due to 
16 
 
 
 
the increase in life expectancy and also due to the relatively high number of births in the years 
following World War II and during the 1960s, and the impact of these groups moving into the 
higher age groups 14. In 2014, 18% of the population was aged 65 or over, in 2024 this is 
projected to rise to 20%. 14-16. Currently there are two million people in the UK with sight 
problems 5.  
 
Owen et al.’s estimated that 2.4% of the total population had late stage AMD in 2012, which is 
equivalent to 513000 cases 16. They estimate this will increase to 679000 cases by 2020 due to 
the aging of the population. The prevalence was found to be 4.8% in those aged over 65 years 
and 12.2% in those aged over 80 years. GA prevalence rates were 1.3%, 2.6% and 6.7%; 
neovascular AMD 1.2%, 2.5% and 6.3%, respectively. The estimated number of prevalent 
cases of late AMD were 60% higher in women versus men. The annual incidence of late AMD, 
GA and neovascular AMD per 1000 women was 4.1, 2.4  and 2.3; in men 2.6, 1.7 and 1.4, 
respectively. Approximately 71 000 new cases of late AMD were estimated per year. 
 
US prevalence: 
One in 28 US adults older than 40 are visually impaired 17. Adults older than 80 years comprise 
8% of US population but account for 70% of cases of severe visual impairment 17. In 1990, The 
Beaver Dam Eye Study estimated that there were 640000 people in the US who had signs of 
late stage AMD, and 95.5% of the over 43 years-of-age population had one or more drusen 
present in the macular area 18, 19. It was thought that this number would at least double in 20 
years. It is estimated that currently there are 55 million people at risk of having AMD in the US 
20. However, the prevalence of any AMD in the 2005-2008 National Health and Nutrition 
Examination Survey was 6.5%, which is lower than the 9.4% prevalence reported in the 1988-
1994 Third National Health and Nutrition Examination Survey18. While this finding might be 
explained in part by differences in study methods, Klein et al. controversially hypothesise that 
these estimates are consistent with a decreasing incidence of AMD 18. 
1.5 Hypotheses for the origin of AMD 
The current hypotheses can be categorised below: 
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1) Bruch’s membrane changes 
Bruch’s membrane is a pentalaminar structure composed of several layers of elastic and 
collagen fibres which separates the RPE from the choriocapillaries - the main blood supply to 
the outer retina. Nutrients must cross this membrane to enter the RPE and photoreceptors, 
which is crucial as photoreceptors do not have their own blood supply 21, 22.  
Conductivity of Bruch’s membrane declines with age, and the lipid content of the membrane 
increases.23-25. This, in turn, changes the diffusion characteristics of the membrane which may 
contribute to the onset of AMD 26. 
 
                
Figure 1.4  Layers of the retina. Bruch’s membrane lies between the RPE and the choriocapillaries.27  
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2) Vascular Insufficiency 
Changes to the choroidal circulation may affect the normal diffusion of substances and gases 
across the RPE to Bruch’s membrane. Removal of waste products slows down, leading to a 
build-up of waste materials and a disturbance to the supply of gases and metabolites to the 
neural retina 25. The RPE can then deteriorate through ischaemia (‘zone hypoxia’) or as a 
direct consequence of the waste material, and the blood flow will decrease. Smith et al. 28 
hypothesise that since a decreased blood flow is evident in early AMD, the vascular 
insufficiency theory is supported in the aetiology of AMD. 
3) Genetics 
Numerous studies have shown there is a genetic predisposition for AMD, as the incidence 
appears to run in families, and especially in first-degree relatives 28, 29. The Y402H allele in the 
complement factor H gene (chromosome 1g31) has been researched as it helps to regulate the 
body’s inflammatory response by protecting against uncontrolled complement activation. The 
allele’s polymorphism appears to exert a strong influence on the risk of developing AMD 30. 
There are also many other gene or genes on other chromosomes that have also been research 
for their ability to modify AMD risk 31.  However, susceptibility is determined by multiple factors 
that include environmental influences such as UV exposure as well as inherited influences.  
Clinicopathogenesis of AMD 
The deposition of metabolic debris between the basement membrane of the RPE and Bruch’s 
membrane is often the first clinical feature of an altered retinal metabolic state. This will consist 
of the outer segments of photoreceptors that have not been metabolised and are in a lipid state 
(lipofuscin) 32. This lipid accumulation can be seen as drusen – they also contain proteins such 
as ubiquitin, inflammatory mediators and advanced glycation end products 33. 
4) Oxidative stress hypothesis 
Photoreceptors are exposed to an extensive amount of oxidative stress; an imbalance between 
the systemic production of reactive oxygen species (ROS - chemically reactive molecules 
containing oxygen), and a biological system's ability to swiftly detoxify the reactive 
intermediates or to restore the resulting destruction 34.  The retina has antioxidant processes to 
delay or prevent oxidation (the removal of electrons), but also generates activated forms of 
oxygen known as free radicals (any atom or molecule that has one or more unpaired 
electron35). Free radicals try to become stable by removing electrons from other molecules, 
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thereby damaging them and causing a cytotoxic oxidative chain. Other diseases such as 
Parkinson’s disease, cervical cancer and diabetes have been linked with oxidative damage 36. 
Researchers have used measurements of thiol metabolites and lipid peroxidation products in 
plasma to quantify the amount of oxidative stress an individual might have. These are known 
as oxidative biomarkers, and they consist of cysteine (a thiolated amino acid), glutathione (a 
cys-derived antioxidant), cystine, isoprostant and isofuran (lipid peroxidation products) 37. 
Studies by Brantley et al. have shown that mean plasma levels of these biomarkers appear to 
be higher in AMD patients than in case-control studies 38.  
 
 
The eye is particularly susceptible to oxidative damage due to: 
1. The high percentage of polyunsaturated fatty acids such as docosahexanoic acid 
(DHA) that are within the outer membrane of photoreceptors.  These have a large 
amount of electrons due to their double bonding, and therefore can be readily oxidised. 
This will lead to lipid peroxidation causing loss of function and structural integrity within 
the membrane. 35  
2. The exposure to light (particularly blue) is a strong oxidising agent, causing free radical 
production 39 This was found by the extensive work carried out by Ham et al on Rhesus 
monkeys 40, Wiegand et al. on albino rats 41 and more recent studies which have 
shown light damage causes cellular apoptosis, and oxidative stress proteins to be 
released 42.  
3. The eye’s oxygen consumption and blood flow is high (higher than the brain in a gram-
for-gram basis), thereby making it very active metabolically. 43  
4. It contains chromophores – molecules that absorb light in order to cause a chemical 
reaction – such as rhodopsin, melanin, lipofuscin and the mitochondrial respiratory 
enzymes. 
5. Retinal pigment epithelial phagocytosis is, in itself, a free radical producing process. 
 
A recent study by Yildirim et al. showed that reductions in the antioxidant defence system, 
increased oxidative stress causing oxidative damage to lipids and proteins, and decreases to 
antioxidant capacity may lead to irreversible damage in the form of AMD 44.  
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Figure 1.5. Mechanism of dry and wet AMD formation. Reproduced from ‘Nature Reviews Drug Discovery’45. 
 
1.6 Nutrients and AMD 
Antioxidant therapy is an attempt to reduce the number of circulating ROS due to oxidative 
stress. The antioxidants in the next few paragraphs have been researched for their effect on 
the progression and development of ARM and/or AMD. A clinical breakthrough in positive 
antioxidant intervention (a 25% risk reduction) was the aforementioned Age-Related Eye 
Disease Study (AREDS) in 2001 12 – this is covered in the ‘Clinical Intervention of other 
Nutrients’ section 1.9 – the most current research is AREDS 2, the results of which were 
released in May 2013 (see ‘Lutein and zeaxanthin: a review of evidence’ section 1.7). 
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Recommended Daily Allowances 
Recommended Daily/Dietary Allowances (RDA), are recommendations for the minimum 
amount of a nutrient that is needed for most individuals to stay healthy. They were developed 
by the Food and Nutrition Board of the National Academy of Sciences/National Research 
Council in the US during World War I, and were updated every five to 10 years. They are 
different for children, young adults, older adults and males and females 46.  
In 1997, RDAs became one part of a wider set of dietary guidelines called the Dietary 
Reference Intake (DRI) which includes the following nutrient measures as well: Adequate 
Intakes, known as AI; Estimated Average Intakes, known as EAR; and Tolerable Upper Intake 
Levels, known as UL. 
DRI is becoming the more accepted form for nutrient recommendations in the US. In the UK, 
many agencies still use RDA or GDA – ‘Guideline Daily Amount’. 
 
Nutrients that are considered beneficial for AMD 
Vitamin C 
This is a water soluble antioxidant that can protect against free radical-mediated oxidative 
tissue damage. Low levels have been associated with an increased risk of AMD, but high 
levels have not shown to be protective 47. The UK’s NHS website states that adults need 40mg 
per day, whereas the National Institute for Health, USA recommends at least 75mg in adults, 
increasing to 110mg in smokers. See Appendix 1 for examples of vitamin C rich foods.  
 
Vitamin E 
These are a group of eight fat soluble compounds that have many biological functions – the 
most important being a distinctive antioxidant ability to stop the production of ROS when fat 
undergoes oxidation. Tocopherol is one of the compounds in the vitamin E group: the four 
common forms of tocopherol include: α, β, ϒ, and δ. In the human retina, the alpha form is the 
most predominant in high concentrations 48. A relationship has been found between high 
plasma vitamin E levels and a reduced risk of AMD. Appendix 2 shows the US RDA for US 
citizens. The UK’s NHS website advises that males require 4mg per day, and females require 
3mg per day. Please also see Appendix 3 for examples of vitamin E rich foods. 
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Zinc  
This metallic element is very concentrated in human tissue, especially in the retina and RPE. It 
is important as it acts as a cofactor for retinal dehydronase and catalase – both of which are 
antioxidant enzymes. A low concentration of zinc can compromise macrophages and through 
increased apoptosis, T and B lymphocytes also become reduced. Zinc deficiency can result in 
an increased vitamin A uptake 49, causing toxicity, and lipid peroxidation and damage to lipid 
membranes. In the human body, zinc stimulates the protein metallothionein in the intestinal 
wall, causing it to bind to dietary copper and preventing copper absorption. For this reason, 
zinc is often supplemented alongside copper. Appendix 4 shows the US RDA for zinc. The UK 
RDA of zinc is 5.5 to 9.5 mg for men and 4 to 7 mg for women.  
Omega-3 Fatty Acids 
Docosahexaenoic acid (DHA) (C22:6 omega-3), the major dietary and structural omega-3 long-
chain polyunsaturated fatty acid (LCPUFA) of the retina, may modulate metabolic processes 
and stop the  effects of environmental exposures that activate molecules implicated in the 
pathogenesis of retinal diseases. These processes and exposures include chronic light 
exposure, oxidative stress, ischaemia, inflammation, cellular signalling mechanisms, and aging. 
Eicosapentaenoic acid (EPA) (C20:5 omega-3), the precursor to DHA and the other major 
dietary omega-3 LCPUFA, can exert similar actions to DHA 50. There is currently no 
recommended daily allowance of any fatty acid, but supplement companies suggest 
somewhere between one to three grams per day. 
 
Carotenoids 
Carotenoids are organic pigments synthesised by plants, algae, fungi and some bacteria. They 
cannot be synthesised by humans or animals, and so have to be consumed. The two types of 
carotenoids are carotenes (composed entirely of carbon and hydrocarbons) and xanthophylls 
(contains oxygen atoms). 
In humans, four cartenoids (beta-carotene, alpha-carotene, gamma-carotene, and beta-
cryptoxanthin) have vitamin A activity, and these and other carotenoids can also act as 
effective antioxidants. Beta-carotene in particular is able to reduce single oxygen radicals 51. 
Certain other xanthophylls (lutein, meso-zeaxanthin and zeaxanthin) form the macular pigment 
(MP), giving it its characteristic yellow appearance. The largest concentration of lutein and 
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zeaxanthin lie at the fovea, and reduce with eccentricity 52, 53. The measurement of MP has 
recently become the focus of AMD research – some studies have shown those with low MP 
optical density (MPOD) are at risk of AMD compared with age-matched controls (please see 
the research in section 1.7,  ‘Lutein and Zeaxanthin for AMD; a review of evidence’). 
                                    
Figure 1.6. Chemical structure of Lutein, cryptoxanthin and zeaxanthin, showing a long straight chain composed of 
two identical units joined by a double bond between carbon 15 and 15’. 
As well as being antioxidants, the xanthopylls act directly to absorb damaging blue and near-
ultraviolet light around the 400-460 nm region of the spectrum which would protect the outer 
retina, RPE and choriocapillaries from oxidative damage 54. Studies have shown that in rhesus 
monkeys that have no previous exposure to xanthophylls and no detectable macular pigment, 
foveal protection has been absent, but became evident after supplementation of the nutrients 
55. The methods used to prevent oxidation are firstly the energy transfer to the carotenoid 
which will quench singlet oxygen due to the conjugate double bond within their molecular 
structure, and secondly the reaction with peroxy radicals that are involved in lipid peroxidation.  
As mentioned, xanthophylls are not synthesised by the body and can only be obtained from 
consumption. They are abundant in dark green leafy vegetables such as spinach and kale 56, 
as well as yellow and orange fruits and vegetables such as peppers 57 (please see Appendix 5 
for lutein and zeaxanthin rich foods). The foremost research into carotenoids in recent years is 
AREDS in 2002, with the secondary study having been completed in 2013. From these studies, 
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the current RDA for AMD sufferers or those with an AMD risk is 10mg of lutein and 2 mg of 
zeaxanthin per day.  A comprehensive review of these studies is presented in the next chapter 
‘Lutein and zeaxanthin: a review of evidence’ and section 2.9, ‘Clinical intervention of other 
nutrients’.  
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Chapter Two 
Lutein and zeaxanthin for AMD – a review of evidence 
The body of evidence supporting a role in AMD risk and/or progression ranges from basic 
experimental studies with animals to clinical and epidemiological investigations 58, 59. Whilst 
some epidemiological studies suggest a beneficial role for carotenoids in the prevention of 
AMD, others did not find a relationship. Despite this contradiction, the positive outcomes of 
many of the studies have given hope that variation of the antioxidant balance through 
supplementation can slow progression of ARM to AMD 60.  
2.1 Search 
A search of the research into dietary intake and supplementation of lutein and zeaxanthin was 
performed from the calendar dates of September 2011 to September 2012 using the following 
search terms: ‘Age-related macular degeneration’, ‘Nutrition’, ‘Lutein and zeaxanthin’, ‘Diet’, 
‘Supplements’  on the following databases: Web of Knowledge, The Cochrane Library, Optics 
Infobase, PubMed, Ovid Journals, PsycArticles, National Center for Biotechnology Information 
(NCBI) databases, and Wiley Online Library. Since the ‘outcome’ for much of the research 
varies – i.e. using visual acuity, retinal signs or macular pigment optical density (the amount of 
macular pigment within the retina often abbreviated to MPOD) as a standard - studies were 
included no matter what measure the researcher decided to use. Epidemiological studies were 
included as well as intervention studies. There were 103 papers that fit the search criteria, and 
62 were identified as supplementation or dietary studies in participants with AMD.  
Positive findings - observational studies 
Firstly, the following research studies found that a diet high in lutein and zeaxanthin effects 
AMD risk and progression. Moeller et al’s - Cartenoids in Age-related Eye Disease Study 
(CAREDS)- research showed that a diet rich in lutein and zeaxanthin in 34 participants with 
advanced AMD resulted in protective, but statistically non-significant, associations in the 
overall sample and in women younger than 75 years 54. 
 
Lutein and zeaxanthin has been shown to reduce the risk of acquiring the condition in high risk 
patients, or slowing progression to an exudative form. The AREDS authors evaluated the 
relationship of the dietary intake of carotenoids lutein and zeaxanthin, and vitamins A, C and E 
on 4519 participants using food frequency questionnaires. A higher dietary intake of 
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lutein/zeaxanthin was independently associated with decreased likelihood of having 
neovascular AMD, GA, and large or extensive intermediate drusen after all covariates were 
taken into consideration 61. This finding was similar to those reported by Lintje Ho et al. 62 – 
participants of the Rotterdam Study (a large population based prospective study that has been 
on-going since 1990, investigating hepatic, cardiovascular, neurological, ophthalmic, 
psychiatric, dermatological and oncological diseases) who were calculated to be at risk of 
developing AMD due to their genetic variants had their dietary intake assessed. Those with 
high intakes (above the median) of DHA/EPA, zinc, lutein and zeaxanthin all reduced their risk 
of acquiring early ARM. The Blue Mountains Eye Study 63 assessed the relationship between 
baseline dietary and supplement intakes of lutein and zeaxanthin, carotene (α and β), β- 
cryptoxanthin, iron, zinc, lycopene, vitamins A, C and E, and the long term risk of incident 
AMD. Risk was assessed using logistic models after adjusting for age, smoking, and other risk 
factors. They found that a higher dietary lutein and zeaxanthin intake reduced the risk of long-
term incident AMD, and zinc was also protective if taken both in the diet and supplemented. 
They were unable to definitively associate reduced risk with the other tested antioxidants. 
 
Lutein and zeaxanthin intake has been found to vary with gender, race and age. Johnson et al 
64 investigated dietary intake of lutein and zeaxanthin in participants of the National Health and 
Nutrition Examination Study in 2002 – 2003. The study revealed that amongst all age groups, 
both sexes, and all ethnicities, intakes of lutein were greater than of zeaxanthin. Relative intake 
of zeaxanthin to lutein decreased with age, with zeaxanthin to lutein ratios lower in females. 
Zeaxanthin to lutein ratios in Mexican Americans was considerably greater than other 
ethnicities. Lower zeaxanthin to lutein ratios were measured in groups at risk for AMD which 
revealed that the relative intake of lutein and zeaxanthin may be important to AMD risk.  
 
Concentrations of lutein and zeaxanthin can be measured by looking at the serum content in 
the blood. Delcourt et al. 65 in the population based Pathologies Oculaires Liees a l’Age study, 
measured the plasma levels of lutein and zeaxanthin using high-performance liquid 
chromatography in 800+ subjects. They found that increased plasma levels of these 
carotenoids were associated with lower rates of AMD and cataracts, but particularly zeaxanthin 
seem to play a protective role. 
 
A systematic review and meta-analysis by Ma et al. found six cohort studies (van den 
Langenberg, van Leeuwen, Moeller, Tan, Cho and Cho et al.) that positively correlated a high 
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intake of lutein and zeaxanthin with a reduction of risk in late AMD. None of the six studies 
found a relationship in early AMD 66.  
 
Positive findings – intervention studies 
 
Lutein and zeaxanthin have been given to participants in supplement form in some studies. 
Piermarocchi et al. - Cartenoids in Age-related Maculopathy Italian Study (CARMIS) 67-  treated 
153 patients with AMD and VA of greater than 0.3 LogMAR with lutein, zeaxanthin, 
astaxanthin, vitamin C, vitamin E, zinc, and copper. Patients received baseline, 6-month, and 
1-year follow-up with ETDRS and the 39-item Visual Function Questionnaire (VFQ). After 1 
year, treated patients showed stabilization of VA and significantly better ETDRS scores 
compared to controls. VFQ-39 scores were significantly increased in the treatment group. In 
the Lutein Antioxidant Supplementation Trial (LAST), patients with atrophic AMD were given 10 
mg lutein or 10 mg lutein and other antioxidants over a 12 month period. The authors found 
lutein combined with other antioxidants to be more effective that just lutein alone, but both 
groups displayed improved contrast sensitivity, glare recovery and visual acuities 68.  
Lui et al. conducted a meta-analysis of eight randomly controlled trials (RCT) of lutein and 
zeaxanthin (Piermarocchi, Bartlett, Richer, Ma, Weigart, Murray, Dawczynski and Beatty et al.) 
They found that xanthophyll carotenoids supplementation was associated with significant 
improvements in VA and CS in a dose-response relationship. In addition, a linear association 
was indicated between MPOD increase and the improvement of VA and CS at middle 
frequency 69.  
The foremost and most current research into lutein and zeaxanthin supplementation is the 
follow up to the original Age-related Eye Disease Study – AREDS 2 70. The AREDS team 
recently released the results for AREDS 2 in which lutein and zeaxanthin was encompassed 
into the original AREDS supplement formulation 71. The study found that adding lutein and 
zeaxanthin did not further reduce the risk of progression to advanced AMD. However,  
participants who took the AREDS formulation with no beta-carotene but with lutein and 
zeaxanthin, had their risk of progression to advanced AMD reduced by 18% compared to those 
participants who took the AREDS formulation that contained beta-carotene but no lutein and 
zeaxanthin. In addition, participants who had ≤ 0.823 mg per day dietary intake of lutein and 
zeaxanthin at the start of the study, but who took the AREDS 2 formulation, were 25% less 
likely to develop advanced AMD compared with participants with similar dietary intake who did 
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not take the supplementation. There was no benefit from supplementation to those who 
consumed ≥ 1.030 mg of lutein and zeaxanthin per day in their diet. 
Investigators suggested that beta-carotene may have masked the effects of lutein and 
zeaxanthin in the overall analysis because it competes for absorption in the body – participants 
who took beta-carotene along with lutein and zeaxanthin had lower serum levels compared 
with those who only took lutein and zeaxanthin. It can therefore be concluded that lutein and 
zeaxanthin may be useful substitutes for beta-carotene in the original formulation as beta-
carotene has been linked with increased risk of lung cancer in smokers 72. Leading AMD 
researchers in the UK have commented on how these results should form the standard of care 
for all patients with or at risk of AMD 73. 
Negative findings – observational studies 
Bartlett et al. 74 was one of the research teams that investigated diet and supplementation. 
They conducted a prospective study of 74 patients that were either under 50 years of age, over 
50 or over 50 with AMD, investigating their overall diet and supplementation using food diaries 
over a three-day period. Participants over 50 consumed more vitamin C and fibre than the 
under 50 group. The AMD group showed no deficiency of any specific nutrient in the diet 
compared with age and gender matched controls, and consumed more protein and zinc 
compared to the other groups. The AMD participants consumed more ocular health 
supplements than the other groups, but the under 50 group consumed more multivitamin 
supplements, but less dietary vitamin C and fibre.  
Another diet study by Cho et al. 75 followed patients 50 years of age or over with no diagnosis 
of ARM or cancer at baseline for up to 18 years for women and up to 12 years for men. Fruit 
and vegetable intakes were assessed with a validated semi-quantitative food-frequency 
questionnaire up to five times for women and up to three times for men during follow-up. Fruit 
intake (especially oranges and bananas) was inversely associated with the risk of neovascular 
ARM. Participants who consumed three or more servings per day of fruits had a pooled 
multivariate relative risk of 0.64 compared with those who consumed less than 1.5 servings per 
day. The results were similar in women and men. However, intakes of vegetables, antioxidant 
vitamins, or carotenoids were not strongly related to early or neovascular ARM.  
Other studies report findings that do not support the association between lutein and zeaxanthin 
and the reduced risk of AMD 76, or were observed only in population sub-groups 77. Mares et al. 
78 did not specifically screen for lutein and zeaxanthin in the diet, but they looked at healthy 
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diets as a whole, and used the Healthy Eating Index to assign scores to the diets of women 
who were enrolled in the CARED study. They found that those participants that scored high 
had a 46% lower risk of early AMD, than those that scored low. The study was limited to those 
with a high socio-economic status, so the sample was not a true representation of the 
population. 
Because lutein and zeaxanthin make up the MP, studies investigating possible links between 
MPOD and AMD have been conducted, using a variety of measurement techniques 79. These 
will be discussed in the next section. 
 
2.2 Macula pigment and optical density 
Some of the MPOD studies have supported an MPOD-AMD association, that is, high values of 
MPOD mean less risk of developing AMD 80-82 and others have not 83, 84. Macular pigment 
optical density measurements, however, can be unreliable. The most common method for 
measuring MPOD is heterochromatic flicker photometry (HFP), in which an observer is 
required to ‘flicker match’ using one wavelength of light that is absorbed by MP and one 
wavelength of light that is not. Traditional heterochromatic flicker photometry requires the 
observer to adjust the luminance ratio of the two wavelengths of light at a central macula area 
and a peripheral area, until the flicker is perceived to disappear or be reduced to a minimum. 
This can be conceptually difficult to achieve, and as Bartlett et al point out, differences in 
training in the technique provided to participants or by differences in instrumentation can 
provide differences in reliability 85. These reliability issues must be taken into consideration 
when reviewing the following studies. 
 
Studies also show a link between increased intake of lutein and zeaxanthin, and higher MP 
levels, such as the study by Mares et al. (the same research group mentioned previously) 
where MPOD was measured using HFP in the CARED cohort. They found that MPOD was 
directly related to dietary intake of lutein and zeaxanthin and even more strongly related to 
serum concentrations 86. Other studies have found similar results 87-89.  
 
Supplementation studies report increases in MPOD of between 21 and 57% following lutein 
and zeaxanthin supplementation in people with healthy eyes. Increases in MPOD of between 
24 and 36 % have been reported in people with retinal disease. In the LAST II study, the 
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authors were interested in investigating those specific characteristics that increase MPOD, to 
determine why MPOD does not appear to increase despite supplementation in some 
individuals. Some 90 patients with atrophic AMD were given the same supplementation as the 
original LAST study, for 12 months, and MPOD was evaluated over that time period. The 
results showed that MPOD increased with supplementation and decreased slightly without 
supplementation – those with the lowest MPOD initially, had the highest increase of MPOD 90. 
Schalch et al. - The Lutein Xanthophyll Eye Accumulation Study (LUXEA) 91- investigated the 
effect of a daily lutein and/or zeaxanthin supplement on MPOD as well as blue light sensitivity 
after 6-12 months use. They found that average xanthophyll plasma concentrations increased 
up to 27-fold and MPOD increased by 15% upon just lutein or lutein and zeaxanthin 
supplementation. Supplementation of zeaxanthin alone produced a 14% MPOD increase 
especially in the parafoveal area. The authors concluded that lutein is predominantly deposited 
in the fovea, while zeaxanthin deposition appears to cover a wider retinal area. 
 
Bone et al. gave their subjects a 120-day supplement regime containing primarily meso-
zeaxanthin, but also lutein and zeaxanthin , and measured serum levels and MPOD92. Serum 
levels of all three cartenoids naturally increased during supplementation, and the macular 
pigment rate of change (measured at 460nm) rose at an average rate of 0.59 mili-absorbance 
unit/day; which was significantly higher than the placebo group. 
 
However, Berrow et al. 93 compared the macular pigment in different age ranges. The findings 
showed that there was no statistical significance in dietary lutein and zeaxanthin intake 
between the MPOD of different age groups, and no differences in the macular pigment of the 
age groups when lutein and zeaxanthin were supplemented in the diet. Another study group 
found that some subjects failed to show a change in MPOD after their dietary intake of lutein 
and zeaxanthin was increased 94.  
 
2.3 Clinical Intervention of other nutrients 
Zinc 
Zinc has often been investigated alongside other nutrients. Of the studies that investigated zinc 
alone, Newsome et al found a positive effect of taking 100 mg of zinc sulphate twice per day 
for participants with ARM/ AMD of improved visual acuity and fewer drusen compared to the 
placebo group. However, this study had some limitations since the number of subjects in each 
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group was relatively small 95. More recently, Newsome investigated the use of zinc-
monocysteine supplementation by prescribing 25mg to dry AMD participants for a period of 6 
months. Improvement of visual acuity, contrast sensitivity and macular recovery time in the 
AMD participants was reported. The investigator did not, however, look at the effect on drusen 
or other AMD signs such as hyper/hypo pigmentation at the macular 96. 
However, Stur et al. gave 200mg of zinc sulphate once per day to exudative AMD participants’ 
‘better’ eye. The trial showed no short term effect on the progression of AMD in the second eye 
97. 
Alpha-tocopherol beta-carotene  
Male smokers aged over 65 years were given alpha-tocopherol and/or beta carotene 
supplements for 6 years in Teikari et al’s study. The authors concluded that both supplements 
had no effect on the prevalence of AMD or ARM; again, the study had its limitations by not 
collecting baseline measurements and not using clinical visual parameters 98. 
 
Vitamin Combinations 
 
The Age-related Eye Disease Study (AREDS) 12 is the largest supplementation study of recent 
years. The team investigated a combination of high dose nutrient supplementation on AMD 
and cataracts over a period of 6 years. The AREDS formulation of vitamin C 500 mg, vitamin E 
400 IU, b-carotene 15 mg, and zinc (zinc oxide 80mg and cupric oxide 2 mg) showed a 25% 
risk reduction in progression to advanced AMD over 5 years in patients with intermediate AMD 
(extensive intermediate drusen in one or both eyes, one or more large drusen in at least one 
eye, or nonsubfoveal geographic atrophy in one eye) or advanced AMD (subfoveal geographic 
atrophy or choroidal neovascular membrane) in one eye. The risk of losing vision of three or 
more lines on a Snellen chart also was reduced by 19% with this combination treatment. The 
AREDS formulation showed no effect in preventing the development of large drusen in 
participants who had small drusen at baseline, and the incidence of advanced AMD in this 
group was very low (<1%).   
 
Brantley et al. 37  used the original AREDS formulation of supplementation to determine if a 
short five day course would increase mean plasma levels of oxidative stress biomarkers. They 
found that the plasma levels of cystine were significantly lower in all participants (AMD and 
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controls), with no particular differences between the two cohorts. No real differences were 
found with the other biomarkers however. 
 
It is also not known whether it was one or all of the nutrients working in tandem that gave these 
positive results in the AREDS study. Because of the high dosage of zinc, and the inclusion of 
beta-carotene, some ophthalmologists and other eye professionals became concerned with the 
safety of the formulation for smokers and were reluctant to advise patients to use it. A further 
study (AREDS 2) 70 was warranted, and it was hoped that the results from this study would 
give clear guidelines for eye professionals to use. As stated previously, the AREDS team 
released the results for their follow-up study (AREDS 2) which encompassed lutein and 
zeaxanthin to the original AREDS supplement formulation 71. The study found that adding 
lutein and zeaxanthin did not further reduce the risk of progression to advanced AMD, but 
because of the large nature of the study, the researchers were not able to measure MPOD and 
recognise that this would have been a useful dimension to take into consideration. However, as 
mentioned, the conclusions show that lutein and zeaxanthin may be useful substitutes for beta-
carotene in the original formulation as beta-carotene has been linked with increased risk of 
lung cancer in smokers 72. 
 
To address the risk of lung cancer among smokers supplementing with beta-carotene, 
Cangemi et al. in the Taurine, Omega-3 Fatty Acids, Zinc, Antioxidant, Lutein Study (TOZAL) 72 
gave participants with dry AMD a mixture of zinc, taurine, antioxidants (beta-carotene and 
vitamin A) and Omega-3 for six months. The results showed an increase in VA above the 
expected baseline decrease in the majority of patients in this population with dry AMD. 
 
Parisi et al. 99 – this Italian research group investigated the effect of carotenoid and antioxidant 
supplementation on retinal function in early AMD patients and age-matched controls using 
multifocal electroretinograms (a method to record the responses of photoreceptors). 
Participants were given oral supplementations of vitamins C and E, zinc, copper, lutein, 
zeaxanthin, and astaxanthin daily for 12 months. Multifocal electroretinograms were assessed 
initially and, in nonadvanced AMD patients, after six and 12 months. The AMD patients had 
reduced responses at baseline when compared to the ‘normal’ cohort, but after six and 12 
months of supplementation, central responses significantly increased (but peripheral 
responses did not). 
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In 2005, van Leeuwen et al. 100 assessed the diets of some of the Rotterdam Study cohort who 
had been considered ‘at risk’ of developing AMD by the ophthalmic study group. They found 
that dietary intake of both vitamin E and zinc was inversely associated with incident AMD. An 
above-median intake of all four nutrients, beta carotene, vitamin C, vitamin E, and zinc, was 
associated with a 35% reduced risk of AMD. Exclusion of supplement users did not affect the 
results. In this study, a high dietary intake of beta carotene, vitamins C and E, and zinc was 
associated with a substantially reduced risk of AMD in elderly persons.  
 
However, as before, not all the research has yielded positive results. Christen et al. 101 tested 
whether supplementation of vitamin E taken on alternate days, and a daily vitamin C 
supplement would affect the incidence of AMD diagnosis amongst a male physician cohort who 
had not been given a AMD diagnosis previously. The supplements were taken over an 8 year 
period. The researchers found no appreciable beneficial or harmful effect of the 
supplementation to the risk and therefore diagnosis of AMD. 
 
Overall, due to the negative conclusions of a few of the intervention and MPOD studies, the US 
Food and Drug Administration and the US National Institutes for Health concluded that the 
evidence is insufficient to prove that lutein, zeaxanthin and other antioxidants/ vitamins would 
be beneficial to reduce the risk and progression of AMD and other health conditions 102, 103. 
Coleman et al dispute this, and hypothesise that if the eight million people in the US who they 
estimate are at high risk of AMD would take supplement therapy, more than 300,000 of them 
could be saved from advanced AMD in the next five years 20. A recent review by Evans and 
Lawrenson concludes that there is “moderate quality evidence that people with AMD may 
experience a delay in progression by taking specific antioxidant vitamin and mineral 
supplements.”104  
 
2.4 Knowledge and attitudes towards nutrition and supplementation 
 As shown, there is a growing body of evidence that suggests that consuming antioxidants 
particularly lutein and zeaxanthin, can have a positive effect on risk of progression, and 
perhaps onset, of AMD. However, hypothesising aside, expecting people to understand and 
comply with diet changes can be extremely problematic.  
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Because of the conflicting research results, neither patients nor practitioners are clear about 
what kind of supplements to take, or how foods should be prepared and consumed in order to 
maximise absorption of useful nutrients. To add to the confusion, there are many nutritional 
supplements aimed at those with AMD currently on the market, with varying degrees of dosage 
despite the fact that only the AREDS formulation is supported by a large scale randomised 
controlled trial. Research has shown that given more choices, patients are much more likely to 
be overwhelmed 105. Supplements are not regulated in the same manner as medication in the 
UK 106 and it is very difficult to identify which supplements are likely to be of any benefit.  
In a similar way, the information available in newspapers and magazines and on the internet 
can provide confusing advice as to which are the best dietary sources of lutein and zeaxanthin. 
For example, the Royal National Institute for the Blind (RNIB) website states that ‘Lutein can be 
found in yellow peppers, mango, bilberries, and green leafy vegetables such as kale, spinach, 
chard and broccoli’ 107. This statement suggests that all of these foods are good sources of 
lutein. In fact, as can be seen in Appendix 5, the lutein and zeaxanthin content varies in 
different fruit and vegetables – the difference between 2 mg/cup (mango) and 24 mg/cup 
(kale).  
Marketing can also send out the wrong message to people and practitioners. For example, the 
drinks manufacturer Rubicon uses the fact that papaya contains lutein to market their juice 
product. However, papaya juice contains just 0.06 mg lutein per cup. People would have to 
drink 167 cups of Rubicon papaya juice per day in order to consume 10 mg of lutein.  
Other barriers to patients taking preventative measures include poor communication with 
practitioners, misinformation in the marketplace and age-related compliance problems 105.  
Overall, possibly due to the conflict and confusion, recent data suggests that dietary intake of 
carotenoids have declined in Europe and the US 108, 109. It is important to investigate the affect 
that knowledge and attitudes towards nutrition have towards diet and dietary behaviours.  
 
Knowledge and attitudes 
 
Knowledge mediates the relationship between motivation and decision accuracy, and therefore 
is key to making choices 110. Nutrition advice is currently available from a vast array of sources 
– books, the media, old-wives tales, medical practitioners, alternative medicine practitioners, 
nutrition clubs, support groups, online forums. These sources often convey overly negative 
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messages or exaggerated good/bad food distinctions 111, (e.g. “Sugar is poison”, 
“Carbohydrates can make you fat”, “Fat causes heart attacks”) and it can result in 
unconditional rejection of nutrition guidance by eliciting feelings, such as guilt, anxiety, 
helplessness, and fear 111. Many people are not only confused about the ‘correct’ food choices, 
but are actually fearful and can become obsessed – a new form of eating disorder known as 
orthorexia 111, 112. 
 
Dr Bressler, who was one of the original AREDS team members, reports that misinformation 
about supplements is rife in the US, mainly due to the media, well-meaning friends and family, 
and practitioners 105. Part of the problem might lie with the plethora of formulations that are 
available – for example, Bausch & Lomb offers at least six different eye-related vitamins (six 
versions of Ocuvite and nine versions of PreserVision105). This is combined with the fact that 
many people with AMD are older and may already be taking many drugs, and fundamentally 
do not understand how medications work. Many individuals feel that taking more vitamins than 
the recommended dose will not do them any harm 105. 
 
In Germany, 60 pharmacies were contacted to see what advice was being given to AMD 
patients. Of the 90, 36 of them recommended specific nutritional supplementation, but the 
supplements recommended were not the AREDS formulation or the correct dosage 113. 
 
The knowledge base of an urban community of mainly older adults in Massachusetts was 
assessed using a series of surveys in a study by Starkey 114. A total of 83% of the respondents 
were aware of a link between healthy food and healthy eyes, but fewer knew of the specific 
nutrients involved and hence what they should be eating to benefit. Some 40% ate green leafy 
vegetables three to four days per week, and 73.3% reported that they would take supplements 
or change eating habits if they knew what supplements to take and which changes to make. 
 
In 1998, a large sample of Irish adults were surveyed for their attitudes towards and beliefs 
about nutrition and health. The study found significant differences due to several factors: 
gender (females were more likely to want to eat a healthy diet), education (those with a tertiary 
education were more motivated to select a healthy diet), and age (younger subjects were less 
concerned about nutrition than older subjects). Older, more educated, female subjects 
therefore appear the most motivated to want to eat healthily, but the barrier to this appears to 
be knowledge on the topic 115. 
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In fact, the Irish Longitudinal Study on Aging (TILDA) measured the MPOD on subjects from a 
variety of socio-economic groups. They found that the more educated the subject was, the 
higher the MP was, and hypothesised that this was due to the knowledge that the subject had 
of what constituted a healthy diet 116. 
 
 
Compliance 
 
After their initial study, the AREDS team investigated the compliance of their cohort to their 
recommendations. Of those participants who met the criteria, only 43% reported taking AREDS 
vitamins in the recommended dosages. Participants with intermediate or advanced AMD in at 
least one eye showed a low adherence rate to the AREDS recommendations for vitamin 
supplementation.  Only 59% of all participants reported taking a vitamin supplement for AMD, 
of whom 71% reported taking an AREDS formulation. Of the 40 participants who met AREDS 
criteria for vitamin supplementation, 70% reported taking a vitamin supplement for AMD. Of the 
participants who met AREDS criteria, 43% reported using an AREDS formulation vitamin and 
were taking the AREDS recommended dosages, 13% were taking an AREDS formulation in 
quantities less than recommended, 15% were taking a non-AREDS vitamin, and 30% were not 
taking a vitamin supplement. The six participants who met AREDS criteria for supplementation 
but were taking a non-AREDS vitamin reported using a vitamin marketed for eye or vision 
‘‘health,’’ including two who were taking a lutein supplement. All 17 of the participants taking 
vitamin supplementation according to AREDS recommendations reported that a retina 
specialist was the source of recommendation for supplement use. Participants who met 
AREDS criteria for vitamin supplementation but were taking no vitamin supplement for AMD 
most commonly reported that vitamin use had never been recommended to them. Other 
reasons reported for non-use were patients did not think a vitamin would benefit AMD, they 
were already taking another multivitamin, or they were advised not to take a vitamin by a 
primary care provider.                                                                                            Their study 
also shows that lack of awareness of recommendations for supplement use among eligible 
participants with AMD is a major factor for their non-use of AREDS-type vitamins 117. 
 
A study of 100 patients with advanced AMD conducted at the University of Adelaide found that 
only 53% were aware of the AREDS supplementation, and only one patient was taking the 
correct dosage of supplementation 118. Among those who were aware of the supplement but 
not taking it, cost was the most common reason, and some were not taking it because of actual 
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side-effects experienced, fear of potential side-effect and/or fear of interaction with other 
medications. 
 
Recall of advice is a problem for all age groups, but more so in the elderly. For instance, in one 
study of smoking cessation with AMD patients, most of the subjects reported never being 
advised to quit even though their health care providers had records indicating that advice had 
been given 119.  
There is evidence to support poor recall and incomplete adherence to non-pharmacological 
advice in elderly patients with a variety of medical conditions 120, 121 – not just eye conditions.  
 
Marinac et al’s survey into attitudes, use and knowledge of herbal products and dietary 
supplements 122 found that there were substantial misconceptions among older Americans, and 
most of the cohort felt that they required significant additional information about these products. 
 
Baker and Wardle’s research into fruit and vegetable intake in older adults 123showed that 
overall the cohort consumed well below the recommended five-per-day quota. There were 
gender differences also- men consumed fewer servings of fruit and vegetables compared to 
women. There were low levels of nutritional knowledge in relation to fruit and vegetables, with 
men having even poorer knowledge about current dietary requirements and fewer men being 
aware of associations between diet and disease. 
 
In a Minnesota community, Eikenberry et al conducted surveys of low-income subjects to find 
out their perception, motivations, barriers and promoters of healthy eating 124 . The main 
motivation for healthy eating amongst higher income subjects was the prevention of disease 
and for their family; lower income subjects were more concerned with looking good. The 
barriers to eating healthily appeared to be mainly time, cost and money. Higher income 
subjects also listed discipline and laziness. Promoters for healthy eating appeared to be family, 
how the subjects were raised and having a garden and growing produce. Interestingly, most of 
the subjects had an understanding of the definition of healthy eating (i.e. fruit and vegetables 
etc.) but did not put this knowledge into practice. 124  
As mentioned formerly, some research has shown that patients with medical conditions that 
are affected by nutrition, display low compliance with dietary alterations 121. Reasons why 
patients might not comply with the evidence include excessive reliance on pharmacological 
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intervention, lack of knowledge of dietary alterations, disbelief of dietary effectiveness, and 
ingrained dietary habits121.  
The aforementioned survey of older adults in Massachusetts 114 showed that once the cohort 
was correctly educated, 75% reported they had changed their eating habits one month later. 
Although it was not determined what the changes were, it is evident that the value of 
educational intervention is high.  
Overall, knowledge and motivation have been identified as being important for nutrition 
information processing. 
2.5 Complementary Medicine 
Supplements that are marketed for ocular conditions are considered to be complementary or 
alternative medicines and can be sold in pharmacies and health shops. As lutein and 
zeaxanthin are now ‘generally recognised as safe’ (GRAS), they can also be added to foods 
such as cereals. 
Eisenberg et al.’s 1993 study into US prevalence, cost and usage of complementary medicine 
showed that expenditure on commercial diet supplements and megavitamins (over the counter) 
averaged $228 per person  per year for diet, $203 for megavitamins yielding national 
projections of approx. $1.2 billion and $0.8 billion respectively. The study also inferred that a 
substantial amount of unconventional therapy is used for non-serious medical conditions, 
health promotion or disease prevention rather than serious medical concerns. However, 
respondents who reported poor health had higher rates of use of unconventional therapy than 
those that perceived themselves to be in better health.125 
Marinac et al’s survey into older adults’ use of supplements found that Caucasian women in 
this age group with a college education were most likely to take supplements. Preservation of 
health was the most predictive indicator for use. Worryingly, primary care physicians generally 
were unaware of non-prescribed therapies their patients were taking. Most patients did not 
share this information with their healthcare provider even if they experience adverse effects. 
122. 
Estimated amount of use in the UK 
In 1998, a survey reported substantial use of practitioner-provided complementary/ alternative 
medicine in the UK, and that 10% of the adult population was estimated to routinely use these 
medicines over a 12 month period 126. In 2000, a telephone survey showed that the use of 
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complementary and alternative medicine in the UK was 20% in the sample 127. This was 
predicted to hugely rise due to the aging of the population, the increase in the overall 
population and the popularity of alternative medicines in Europe 128.  
In 2007, research showed that there had indeed been a dramatic increase in sale and use of 
herbal/ food supplements within UK 129.  This was attributed to a variety of factors including 
education, media, health-promoting programmes, affluence, fashion trends, type of disease, 
geography and ultimately public opinion.  Individuals who are most likely to use these 
alternative medicines were identified as young to middle-aged females who are educated and 
more affluent – especially breast cancer sufferers 129.   
Although younger individuals were more likely to use complementary/ alternative medicines, a 
growing number of older people were beginning to take alternative medicines, but were unsure 
of the efficacy of drugs that are perceived by some patients as being safe and traditional 129. 
The Hertforshire cohort study In 2012 Investigated the patterns of supplement use in a UK 
population of older adults 130. 45% of men and 57% of women reported taking at least one 
supplement in the last three months, and that there were distinct patterns of use which were 
related to socio-demographic and lifestyle characteristics ; for example,  those that were taking 
oil type supplements (fish oil, omega 3) ate a more unhealthy diet than those that didn’t. Those 
that took glucosamine (or other arthritic supplements) tended to have a higher socio-economic 
status and a career that consisted of non-physical labour. The researchers hypothesise that in 
an older age-group, subjects are more concerned with self-medicating or preventing specific 
diseases rather than general vitamin use for overall health. 
 
In summary, complementary and alternative medicines are being used by the older population, 
but not necessarily with the correct knowledge of use and dosage. There is a need to educate 
and inform patients about how best to use such medication. 
2.6 Research rationale 
Age related macular degeneration is an increasing threat to older adults’ sight and quality of 
life. The current evidence suggests that a consumption of the carotenoids lutein and 
zeaxanthin – in supplement form or dietary – is likely to help halt the progression of the 
disease. However, research shows that many individuals with AMD do not consume sufficient 
quantities of either carotenoid to benefit from these effects.  
40 
 
 
 
Due to the conflicting research, poor patient education and poor medical compliance in this age 
group, it is hypothesised that many patients either do not know about antioxidant intake or are 
not complying fully. It is vital to find out if this hypothesis is true, so educational dissemination 
can be studied and intervention strategies can be formed. 
It is proposed that a cross-sectional survey should be designed with open ended questions 
(where appropriate), to find out the knowledge and attitude AMD patients have towards 
nutrition, and to find out whether their behaviour reflects their attitude.  
Use of surveys 
Although most survey research is conducted in social sciences fields such as economics and 
psychology, surveys have been used for many years in healthcare and medicine 131. They are 
invaluable in extracting large amounts of important data from a large sample of participants 
very swiftly, of which the researcher is able to make inference about the wider population.  
In healthcare, the advantages of using surveys lie in the non-invasiveness of the research. The 
participants do not have to undergo any form of treatment or testing in order to find out the 
answers to specific health questions. Much can be learned from a respondent’s attitude, 
knowledge or behaviour at a point in time, and this can be monitored over a period of time 132. 
However, this needs to weighed against the possible low response rates from patients 
(especially in electronic surveys), and the variety/ bias of responses that occur when a 
participant is self-reporting. This is of particular note in nutrition surveys, as studies have 
shown that participants tend to under-report food intake even when novel techniques are used 
133, 134. Both of these drawbacks will be explored in the following chapter. 
2.7 Summary 
The aim of this thesis is to explore the hypothesis that AMD patients either do not know about 
antioxidant intake or are not complying fully with supplement use and/or dietary modification. 
Literature pertaining to L&Z has been reviewed, and a research rationale has been proposed. 
The following chapter will cover the methods and protocol for the research to be carried out. 
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Chapter Three 
Methods 
The previous chapter discussed the literature concerning AMD, nutrition and patient 
understanding and adherence to medical advice. A research rationale was proposed to explore 
the attitudes and behaviour in those affected by AMD, with the choice of survey design 
explained. 
 
3.1 Objectives 
The first aim of this project was to design a questionnaire that was effective at assessing 
attitudes towards, and understanding of, nutrition and nutritional supplementation for AMD 
amongst people with the condition and amongst age-matched controls. This project was 
carried out in partnership with the Macular Society. Outcomes of the project include 
development of educational materials for health professionals, and dissemination of the 
materials via continuing educational training journals.  
 
3.2 Questionnaire design and validation   
 
A narrative literature review of research on AMD patients’ perceptions of nutrition and AMD 
was conducted from September 2011 to September 2012, using the following databases: Web 
of Knowledge, The Cochrane Library, Optics Infobase, Ovid Journals, PsycArticles, PubMed, 
National Center for Biotechnology Information (NCBI) databases, and Wiley Online Library. 
The following key terms were used: ‘Age-related macular degeneration’, ‘Nutrition’, ‘Survey’, 
‘Attitudes’, ‘Behaviours’, and ‘Diet’. Although there were studies that fitted into the search 
criteria, this review did not identify any existing measure of AMD patients’ perceptions of 
nutrition, but found most surveys looked at nutritional behaviours. Therefore an original survey 
was developed afresh. A cross sectional survey was deemed most appropriate to elicit 
observational data at one specific time; designed with open and closed questions. After 
discussion with the Macular Society, it was decided that it was important to try and keep  
participants’ answers as ‘pure’ as possible by not biasing their opinions, and allowing them 
freedom to express themselves in their own words.  
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The survey covered three main areas: 
1. Demographics: i.e. what are the characteristics of the participant being interviewed? 
Questions included age, gender, living arrangements, occupation, AMD type and duration, 
vision impairment registration and health/vision perceptions. 
2. Knowledge of AMD patients (or age-matched controls): i.e. what does the participant know 
about nutrition and the eye, where have they got their information from and do they feel is it 
enough information for their needs? Questions include whether the participant has 
discussed supplements with a health professional, do they feel they have enough 
information, where has that information come from, do they feel specific foods affect 
eye/general health, do they believe AMD can be affected by nutrition, whether they take 
any supplements and their beliefs about consumption of specific vegetables and fruits 
linked to eye health. 
3. Diet of participants: i.e. what are participants actually eating? Questions include frequency 
of vegetables eaten, a 24 hour food diary, who cooks/ prepares food, preventions to 
cooking/ preparing food, who food shops, where do they shop for food, barriers to changing 
diets, and supplements and dosage. 
The items included in the survey were:  
 
• Age  
• Gender 
• Living arrangements  
• Occupation 
• General health 
• Visual health 
• Confirmation of AMD with duration and type 
• Visual impairment register details 
• Who mostly prepares food? 
• Who mostly cooks food? 
• Preventions to preparing and cooking food 
• Confirmation of ability to cook a hot meal alone 
• Who mostly food shops? 
• Where the food is mostly obtained from? 
• The most important factor that dictates what food is eaten 
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• Would the participant like to change diet? 
• Preventions to dietary change 
• 24 hour food diary, split up into breakfast, lunch, dinner and snacks 
• If vegetables were eaten in the previous 24 hours, were they mostly cooked or raw? 
• Agreement/ disagreement with a statement that foods can affect general health 
• Agreement/ disagreement with a statement that foods can affect visual health 
• List of fruits and vegetables that may be beneficial for eye health – participant to say if 
they agree/ disagree and why 
• Which vegetables were eaten in the preceding week 
• Has nutritional supplementation been discussed by a health professional 
• Are nutritional supplements taken (if not, why) 
• Which supplements are taken and how often 
• How much money for supplements would participants be willing to pay 
• Agreement/ disagreement with a statement that AMD patients are given enough 
information on how their lifestyle affects their eye health.   
• Where have participants received information on AMD from  
• Do participants believe that age related macular degeneration can be prevented by 
lifestyle changes?   
 
3.3 Diet 
 
Food frequency questionnaires (FFQs) have often been used instead of food diaries in nutrition 
research – the debate over which is more reliable has not been resolved. Many studies show 
FFQs are useful for foods eaten frequently but not so useful for foods that are eaten 
infrequently 135. Some studies have shown there is less measurement error in food recording 
than in food frequency questionnaires, and the ability to study associations between diet and 
chronic diseases is slightly easier with food diaries 74, 136. In one study, 24 hour food recall 
interviews were shown to overestimate energy and nutrient intakes 137 but were much more 
accurate than a written food diary in other studies 138. It was decided that despite the 
drawbacks seen in some studies, a 24 hour food recall would be the most appropriate method 
of assessing the participant’s diet. 
 
 
 
44 
 
 
 
 
3.4 Survey piloting 
 
The survey was piloted with eight AMD patients who were members of the Macular Society 
and volunteered to take part. These volunteers formed a focus group to test the reliability, 
clarity, and understanding among an informed population. This ‘face validity’ (i.e., does the 
questionnaire measure what it intends to measure), was the only means of validation that it 
was possible to perform, due to a lack of other instruments to compare the results with. The 
focus group had a guided informal discussion structured by a moderator (RS) – the survey 
questions were asked again to check if the answers matched, and then the volunteers were 
asked to comment on how easy the questions were to understand and their opinions on the 
topics covered. The meeting was recorded and analysed to further refine the survey, which 
was altered accordingly –  
1) the type of AMD were made simpler for participants to understand by categorising it ‘wet’ or 
‘dry’  
2) adding a ‘meals-on-wheels’ category as to where participants might have obtained food from 
3) adding ‘more information’ if the participant was having trouble understanding a question, 
which would allow the interviewer to clarify without biasing the answer.  
Please see a transcript of the meeting in Appendix 6. The final survey (see Appendix 7) was 
then administered to future participants. 
Because of the age group and visual impairment of the participants, it was decided it would be 
best to deliver the questionnaire verbally. It was not practical to administer a verbal 
questionnaire face-to-face, as participants live across the country, so a telephone interview 
was conducted instead. In order to keep all the information in one place, survey software was 
used by interviewers to record the results. Bristol Online Surveys was the software used 
(University of Bristol, 8-10 Berkeley Square, Bristol BS8 1HH, UK). The survey was created 
with ‘branches’ that would appear/disappear according to what was answered, so that an 
interviewer did not have to record ‘not applicable’ to inappropriate questions. 
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3.5 Sample size  
 
The sample size required for questionnaire studies can be estimated by using a sample size 
chart. There are roughly 500,000 people with AMD in the UK. In order to be 95% confident that 
our sample represents the UK AMD patient population, we would need to recruit 383 subjects 
with AMD. To represent the number of Macular Society members (approximately 16000+), we 
would need to recruit 370 subjects. When compared to other surveys, however, both of these 
figures are unrealistic due to the amount of data that is collected. Using data from a previous 
study from Bartlett et al. 74, a minimum sample size of 96, confidence interval of 10 and a 
confidence level of 95% would be appropriate.  
 
3.6 Recruitment  
 
The Macular Society is the only UK charity that is dedicated to helping those with diseases of 
the macula. They provide impartial information and practical support for visually impaired 
people, their families and carers. They also “provide information for health professionals, 
campaign for better services, sponsor research and raise awareness of macular degeneration 
and preventative measures” 139. Because of their work and dedication to improving education 
to patients, we approached the Chief and Chief executive to ask for assistance with recruitment 
with a mutual sharing of results. Patients that rang the society helpline over a period of time 
(January 2012 – May 2012) were invited to take part in the study, in a ‘first come, first served’ 
basis. However, by March 2012, there were sufficient numbers of participants and recruitment 
finished early. 
Four Macular Society workers administered the questionnaire. They were given extensive 
written instructions on how to administer the questionnaire by asking the questions exactly as 
they were written (see final survey in Appendix 7), with no emphasis on any word and no 
promptings. For the questions that required greater clarification, an ‘additional information’ tab 
was included, which the worker could then read out. The workers listened in to at least two 
mock interviews and had the chance to pilot the questionnaire on themselves. The workers 
were able to contact the principle investigator and supervisor for any help they required 
(however, none did). 
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2.7 Inclusion/exclusion criterion 
 
The inclusion criteria were that participants should be aged over 55 and have been diagnosed 
with a form of AMD. The only exclusion criterion was the inability to hear and reply to questions 
in English over the telephone.    
 
3.8 Ethics 
This study was conducted according to the guidelines laid in the Declaration of Helsinki and all 
procedures involving human subjects were approved by the Aston University Ethics 
Committee. Verbal informed consent was obtained from all subjects and formally recorded. 
 
3.9 Questionnaire delivery protocol 
 
When a patient agreed to take part in the study, they were telephoned at a convenient time to 
complete the questionnaire. Information about the study and a consent statement was read out 
to each participant at the start of the follow-up call, before the questionnaire was delivered. The 
participants had the opportunity to ask questions about the study at recruitment and when they 
were called by the interviewer.  
 
Summary of telephone interview protocol: 
1. Introduction and confirmation that the participant is willing to participate at that time 
2. Arrangement of an alternative interview time if required 
3. Withdrawal from the study if required 
4. Study information read out to the participant 
5. Consent statements read out to the participant and consent confirmed 
6. Questionnaire delivered and responses recorded 
7. Participant given the opportunity to ask questions 
8. Participant provided with contact numbers in case any questions arise later 
9. Telephone interview is ended. 
 
Participants had the opportunity to ask questions about nutrition for eye health that may have 
been prompted by the questionnaire at the end of the interview –if they felt they required 
written material they were posted a leaflet with diet and nutritional supplement information. 
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They were also given a contact number if they thought of any questions after the interview 
ended, and one participant called for advice regarding supplements at a later date.  
 
3.10 Analysis 
 
Microsoft Excel (Microsoft Thames Valley Park, Reading, West Berkshire RG6 1WA) was used 
to perform initial analysis; quantitative data was summarised using percentages and graphs. 
The data from the diet based question (“What did you eat yesterday?”) was entered into dietary 
analysis software ‘A La Calc’ (Red Hot Rails LLP, Unit 9, Eurolink Business Park, Middle Bank, 
Doncaster, South Yorkshire. DN4 5JJ). Each participant’s food was entered into the software 
as a ‘recipe’, which allowed the software to then analyse calorific intake, nutritional 
characteristics and most essential nutrients, including lutein and zeaxanthin. All these details 
were exported into Excel for further analysis. 
 
Data from Excel was then used in statistical software IBM SPSS to draw comparisons between 
people with and without AMD, using T-tests or Chi-squared analysis in the case of categorical 
data. For example, an independent t-test was used to compare the ages of participants in each 
group. Pivot tables were used to summarise the data and for cross-tabulation. Qualitative data 
was grouped into categories and general themes were extracted to then use in SPSS. 
 
3.11 Conclusion 
 
In this chapter the methods and protocols employed to design, validate and deploy a nutritional 
survey for patients with age-related macular degeneration have been discussed. In the 
following chapter the results that were obtained from the survey in participants with AMD, and 
an age-matched control cohort will be described. 
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Chapter Four 
Age-related macular degeneration patients’ awareness of nutritional factors. 
This chapter has been published in the British Journal of Visual Impairment 140 See 
Appendix 15 for a copy. 
 
The previous chapter outlined the methods and protocol in delivering a cross-sectional 
qualitative survey to patients with and without AMD. In this chapter, some of the data and 
demographic results from the survey will be described. 
 
4.1 Introduction 
Age-related macular degeneration (AMD) is the leading cause of visual impairment in older 
adults (> 50 years) in the UK 5. Currently, there are several AMD classification schemes which 
have been developed to try to standardise research and clinical practice. Ferris et al.11, 
proposed a five stage classification scale in which the investigators claim some consensus 
among AMD specialists: Stage 1) No apparent aging changes, 2) Normal aging changes, 
known as ‘drupelets’ (small drusen ≤63 µm) 3) Early AMD – medium sized drusen ≤125µm 4) 
Intermediate AMD - large drusen and pigmentary (hyper or hypo) anomalies and 5) Late AMD 
– geographic atrophy and/or neovascularisation 11. AMD can cause a gradual loss of central 
visual function occurring within months, or over many years, and late AMD can cause central 
visual loss and metamorphopsia within days or even hours. Many AMD patients have been 
given a simplified classification using the terms ‘dry’ to describe geographic atrophy and ‘wet’ 
to describe neovascularisation or exudation.  Visual loss is strongly associated with a reduction 
in quality of life as it will limit the ability to perform daily activities. Subsequently, depression 
often occurs in these patients 141. It has been predicted that the prevalence of AMD will 
increase significantly by 2020 due to the generalised aging of the population 15, 16, but also due 
to socio-economic factors such as poor nutrition and increased smoking in some areas 142, 143. 
Therefore it can be expected that there will be a growing need for support services for people 
with this condition. 
In the UK, diagnosis for AMD occurs via an ophthalmologist 5. Often, after the initial diagnosis, 
the patient will receive written information regarding the disease from the ophthalmology 
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department. The decision then rests with the ophthalmologist as to whether the patient requires 
any treatment. This might take the form of anti-vascular endothelial growth factor medications 
(e.g. Lucentis®) or surgery/laser for wet AMD conditions, low vision services or placement 
upon a sight impairment register. If the AMD is of an early or intermediate stage, the patient will 
have very little contact with any hospital services for some years – if at all – unless the AMD 
changes to a late stage. Patients are advised to have a yearly eye examination with an 
optometrist who will monitor the condition, but is often unable to provide physical or 
psychological help without referral 13. 
Whilst specialists agree that smoking has an impact on AMD and that cessation will halt 
progression of the disease 119, there are conflicting research findings and therefore conflicting 
information provided by eye care practitioners regarding the impact of nutrition on AMD 105. 
The Age-Related Eye Disease Study reported that nutritional supplementation in people with 
intermediate AMD can reduce their risk of progression to advanced AMD by 25 % 12. While the 
AREDS was in progress, evidence emerged to suggest that the dietary nutrients lutein and 
zeaxanthin may be more effective than other nutrients in reducing AMD risk or progression due 
to their antioxidant and photo protective properties 144. The plausibility for this hypothesis is due 
to the high concentration of lutein, zeaxanthin, and a related compound meso-zeaxanthin, in 
the macula, particularly in the fovea, which form the MP  145. The protective properties of the 
MP are now well established and include the ability to interact with free radicals, prevent lipid 
peroxidation and filter out incoming, high energy blue light 146 39 147 5. Some studies also show a 
link between increased intake of lutein and zeaxanthin, and higher MP levels  89 87 148. 
Supplementation studies report increases in macular pigment of between 21 and 57% following 
lutein and zeaxanthin supplementation in people with healthy eyes. Increases in macular 
pigment of between 24% and 36% have been reported in people with retinal disease. One 
randomized controlled trial reported an improvement in several measures of visual function in a 
group of veterans who supplemented with 10 mg of lutein for one year 68 113.  
A recent study by Loughman et al. 149 suggests that supplementation with all three macular 
carotenoids may offer advantages both in terms of macular pigment optical density (MPOD) 
response and visual performance enhancement. The AREDS team recently released the 
results for their follow-up study (AREDS 2) which encompassed lutein and zeaxanthin to the 
original AREDS supplement formulation 150. The study found that adding lutein and zeaxanthin 
did not further reduce the risk of progression to advanced AMD. However, investigators report 
that lutein and zeaxanthin may be useful substitutes for beta-carotene in the original 
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formulation 72. Despite the conflicts, overall, the research evidence suggests that high macular 
pigment levels could reduce risk for onset or progression of AMD. 
Because carotenoids are not synthesised by the human body, they have to be acquired either 
in the diet or by supplementation. Research shows that the highest mole percentage of lutein 
and zeaxanthin are in egg yolk, maize (corn), spinach, collard greens (like cabbage) and kale 
151 152. Maize has been identified as the vegetable with the highest quantity of lutein and orange 
pepper was the vegetable with the highest amount of zeaxanthin. Amounts of lutein and 
zeaxanthin are also reported to be present in kiwi fruit, grapes, orange juice, courgettes, and 
different kinds of squash. Predominantly, leafy green vegetables have a highest content of 
lutein and zeaxanthin. 
Despite the body of evidence in support of a role for dietary modification or nutritional 
supplementation in reducing risk of progression of AMD, neither patients nor practitioners are 
clear about what kind of supplements to take, or how foods should be prepared and consumed 
in order to maximise absorption of useful nutrients 105. To add to the confusion, there are many 
nutritional supplements aimed at those with AMD currently on the market, with varying degrees 
of dosage and some without any research basis at all 153 149. Many do not contain the AREDS 
formulation. Research has shown that given more choices, patients are much more likely to be 
overwhelmed 105. Supplements are not regulated in the same manner as medication in the UK 
106 and it is very difficult to identify which supplements are likely to be of any benefit.  
Since many local authorities do not have standardised rehabilitation services in place 154, some 
patients have been turning to non-professional charities, such as The Macular Society, to 
acquire information and support. The Macular Society is the only national UK charity that is 
dedicated solely to helping those with diseases of the macula. The Macular Society provide 
impartial information and practical support for visually impaired people, their families and 
carers. They also “provide information for health professionals, campaign for better services, 
sponsor research and raise awareness of macular degeneration and preventative measures” 
139.  
The objectives of this study were firstly to find out who pursues the help of a non-professional 
charity, and secondly, to determine the beliefs and understanding that these AMD patients 
have about the impact of nutrition on the condition, and where patients have obtained 
information about nutrition. 
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4.2 Methods 
Participants 
A total of 158 participants were recruited between January 2012 and March 2012. Recruitment 
was via the Macular Society helpline volunteer worker. Patients aged over 55 years of age who 
contacted the Macular Society helpline between January 2012 and March 2012 were asked if 
they would like to take part in a telephone survey (once they had received all the assistance 
they needed from the Macular Society). Pre-requisites for potential participants were that they 
should be aged over 55 years and have been diagnosed with a form of AMD; exclusion criteria 
were the inability to hear and reply to questions in English over the telephone.  No attempt was 
made to define and categorise the amount of visual loss the participant had, as the objective 
was to assess typical patients seeking the Macular Society services.  
Ethics 
The procedures followed were in accordance with the ethical standards of the Aston University 
Ethics Committee on human experimentation that conform to the Declaration of Helsinki 1975, 
revised Hong Kong 1989. 
 
Survey Design 
 
A literature review of research on AMD patient’s perceptions of nutrition and AMD was 
conducted of the following databases: Web of Knowledge, The Cochrane Library, Optics 
Infobase, Ovid Journals, PsycArticles, PubMed, NCBI databases and Wiley Online Library. The 
following key-terms were used: “Age-related macular degeneration”, “Nutrition”, “Survey”, 
“Attitudes”, “Behaviours” and “Diet”. This review did not identify any existing measure of 
patient’s perceptions of nutrition, but found most surveys looked at nutritional behaviours 155. 
As a result, a 36 question cross sectional survey was designed to explore nutritional habits, 
supplement usage, physical abilities in food preparation and cooking, and sources of 
knowledge in order to ascertain the beliefs AMD patients have, and compare their beliefs with 
their behaviours. Because the survey was exploratory, it was designed mainly with open ended 
questions in order to ensure responses reflected participants’ true beliefs. In addition, some 
closed ended questions were included with response scales to grade participants’ feelings.  
The survey was then piloted on eight AMD participants, from the Macular Society, to test the 
reliability, comprehensibility, and understanding among an informed population. This ‘face 
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validity’ (i.e., does the questionnaire appear correct at face value) was the only means of 
validation that it was possible to perform, due to a lack of other instruments to compare the 
results with. Initially, the eight patients completed the survey via a telephone interview.  Three 
weeks later, the patients attended a focus group that had two parts: firstly, the participants 
completed the survey once more. Next, the participants had a recorded, guided informal 
discussion structured by a moderator – the volunteers were asked to comment on how easy 
the questions were to understand and opinions on the topics covered. The results of this 
meeting were analysed to further refine the survey, which was altered accordingly (e.g. the 
terms ‘wet’ and ‘dry were employed to coincide with many patient’s understanding of AMD 
classification, extra options were added to some questions, some questions were removed or 
re-worded and additional instructions were added). The final survey (see Appendix 7.) was 
then administered to the cohort. 
The initial questions covered demographic topics such as gender, age, employment, social 
history, type and length of time with AMD and visual impairment registration. Opinions on diet 
and supplementation were obtained, with particular interest in whether participants could 
identify lutein and zeaxanthin rich foods (e.g. kale) amongst other vegetables. Participants 
were also asked where they had acquired any information about the condition from (for 
instance, an ophthalmologist, optician, Macular Society). The questions subsequently focused 
on perceived state of vision and health, and ability to perform preparation and cooking of food. 
Participants also provided a food diary for 24 hours, as studies have shown there is less 
measurement error in food recording than in food frequency questionnaires, and the ability to 
study associations between diet and chronic diseases is slightly easier with food diaries 74 136. 
The results of the questions relating to cooking abilities, perceived health and vision states and 
the food diary is beyond the scope of this paper and will be discussed in a future paper. 
Procedure 
 
If a patient agreed to take part, their name and contact details were taken by the helpline 
worker.  The potential participants were read an information factsheet informing them what the 
survey would involve, how long it would take and how the information would be stored. If the 
patient decided to participate, an oral informed consent was obtained over the telephone and 
they were advised that they could withdraw at any time. Usually an appointment was 
scheduled for a future telephone interview or the interview began immediately if the patient 
wished.  
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They were then contacted at a convenient time by one of four Macular Society employees who 
administered the telephone interview and filled in the survey online at the same time (Bristol 
Online Surveys). The telephone interview lasted approximately 25 minutes, and was not 
recorded. Each volunteer was trained (by RS) to ask the questions only, without bias, and if the 
participant had any questions regarding the survey, they were given the author’s contact 
details, although no participant made any contact. 
 
Data Analysis 
The results were analysed to find the mean, median and standard deviation using the software 
Microsoft Excel. Data from Excel was then used to create charts, and used in statistical 
software IBM SPSS (version 20) to draw comparisons between supplement cost and usage 
using chi-square statistics. Qualitative data was grouped into categories and general themes 
were extracted to then use in SPSS. 
 
4.3 Results 
Sample Characteristics 
Table 4.1 shows the demographic characteristics of the sample. The gender distribution of the 
158 participants showed that there were significantly more females (61%) in the sample than 
males (39%) (Chi-square p= 0.05). The participants ranged in age from 56 to 95 years; the 
median age was 80 years. There was a nearly even split between ‘wet’ (47%) and ‘dry’ types of 
AMD (49%), with a small percentage of participants who were unsure of their AMD 
classification. The median duration of having the condition was 5 years, ranging from 1 to 25 
years. The majority of participants lived in their own home – either rented, mortgaged or owned 
outright, and participants mainly either lived with their partner or alone. The majority of 
participants were not registered partially sighted or blind, although there was a trend for those 
participants that had the condition for longer to be on a register ( Kruskal Wallis H p= 0.09). 
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Characteristic                                                                         Percentage of Participants 
Living Arrangements         Own home                                                   88% 
                                              With family/friends                                    3% 
                                              Sheltered accommodation                        7% 
                                              Other                                                             2% 
With                                     Partner                                                          50% 
                                              Alone                                                             47% 
                                              Other family members                                4% 
Registration                        Blind                                                               16% 
                                              Partially sighted                                           21% 
                                              None                                                              63% 
Supplement price               No cost                                                          17% 
   willing to pay                   £1-5                                                                10% 
                                              £6-10                                                              21% 
                                              £11-15                                                            24% 
                                              £16-20                                                           12% 
                                              £20+                                                               17% 
 
Table 4.1. Demographic characteristics of participants. 
Patient’s perceptions of diet and eye health 
When asked their overall opinions on diet and health, 87% of participants believe that diet 
affects general health, and 68% believe that diet affects eye health.  
Figure 4.1 shows the beliefs that participants held about specific foods:- leafy green 
vegetables, which are good sources of lutein and zeaxanthin, other fruit and vegetables, and 
dairy products . Participants were asked if they believed each food was beneficial for eye 
health, and if they answered ‘Yes’, they were asked why they thought so. 
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Figure 4.1. Participant’s beliefs about the eye health benefits of several foods. ‘Yes’ indicates the participant 
believed the food was beneficial, ‘No’ indicates the participant did not believe that the food was beneficial, and ‘DK’ 
indicates the participant didn’t know. 
As shown, the majority of participants were accurate in their perceptions of the food which 
would be beneficial for eye health. Leafy green vegetables such as spinach, cabbage and kale 
were identified as being beneficial by over 80% of participants. Ice-cream was identified as not 
beneficial for eye health by 72% of participants. For mango, bilberries and peppers, 25% or 
more participants answered ‘don’t know’, and responses were more mixed. Males responded 
with ‘Don’t know’ on average 10% more than females. 
When asked why they felt a particular food was valuable for eye health, the majority of 
participants (81%) struggled to verbalise why they held that belief. Of those that did express 
the reasoning behind their beliefs, the majority of the responses had nothing to do with 
nutrients. Only 2% of those that felt spinach and kale are beneficial for eye health knew that 
they contain lutein. Some participants responded that leafy green vegetables were known to be 
good for eyes (spinach 5%, kale 3%, and cabbage, 6%), while others merely responded that 
coloured foods were good for eyes (carrots 2%, peppers 5%, and mango 1%). Some 
participants (1%) responded that spinach and kale contained iron, which was why they felt it 
would be beneficial for eye health. One percent of participants felt that carrots were beneficial 
because they contained carotene, and that peppers were beneficial because they contained 
vitamin C. Participants also included the following reasons for carrots: “They help you see in 
the dark” (6%), “war propaganda” (6%), “We were told to eat them by parents” (6%). One 
percent of participants responded that their optician had told them that mango was good for 
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eye health. Participants also responded that they had “read it was beneficial somewhere” for 
some foods (peppers 1%, bilberries 5%). 
No participant felt that ice-cream was beneficial for eye health. Of the participants that felt that 
cheese was beneficial for eye health (18%), none could give a reason why.  
Nutritional supplementation 
The participants were asked who they had discussed nutritional supplementation with - 30% of 
the participants had discussed it with their ophthalmologist, 15% with their optometrist and 8% 
had consulted their GP. 
Participants were asked if they currently took a nutritional supplement(s). Of those that 
responded ‘yes’ (79%; of males and 79% of females), the majority (60%) took the supplement 
once per day. The most popular brand of ocular supplement used was I-caps by Alcon (24%), 
followed by PreserVision by Bausch&Lomb (19%), Ocuvite by Bausch&Lomb (14%), Viteyes 
(14%), Macushield by Macuvision (11%), Retinex by Healthspan (8%), Visionace by Vitabiotics 
(5%), and Vitalux by Novartis (3%). Some patients took more than one brand with a variety of 
dosing methods. 
                                       
Figure 4.2 . Reasons for not taking Nutritional Supplements. 
Those that responded that they did not take a nutritional supplement (33 participants - 21% 
male and 21% female) were asked to describe these reasons as shown in Figure 3.2. The 
majority felt that they were not sure of the effectiveness of supplementation, but many listed an 
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‘other’ reason for not taking supplements (but did not provide an explanation for what that 
reason might be). 
The participants were asked how much money would they be willing to spend on a supplement 
(per month or 30 day’s supply) if they had proof of its worth. The results are shown in Table 1. 
The supplement usage data were cross-tabulated with the amount of money participants were 
willing to spend on a monthly supplement, using chi-square statistics. The results show a 
significant association between those that do take supplements being willing to spend more 
money on supplements, and those that do not take supplements are willing to spend less 
money on supplementation (p≤0.000). Of the participants that did not take supplements, 67% 
were not willing to spend any money on supplementation even if they had proof of its worth. 
 
Patient information 
Figure 4.3 displays the opinions that the participants held about AMD and living with the 
condition. Over half the participants (51%) believed that AMD patients do not receive enough 
information about nutrition and lifestyle choices; an additional 12% strongly believed this. The 
participants were asked where they had received information on AMD from – (they were 
allowed to pick more than one option): 40% of participants had received information from their 
ophthalmologist. As expected, 92% had received information from organisations such as The 
Macular Society.  Just over half of the cohort believed that AMD could be prevented by lifestyle 
choices such as nutrition. 
                               
Figure 4.3. Knowledge of AMD 
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4.4 Discussion  
The demographic data has shown three interesting findings: 
Firstly, research has shown that females (especially in this age-group) are more likely to ask 
for and utilise health care services 156 157, so it could be speculated that more females than 
males seek out the services of the Macular Society. 
Secondly, only 37% of the participants were registered on a visual impairment register, despite 
47% of participants having ‘wet’ AMD (although this was self-reporting and the severity was not 
assessed). The Royal National Institute of the Blind (RNIB)’s survey into certification and 
registration in 2011 158, shows a steady decline in the number of registrations per year despite 
the fact that the prevalence of visual impairment is increasing 16 5. They attribute this decrease 
in registration not to a lack of interest in registration by the patient, but rather to the length of 
time it takes to complete the Certificate of Visual Impairment (CVI) by the professionals 
involved.   
Finally, nearly half the participants lived alone – this can have a huge impact on their quality of 
life. One study 159 has shown that 63% of all blind and partially sighted people live alone – a 
higher figure than the ‘normal’ sighted elderly population. It would have been useful to find out 
if participants had a mobility issue, as this may have affected why the participants had chosen 
to seek the Macular Society’s services – a helpline is easier to access than physically going to 
see an ophthalmologist or optometrist for advice, and this could explain why patients did not 
report sourcing their information from an ophthalmologist or optometrist. 
 
The cohort was a group of highly motivated individuals who had taken the initiative to contact 
the Macular Society but still felt that they needed more advice, particularly relating to nutrition. 
Although some of the participants needed to rely on others for support and felt they had 
considerable visual impairment, the desire to remain independent and improve their vision is 
evidenced through seeking the services of the Macular Society, and using other healthcare 
professionals such as dieticians and specialist doctors. 
This sample may not represent all patients seeking services from organisations like the 
Macular Society. Access to other organisations would provide a more rounded view. It would 
be important to find out the opinions of those with AMD who have not sought support from non-
professional organisations, and this will form the next step to the overall project.   
Patient’s perceptions 
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This study provides a clear picture of the perceptions of diet and eye health among a sample of 
AMD patients. The majority of participants agreed that specific foods can affect general health, 
and participants also agreed that specific foods affect eye health. The results of the specific 
food questions show that the majority of participants felt that the vegetables and fruit were 
beneficial for eye health, and these perceptions were generally accurate. However, apart from 
a few individuals who mentioned specific nutrients in regard to specific foods (e.g., lutein in 
kale), most participants were not able to identify why these foods helped promote eye health, 
or gave vague responses such as “I read it somewhere”. This suggests that participants, who 
would be expected to be well-informed, were not clear about the links between diet and eye 
health.  
Information 
The majority of participants reported that they did not have enough information on nutrition and 
its relationship to AMD. As expected, all participants reported that they had received 
information from organisations such as the Macular Society. In contrast, not all the participants 
reported getting information from their ophthalmologist, which is consistent with previous 
studies 160 161. The data reported here shows that there are clear gaps in the knowledge 
patients have of AMD risk factors 162. A lack of information might also explain why four percent 
of the participants were not sure what type of AMD they were suffering from. Patients appear to 
be actively seeking advice but not all are getting it from sources such as ophthalmologists or 
optometrists. These findings are similar to results from the Royal College of Ophthalmologists 
audit of AMD services in March 2009 163 which found that there was an insufficiency of 
resources to deliver adequate AMD Services. Evan and Lawrenson’s survey (2012) of eye 
professionals 164 showed that although over 60% of respondents reported that they frequently 
provide dietary and supplement advice to patients with established AMD and those at risk of 
AMD, the nutritional advice given only consisted of leafy green vegetables and oily fish 
recommendations, and type of supplement recommended did not comply with current best 
research evidence, based on the findings of the Age-Related Eye Disease Study (AREDS). 
Only one in three optometrists regularly assessed smoking status and advised on smoking 
cessation 164. The results reported in the present study reinforce those of the survey and the 
Royal College of Ophthalmologists, and provide further evidence that greater support and 
information provision for AMD patients is needed. 
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Nutritional supplementation 
Over 75% of participants reported taking a nutritional supplement (mainly on a once-per-day 
basis) – this is a larger number than other studies into supplement usage have found 165 74 130 . 
The majority of patients that were taking ocular supplements were not taking an exact AREDS 
formulation, and were taking an incorrect dosage or combining it with one or two other brands 
with the same formulation (maybe believing that more might be better). This pattern of 
supplementation could reflect a lack of information from healthcare professionals, with only a 
third of patients having discussed nutritional supplementation with their ophthalmologist, while 
some participants had not discussed supplementation with anyone at all. Those participants in 
our study that reported not taking any supplements listed the primary reason as not believing 
they would be effective, and hence were unwilling to spend much money on an unproven 
supplement. The high number of nutritional supplements marketed towards people with AMD 
makes it difficult for both patients and health professionals to navigate this issue for the 
prevention or treatment of the condition 105.  
There are currently no clear supplement guidelines for health professionals to use; The College 
of Optometrists advises that patients should eat a healthy diet and to stop smoking, adding that 
there “is no definitive scientific evidence of the effectiveness of nutritional supplements”, but 
patients should speak to their optometrist for supplement advice 166. Some institutions might 
have been waiting for the results of AREDS 2, but since the AREDS 2 results have been 
released, there is a need for unified guidelines for all health professionals. When asked how 
much participants would be willing to pay for an effective nutritional supplement, only one 
quarter responded that they would pay more than £11 per month, and there was a significant 
correlation between those who did not take supplements and those that were not willing to 
spend any money on supplements.  
In conclusion 
The development of this survey has created a new measure that can be used again. The study 
has identified that AMD patients have a definite lack of information and understanding of the 
link between AMD and nutrition, and this needs to be corrected. The results of this study will 
inform the design of more effective education and dissemination methods, and help to outline 
guidelines for health professionals. 
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Chapter Five 
 
Dietary analysis and nutritional behaviour in people with and without age-related 
macular disease 
A paper published in Clinical Nutrition E-SPEN 167 See Appendix 16 for a copy. 
The previous chapter showed the demographic results from the survey. This chapter will 
present the remaining data and results yielded from the survey.  To draw comparisons with 
people without AMD in this age group, a control group of 50 non-AMD participants were 
recruited from a group of independent optometric practices across the UK, as well as from 
Aston University Clinics. Six optometric practices (apart from Aston Clinics) from a variety of 
areas agreed to take part in recruitment. They were provided with posters advertising the 
project, information sheets for the patients, and consent forms. If a patient agreed to take part, 
their contact details were recorded and emailed to the researcher, together with a convenient 
time, and the questionnaire would be administered. All patients, who volunteered, took part 
with no drop-outs. For the age-matched control cohort, the only inclusion criteria were that 
participants should also be aged over 55, and the exclusion criteria was that participants 
should have a healthy retina. 
5.1 Introduction 
Age-related macular degeneration (AMD) can result in loss of central vision, and is the leading 
cause of visual impairment in adults (> 50 years) in the UK 5. In 2012, the prevalence of AMD 
was predicted to increase significantly by 2020 due to aging of the population 15, 16.  
The Age-Related Eye Disease Study (AREDS) 12 reported that taking a supplement containing 
vitamins E and C, beta-carotene and zinc reduced risk of progression of the disease by 25%. 
Since then, the carotenoids lutein (L), zeaxanthin (Z) have been identified as nutrients that can 
provide a protective role in the progression of AMD due to their antioxidant and photo 
protective properties 168. Collectively, L and Z form the macular pigment which interacts with 
free radicals and reactive oxygen species, prevent lipid peroxidation and filter out high energy 
blue light 147. Carotenoids are not produced by the body and must be obtained via the diet. 
Recently, the AREDS II 150  found that people who took a supplement containing L and Z 
instead of beta-carotene had their risk of progression reduced by a further 18% compared with 
the original AREDS formulation 150.  
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Despite results from AREDS studies, there remains confusion among patients and practitioners 
in what supplements to take, and what foods should be consumed in order to maximise 
absorption of useful nutrients 105. Many patients turn to other organisations for clarity of 
information such as the Macular Society – the UK charity that is devoted to helping those with 
diseases of the macula. Following the results of AREDS II, the Macular Society have 
advocated the use of the AREDS II formulation, where appropriate, and eating vegetables that 
are L&Z rich. The highest mole percentage of L&Z has been found to be in egg yolk, maize 
(corn), spinach, collard greens and kale 151.  
Patients who have sought the help of the Macular Society could be considered an ‘informed’ 
population as they have information available to them in the form of monthly magazines, 
written material, a helpline and the Society’s website. However, in a recent study, not all were 
taking a nutritional supplement and many of those that did take a supplement were not taking a 
clinically proven formulation or dosage 140. We therefore sought to investigate this population’s 
dietary intake of L and Z, and compare it to a cohort of age matched patients without the 
condition. As dietary patterns are multi-factorial, any other contributing factors will be 
investigated. 
The objectives of this study were to analyse the nutrient intake of a group of AMD patients and 
a group of non-AMD patients, and to determine their ability to prepare and cook healthy food. 
 
5.2 Materials and Methods 
Using data from a previous study by Bartlett et al, it was calculated that for an average effect 
size (Cohen’s d) of 0.4, a minimum sample size of between 15 and 94 would be appropriate for 
each cohort 74. 
AMD Participants 
A total of 158 participants with AMD were recruited between January 2012 and March 2012. 
Recruitment was via the Macular Society helpline. Individuals who contacted the Macular 
Society helpline between January 2012 and March 2012 were asked if they would like to take 
part in a telephone survey. Inclusion criteria for potential participants were that they should be 
aged over 55 years and have been diagnosed with any form of AMD.  
Non-AMD Participants 
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A group of 50 participants without AMD were recruited between August 2013 and December 
2013. Recruitment was via seven optometric practices around the UK and Aston University 
patient clinics. The study was advertised on posters, and individuals who took part volunteered 
of their own accord and provided contact details and a convenient time to be telephoned. The 
only inclusion criterion was that they should be aged over 55 years – individuals with co-
morbidities and other visual problems were not excluded. 
Survey Design 
A 36 question cross-sectional survey was designed to explore nutritional habits, supplement 
usage, physical abilities in food preparation and cooking, and sources of knowledge in order to 
ascertain the beliefs participants have, and compare their beliefs with their behaviours. The 
initial questions covered demographic topics, occupations and participants’ perceptions of the 
link between nutrition and AMD. The terms ‘wet’ and ‘dry were employed to coincide with many 
patient’s understanding of AMD classifications. After a section on nutritional supplement use, 
the questions subsequently focused on perceived state of vision and health, and ability to 
perform preparation and cooking of food. Participants also provided a 24 hour food recall. This 
was done as part of the telephone survey so the patient had little time to prepare and would be 
more likely to report honestly. Participants were asked to quantify the amounts of food eaten by 
using the Zimbabwe Hand method 169 – participants used their palms or fingers to estimate the 
portion size of various foods. The survey was then piloted, refined and administered to the 
cohort. Full details of the piloting process and survey design and are reported in Chapters 
Three and Four 140. The focus of this report  is on the dietary aspects of this survey and 
cooking abilities, hence, not all the results of the 36 questions are covered here  (10). The 
participants’ occupations were divided into 10 major groups using the International Standard 
Classification of Occupations (ISCO) version 08.  
The 24 hour food diary data was analysed using nutritional software A La Calc (Red Hot Rails 
LLP, Doncaster, UK.), where each participant’s daily food was analysed for numerous 
nutrients, calorie values and other constituents using the USDA (United States Department of 
Agriculture) SR25 food database (http://ndb.nal.usda.gov/).  
Procedure 
If an AMD patient decided to participate, oral informed consent was obtained over the 
telephone and they were advised that they could withdraw at any time. An appointment was 
scheduled for a future telephone interview or the interview began immediately if the AMD 
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patient agreed. Non-AMD patients who provided their contact details were telephoned at a time 
that they specified was convenient, and the interview usually began immediately. The survey 
typically lasted 25 minutes and was administered either by one of four Macular Society 
employees who were trained by RS or by RS. All responses were recorded using Bristol Online 
Survey software (University of Bristol, Bristol, UK) 140. 
 
 
Data and Statistical Analysis 
Descriptive analyses were performed using the software Microsoft Excel. Data was then 
analysed in statistical software IBM SPSS version 20 (IBM UK Ltd, Portsmouth, Hampshire) to 
draw comparisons between results using parametric and non-parametric tests as not all the 
data was normally distributed.  
 
Ethics 
This study was conducted according to the guidelines laid in the Declaration of Helsinki and all 
procedures involving human subjects were approved by the Aston University Ethics 
Committee. Verbal informed consent was obtained from all subjects and formally recorded. 
 
5.3 Results 
Sample Characteristics: AMD Participants 
Table 4.1 shows some of the demographic characteristics of the sample; AMD participants 
were aged 56-95 (mean 79 ± sd 7.8 years). Of the AMD cohort, 61% were female, with both 
genders showing similar age distributions. The prevalence of ‘wet’ and ‘dry’ types of AMD was 
almost equal. The mean duration of the disease was 6.08 ± 4.7 years (median 5 years, range 1 
to 25 years). The majority of AMD participants (63%) were not registered sight impaired 
(partially sighted) or severely sight impaired (blind). There was a trend for participants who 
were on a visual impairment register to have had AMD for a longer time period (Mann-Whitney 
U = 977.5, p = 0.07). No AMD participant felt that their vision was “extremely good” on the day 
of the interview - 57% of participants felt their vision was  “poor” or “extremely poor” and only 
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7% felt their vision was “good”.  These results contrast with perceptions of general health in 
that only 21% of AMD participants felt their general health was poor, and 41% felt their health 
was good. For these reasons, the sample was considered to be a healthy population whose 
only health issue was their visual status. 
Sample Characteristics: Non-AMD Participants 
Non-AMD participants were aged 55-89 (mean 67 ± 8.0 years).  Of the non-AMD group, 70% 
were female, with both genders also showing similar age distributions. On the day of the 
interview, the majority of the non-AMD participants felt their vision was either “extremely good” 
(14%), or “good” (46%). No participant felt their vision was “extremely poor”. 70% of the non-
AMD participants reported they felt their general health was either “good” or “extremely good”. 
This cohort can also be considered a healthy population 
 
The cohorts have some similarities in the reported characteristics. A high percentage of 
participants in both cohorts lived in their own home, and only a few lived in sheltered 
accommodation. However, half of the AMD participants lived with their partner, with just under 
half living alone, but in comparison, fewer of the participants without AMD lived alone and more 
lived with their partner. Also, more participants in the AMD cohort answered that they felt their 
general health was ‘poor’ compared to the participants without AMD. Unsurprisingly, the largest 
difference between the cohorts was the self-reported visual ability, with many of the AMD 
cohort reporting ‘poor’ vision. 
Because the non-AMD participants were generally younger than the AMD group (mean 67 
years, versus 79 years), a sub-group of age-matched AMD participants (49 participants in total) 
were used to compare data with the non-AMD cohort. 
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Characteristic Characteristic Percentage of AMD 
participants 
Percentage of non-AMD 
participants 
Living 
Arrangements 
Own home 88% 96% 
With family/friends 3% 0 
Sheltered 
accommodation 
7% 4% 
Other 2% 0 
With Partner 50% 66% 
Alone 46% 30% 
Other family members 4% 4% 
Registration Blind 16% Not applicable 
Partially sighted 21% Not applicable 
None 63% Not applicable 
General Health Extremely good 7% 22% 
Good 41% 48% 
Satisfactory 19% 20% 
Poor 21% 8% 
Extremely poor 3% 2% 
Vision Extremely good 1% 14% 
Good 7% 46% 
Satisfactory 35% 32% 
Poor 42% 8% 
Extremely poor 15% 0 
Table 4.1 Selected demographic characteristics of both AMD and non-AMD participants. 
 
 Dietary Analysis  
Table 4.2 displays the results of the 24 hour food diary data for the AMD and non-AMD 
participants. The mean amounts of certain nutrients or energy consumed for females and 
males in the cohort are displayed, together with the recommended dietary allowances (RDA) 
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for each constituent, as recommended mainly by the UK Food Standards Agency (FSA) for 
those aged over 50 years. Table 4.2 shows that in the AMD cohort, both men and women fail 
to meet the daily RDA for many nutrients such as fibre, calcium, vitamin E, folic acid and 
carbohydrates. Of particular interest is the finding that in the AMD cohort, both genders are 
failing to reach the 10mg amount of daily L&Z recommended by the Macular Society. Although 
not statistically significant, there was a trend that those who were on a sight impairment 
register consumed more L&Z than those AMD participants who were not on any type of 
register (Kruskal Wallis H = 4.951, p=0.08), and females appeared to consume more L&Z than 
males in the AMD group. One male participant’s diet data was excluded as he had unusually 
consumed a large amount of kale, and the results were slightly skewed (the average with this 
participant included is listed in the table in parenthesis). L&Z consumption was compared with 
the type of AMD the participants had (dry vs. wet), occupation, and the number of years they 
had the condition, but no trends were apparent. The amount of L&Z was also low in both 
genders of the non-AMD group. 
 
The largest difference between the two cohorts was the number of calories consumed. The 
number of calories consumed by the AMD cohort was significantly lower than the daily RDA for 
each gender in this age group. This difference in calorie intake between the AMD and non-
AMD cohorts is statistically significant (independent t-test F= 19.2, p = 0.00). In contrast, 
females in the non-AMD cohort surpassed the calorific RDA, and males in the non-AMD cohort 
also consumed nearer to the RDA. Other nutrient differences between the cohorts included 
carbohydrates, protein, fat, fibre and calcium - participants with AMD consumed less compared 
to participants without AMD, but not with statistical significance. 
 
There were no significant gender differences found with respect to the amount of L&Z 
consumed, the number of calories consumed, the ability to cook a hot meal or supplement use 
in either cohort (Kruskal-Wallis and Mann-Whitney U non-parametric tests). Calorie intake was 
also compared with the age of participants and living arrangements in each cohort, but no 
significant results were found. Employment between the two groups were also analysed, but 
the differences between them were not found to be statistically significant (Independent t-test).  
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  AMD 
Female 
(Mean) 
(n = 96) 
AMD 
Male 
(Mean) 
(n = 62) 
Non-AMD 
Female 
(Mean) 
(n = 35) 
Non-AMD 
Male 
(Mean) 
(n = 15) 
Females 
RDA 
>50 yrs 
Males 
RDA 
>50 yrs 
Energy Kcal 1524 1507 2251 2074 1800 2200 
Energy kJ 6375 6076 9417 8674 7200 8700 
Lutein and Zeaxanthin Mg 1.7 1.2 1.6 1.3 10 10 
Protein G 61.8 64.1 94.5 82.0 45 55 
Fat G 65.4 60.5 86.8 82.3 70 95 
of which saturates G 27.7 25.4 30.8 30.6 20 30 
Carbohydrates G 177.2 169.0 278.6 257.5 230 300 
of which sugars G 50.5 44.7 90.9 61.8 90 120 
Fibre G 16.7 16.1 24.6 22.4 24 24 
Cholesterol Mg 252.9 300.8 354.6 408.0 300 300 
Calcium Mg 682.9 644.0 948.0 980.5 800 800 
Iron Mg 14.5 16.1 22.4 20.4 10 10 
Retinol mg 0.4 0.4 0.4 0.6   
Carotene mg 0.4 0.7 0 0   
Alpha Carotene mg 1.1 1.4 1.1 1.3   
Beta Carotene mg 3.5 4.1 3.8 4.0   
Vitamin D μg 2.6 13.5 2.4 3.5 5 5 
Vitamin E Mg 5.0 5.1 7.6 6.0 10 10 
Vitamin C Mg 53.1 62.1 85.6 82.3 40 40 
Folic Acid μg 167.8 252.2 214.4 185.7 400 400 
 
Table 4.2. Mean consumption of various nutrients for males and females in both the AMD cohort and the non-AMD 
cohort, with the corresponding RDA for people aged over 50 years. Kcal refers to Kilocalories, kJ Refers to 
Kilojoules, Mg refers to milligrams, μg refers to micrograms and G refers to grams. Spaces indicate there are no 
RDAs for that nutrient. 
Many participants in both cohorts ate only a small variety of vegetables: 140 participants listed 
carrots, 116 listed peas, 115 listed broccoli. Other popular choices were cabbage (90 
participants) and spinach (49 participants). Interestingly only 25 AMD participants ate kale 
which is considered to be one of the most lutein rich vegetables. No participant in the non-AMD 
cohort ate kale at all. Interestingly, 85% of AMD participants ate mostly raw vegetables on the 
day of the interview, but 62% of non-AMD participants ate cooked vegetables on the day of the 
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interview. On the interview day, 10% of the AMD participants and 8% of the non-AMD 
participants did not eat any vegetables at all. 
 
Food preparation and cooking  
The majority of participants reported they could prepare (65% AMD, 74% non-AMD) and cook 
(68% AMD, 72% non-AMD) their own food, with participants citing that their partner prepared 
(24% in both cohorts)/ cooked (26% in both cohorts) food for them. When asked if participants 
were able to cook a hot meal by themselves if they had to, 81% of AMD and 96% of non-AMD 
participants reported that they could. Participants with AMD who were not able to cook a hot 
meal (n=29) consumed significantly less L&Z (0.85 ± 0.72 mg) than those who were able to 
cook a hot meal (1.68 ± 2.35 mg) (Mann-Whitney U = 1240.5, p = 0.007). Figure 4.1 shows 
that many AMD participants feel that they are able to cook and prepare food and that there are 
no barriers to changing their diets other than that they do not wish to. 
             
Figure 4.1. AMD participants perceived barriers to cooking food, preparing food and changing diet. 
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Fifty six percent of AMD and 86% non-AMD participants were self-sufficient in carrying out their 
own food shopping; whilst for 28% of AMD respondents and 14% of non-AMD respondents, a 
family member did this task for them. Less AMD participants were therefore self-sufficient than 
non-AMD participants, and this will impact on food choices and food consumption. The 
remainder of the respondents used other methods to obtain their food needs such as Meals-
On-Wheels (Social Services) or friends. Participants were asked to identify all of the sources 
from which they acquire food. Supermarkets were reported by 135 participants, and 36 also 
reported they purchased food from a local shop. Some 12 participants harvest their own food. 
Only four AMD participants relied upon delivered ready meals such as Meals-On-Wheels. The 
main reason for selecting the type of food appears to be preference (44% AMD, 46% non-
AMD), secondary to the effect on health (34% both cohorts).  Only 4% of the AMD group, and 
8% of the non-AMD group listed ‘habit’ as an influencing factor.  
Age-matched comparisons between AMD and non-AMD participants 
Because the AMD participants were older than the non-AMD participants, it was appropriate to 
compare the non-AMD group with an age-matched sub-group of AMD participants (n=49). The 
mean age of the sub-group was 68.8 years, and this did not differ significantly from the AMD 
group (Spearman 0.063, p=0.662). Eighty-six percent of the group were female. There were a 
higher percentage of participants in the sub-group that felt that their health was ‘extremely 
good’ (16%) and this is close to the percentage of non-AMD participants ( 22%). 
Table 4 shows the mean diet results of the aged-matched sub-group of AMD participants, with 
the overall mean diet results from the non-AMD cohort alongside. In this comparison, the 
difference between the AMD participants and the non-AMD participants is still significant; the 
non-AMD group consumed more of each nutrient analysed than the AMD age-matched sub-
group. The average energy intake for AMD participants was 1502 kilocalories compared to 
2198 kilocalories consumed by non-AMD participants (paired t-test p<0.001).  However, the 
exception to this rule was the L&Z intake, where the average consumption was not statistically 
significantly different (1.8 mg in the AMD group versus 1.5 mg in the non-AMD group, p= 0.97). 
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 AMD Sub-Group Mean 
(n=49) 
Non-AMD Mean 
(n=50) 
Age (years) 68.8 67.5 
Energy (Kcal) 1503 2198 
L&Z (mg) 1.8 1.5 
Protein (G) 60.9 90.8 
Fat (G) 61.9 85.5 
Carbohydrates (G) 166.9 272.3 
Fibre (G) 15.6 24 
Vitamin E (mg) 5.3 7.1 
Beta Carotene (µg) 3.2 3.9 
Vitamin C (mg) 56.9 84.6 
Folic Acid (mg) 0.2 0.21 
Calcium (mg) 596.1 887.8 
 
Table 4. Mean age and energy/ nutrient consumption for the selected AMD subgroup and the non-AMD group. 
Please note: Kcal refers to Kilocalories, kJ Refers to Kilojoules, µg refers to micrograms, Mg refers to miligrams, and 
G refers to grams. 
 
5.4 Discussion  
This sample of people with AMD consumed an average of 1.4 mg of L&Z per day. This is 
below the 10mg daily amount considered to be required for augmentation of macular pigment 
85. In addition, they were not attaining the RDA of other nutrients such as vitamin E and 
calcium. Those that were not able to cook a hot meal by themselves consumed significantly 
less L&Z than those that were able to cook a hot meal. Participants were not consuming 
enough calories for their age group, and were adhering to a diet with little variety. Many 
participants were not consuming the L&Z-rich vegetables, such as spinach and kale.  A sample 
of non-AMD patients consumed calories and other nutrients much nearer to the RDA, and 
consumed an average of 1.5 mg of L&Z.  
In terms of differences and similarities between the AMD participants and the non-AMD 
participants, the demographic characteristics were similar. Both groups ate a limited variety of 
foods, and consumed similar amounts of L&Z, indicating that AMD participants were not 
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consuming much more than those without the condition. However, the amount of nutrients and 
energy consumed was quite different between the groups, as the non-AMD cohort consumed 
much more than the AMD group and in some cases even more than the RDA. 
The majority of AMD participants felt their vision was poor on the day of the interview. 
However, this visual impairment did not impact on their kitchen abilities as most participants felt 
able to cook a hot meal, go shopping and obtain food from a supermarket themselves. Many 
felt that their vision or physical capability was not preventing them from changing their diet 
should they wish to; many did not want to change their diet. The main factor that influenced 
participants’ food choices was preference, indicating that participants would only eat food if 
they liked it.  
Since the AMD cohort all had a form of AMD, and were motivated to contact the Macular 
Society for assistance, it has been assumed that they were interested in preventing the 
disease from progressing. All would have received diet advice from the Macular Society, if not 
from their ophthalmologist. Overall, however, participants were not consuming enough of the 
majority of the nutrients recommended, particularly L&Z. The reasons behind this are likely to 
be multi-factorial – dislike for the nutrient-rich foods, lack of knowledge of how to cook or 
prepare them, misjudging the amount required per day, or lack of control (family or caregivers 
cook food).  The most likely reason is because dietary habits are difficult to change - especially 
with increased age 170. L&Z intake was associated with those who were able to cook a hot 
meal, indicating that those who were more proficient in the kitchen were able to consume these 
foods more easily. 
There does not seem to be evidence that information received from the Macular Society or 
other sources modified participants’ behaviour. Ley’s model on effective communication in 
medical practice 171 stresses the importance of memory next to factors such as the 
understanding of information and satisfaction with the treatment. Indeed, 40–80% of medical 
information provided by healthcare practitioners is forgotten immediately 172. The greater the 
amount of information presented, the lower the proportion correctly recalled 173,  furthermore, 
almost half of the information that is remembered is incorrect . Studies have proposed three 
explanations for memory loss—first, practitioner factors, such as use of medical jargon; 
second, the type of information (e.g. verbal, written); and, third, patient factors, such as low 
education or specific expectations 172. 
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With respect to medical information, an inverse relationship has been reported between age 
and amount of information correctly recalled 172. However, although older adults have difficulty 
spontaneously recalling medical information, they are able to take advantage of cues to access 
verbally learned information 174. Studies into patient compliance have shown that patients 
rarely adhere fully to practitioner advice 175,  and AMD patients are reported to have not 
complied with recommended dietary supplement advice 118, 140. 
Patients often report that they do not receive any advice from their ophthalmologist or 
optometrist regarding nutrition 140. This may be partly due to the profession’s differing opinions 
on nutrition research REF, but a patient’s recall difficulties when given medical advice may also 
play a role.  
Other nutrients and energy 
With the exception of iron and protein, AMD participants did not meet the RDA of the nutrients 
analysed. AMD participants’ energy intake was lower than recommended for their age-group 
and gender. This lowering of energy intake with increasing age has been found in other studies 
and some suggest that this is a physiological response that older adults exhibit in reaction to a 
decline in physical activity 176. Some studies 177, 178, suggest that those living alone might 
consume fewer calories than those living with others, although we found no such relationship. 
A study into eating habits of older adults found that they eat more when they are presented 
with variety, and this variety is the key to increasing calorific consumption 179. However, the 
non-AMD cohort managed to reach the RDA of many of the nutrients analysed, including 
calories. It may be argued that this was because there were fewer participants in the sample, 
and the average age of the sample was younger. However, when an age-matched cohort was 
analysed, the same differences in dietary intake was found. The non-AMD cohort did not eat a 
more varied diet either; they appeared to just eat more food than the AMD group.  The cause 
of this is likely to also be multi-factoral; it has been shown in studies that poorer vision impacts 
on an individual’s appetite 180, 181. More AMD participants were reliant on other people to shop 
and prepare and cook food, and this also may limit the amount they eat.  
The Hertfordshire cohort study 182  found that two patterns of diet are prevalent in the older 
adult group – a ‘prudent’ pattern that is characterised by fish, fruit, vegetables and wholemeal 
cereals, and a ‘traditional’ pattern characterised by vegetables, processed meat and puddings. 
The comparison between occupation and nutrients did not show any statistical trends in our 
results, but it was noted that 62% of AMD participants and 76% of non-AMD participants 
adhered to a ‘traditional’ pattern of eating with limited choices of vegetables and fruits, and 
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traditional British recipes such as pies, stews and roast meats. This conservative variety of 
vegetables saw only a minority of AMD participants consuming the lutein-rich kale on a weekly 
basis, although more participants did eat spinach. 
 
Strengths and weaknesses 
This sample may not represent all AMD patients seeking services from organisations like the 
Macular Society. It is also important to find out the opinions of those with AMD who have not 
sought support from non-professional organisations.  The sample sizes are different, and have 
been discussed. A more detailed food recall might have enhanced the study, especially to view 
eating patterns. This could be performed over a number of days rather than 24 hours. It would 
have been beneficial to gather other data such as participant’s BMI and activity levels to 
compare to calorific intake. It is conceivable that a difference in BMI between the groups might 
have accounted for some of the dietary differences reported, but as this data was not collected, 
it is impossible to determine this. The investigators feel that it is unlikely that differences 
between the groups are due to differences in BMI alone, as a previous study reported lower 
calorie intake in visually impaired participants 74 and other studies show that food intake and 
dietary patterns do not appear to differ with various BMIs 183-185 
Results show that participants were not in poor health generally, suggesting that results relate 
to issues with visual impairment only. Practitioners need to be consistent and unified in the 
advice that is given to patients, if confusion is to be avoided. The results also show that, in 
spite of advice being given to patients, they primarily eat food they enjoy and are used to. 
Changing eating habits therefore, requires novel intervention methods.  It is essential to design 
effective measures for imparting and disseminating appropriate dietary and supplementation 
advice for patients with, or at risk of, AMD. The following chapter will introduce and discuss one 
intervention design to impart appropriate dietary and supplementation advice for patients – a 
clinical decision making aid. 
 
 
 
 
75 
 
 
 
Chapter Six 
Development of a Clinical Decision Making Aid 
 
Chapters four and five presented the results of the cross-sectional survey administered to 
participants with and without AMD. The results showed that participants with AMD did not feel 
that they had enough information on nutrition and when questioned about particular fruits and 
vegetables, many did not know which would be beneficial for eye health. A twenty-four hour 
food diary showed that participants with AMD were not eating enough of these helpful 
nutrients, and were not eating enough food overall when compared to participants without 
AMD.  
In order to make a difference in AMD patient’s lives, a practitioner based intervention is 
required. Many of the participants expressed a lack of information from their eye-care 
practitioners, and research has shown that the professional opinions are divided in this area 
164. There are no clear-cut guidelines currently for patient or practitioner to follow 166, and the 
latest study AREDS 2 has provided clarity due to the complexity of the study. The logical start 
to an intervention would be to tackle practitioners first to ensure that the correct information is 
being passed on to patients in the first instance. This chapter discusses the background and 
methods employed for the intervention: a clinical decision-making aid. 
6.1 Background 
When presented with a patient, all clinicians ultimately must answer three questions 186: 
1. What disease/ condition does this patient have? 
2. Should this patient be treated? 
3. Should testing be done? 
These three questions are often riddled with uncertainties, and decisions must be made to 
avoid wasting time. Decision making; a “choosing of alternatives” 187 in medicine is varied and 
can range from intuitive decisions through to well-reasoned, analytical, evidence-based 
decisions that drive patient care 188. Practitioners of medicine and allied health will often use 
their experience and intuition to informally decide clinical care in simple, common conditions. 
Decisions will often be made based on existing practice. However, where complex decisions 
with a high level of uncertainty need to be made, practitioners will often use a more methodical 
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approach in order to feel supported 188, such as clinical guidelines, quantitative techniques and 
evidenced-based principles.   
Evidenced-based medicine / practice can be defined as integrating the judicious use of current 
best evidence in clinical decision making, together with patient values and clinical expertise189.  
A series of steps can be used to formulate a strategy for an individual patient. These steps 
include articulating a clinical question, gathering evidence to answer the question, evaluating 
the quality and validity of the evidence, and finally deciding how to apply the evidence to the 
care of a given patient 190. The rationale is that this type of decision making mitigates the use of 
unnecessary resources. However, these steps can be time consuming, and as the pressures of 
current health systems continue to increase, it is often reserved for only the very complex 
clinical cases 190. A case study used by Courtney et al., is of a high-risk intensive care patient 
with a short-term intravascular catheter 191. The decision to be made is whether to change the 
catheter administration set at regular intervals or not – changing the sets is costly and 
obviously involves practitioner time. Many practitioners have historically changed 
administration sets regularly as they believed it reduced the risk of contracting a nosocomial 
infection secondary to the use of an intravascular catheter. When reviewing the evidence 
available, several studies show that infection levels did not differ when the sets were changed 
at different time intervals. One study however, was a randomised controlled trial (a good quality 
study) which showed that the expensive and time-consuming procedure was not effective in 
high-risk intensive care patients with short term catheter use. The decision here becomes 
obvious – for this particular patient, the administration sets do not need to be changed at 
regular intervals.  
Models 
Clinical decision making models in medicine have been described for many years, particularly 
for front-line doctors and nursing staff. Nursing researchers Banning et al proposed that there 
are three main types of models 192: 
Information- processing model  
This model uses a scientific or hypothetical / deductive approach to assist metacognitive 
reasoning that is essential to medical diagnosis193. Decision ‘trees’ are used to assess potential 
outcomes by assigning a number to each potential outcome and a probability of attaining an 
outcome is given. For example, Figure 5.1 shows a decision tree of using a particular 
medication for the treatment of ulcerative rectocholitis. 
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Figure 5.1 Decision tree depicting patients in remission of unspecified ulcerative rectocolitis given the option of 
treatment with a drug (Pentasa) under two dosing schedules (o.d. or b.i.d). Table ?? below shows the probability of 
remaining in remission in both doses tested. 
Probability of maintaining in remission 
Time Adherent Non-adherent 
6 months 100% (90%-100%) 60% (54%-60%) 
12 months 84% (76%-92%) 59% (53%-65%) 
 
Intuitive- humanist model 
Rather than relying on guidelines, procedure and scientific reasoning, practitioners use their 
experience and intuition to make clinical decisions. For example, many optometrists use their 
intuition when recommending certain optical appliances such as contact lenses based on 
previous experience of how the appliances fit, move and are used by various patients. 
O’Neills multidimensional model 
This theoretical model is based on a computerised decision support system that uses both 
hypothesis and pattern recognition for use by inexperienced nurses. This model contains five 
78 
 
 
 
elements including pre-encounter data, anticipating and controlling risk, the provision of 
standard nursing care, client and situational modifications, and finally hypothesis generation 
and testing. This model cuts loose the inflexibility of guidelines by accounting for the many 
variables that exist in life, and inexperienced practitioners can easily input in the data to 
generate an answer. 
Figure 5.2 shows how all the different aspects of decision making overlap, and need to, in 
order to decide which the best solution is for a patient.  
 
                                            
                       Figure 5.2 Intersection diagram of clinical decision-making process 194, 195.  
Clinical guidelines have been created by many speciality societies (e.g. NICE or WHO) using 
the principles of evidence based medicine and also the consensus of a panel of experts. 
Patients are often put into a category or group, and the guideline will follow a ‘if, then’ rule with 
a number of multi-steps if the question is particularly complex 190. These guidelines are often 
inflexible and it can be difficult to place some patients into specific categories, but, for a busy 
overstretched clinical practice, they can be invaluable. Sometimes these guidelines are 
depicted using decision-making aids such as decision trees, flow charts, and brainstorm and 
mind map diagrams. Figure 5.3 shows such an example of a NICE ‘pathway’ – many other 
medical conditions are indexed in the NICE pathway website for practitioners to download.  
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Figure 5.3 NICE pathway for clinical management of primary hypertension in adults. The numbers indicate the 
various steps. 
 
Decision flow diagrams 
As shown in Figures 5.1 and 5.3, decision ‘trees’, flow diagrams, information flow diagrams, 
pathways or flowcharts are tools that show the visual representation of the sequence of steps 
and decisions needed to perform a process linked together by connecting lines and directional 
arrows. They have been historically used by industrial work engineers to structure work but 
now they are used in medicine and many other disciplines196. They can be used as a ‘plan 
map’ to pictorially describe the various stages of a project, or to describe a process. They can 
be used an efficient alternative to written documentation. They can also be used to brainstorm 
computer algorithms, and to help aid decision making. Many flowcharts used in eye care 
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consist of either differential diagnosis or treatment decisions - please see Appendix 8 for an 
example of a flowchart used in optometry 197  
Different flowcharts have evolved over time – swim lane, data flow, influence, work flow, 
process flow and many more. The design of a flowchart is important – the start and end points 
must be decided before hand, with the most efficient path of getting between them, and the 
flow of the diagram must either run horizontally or vertically. The start and end points are 
depicted with shapes that have rounded edges, the decision points are depicted as diamonds. 
Above all, flowcharts must be simple enough for anyone to understand. 
                                         
Figure 5.4 Symbols of flow charts  196. 
As stated, flowcharts have been used in medicine to aid diagnosis, treatment options and 
advice given to patients. Because they use symbols or diagrams, they are able to be used in 
high pressured environments where time is limited, since users can absorb information very 
quickly. Flowcharts are often space efficient too, and can be placed on surgery walls or pin 
boards so practitioners can have easy access. As such, a flowchart would be an ideal clinical 
decision-making aid for all practitioners to use, and an ideal way to implement an intervention 
for better nutritional advice for patients with AMD. 
6.2 Objectives 
The aim of this intervention was to design a flowchart that can be used to decide what advice 
to give to patients seen in optometric and ophthalmic practices, universities or hospitals, by all 
eye-care practitioners with ease. Outcomes of the intervention should include increased 
practitioner knowledge and less inter-practitioner variability when giving patient advice. 
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5.3 Clinical decision-making aid design 
As mentioned, modern medical practice has used flowcharts and diagrams to aid diagnosis 
and decision making 196. For an aid to be successful, it needs:  
1. To answer a particular question (or questions)  
2. To be small enough in size to fit in a folder or be on a wall without taking too much 
physical space 
3. To be succinct enough to fit the important information in one place 
4. To have distinct clinical processes with final outcomes or decisions 
For this intervention, a flowchart design is the most appropriate. The decision or question that 
needs to be answered in the flowchart is: “when and what nutritional advice to give to patients 
with, or at risk of, AMD”. The only large scale clinical research that is currently available to 
answer this question is the AREDS 2 study; the study’s participants’ inclusion and exclusion 
criteria can be used to decide when it is appropriate to advise the AREDS 2 supplementation 
(the only supplement preparation that is appropriate to advise at this point in time).  
AREDS 2 inclusion and exclusion criteria 
The AREDS 2 participants were divided into four primary groups: those that received L&Z only, 
those that received L&Z plus omega 3 fatty acids, those that received omega 3 fatty acids only, 
and those that received a placebo. The four primary groups were further divided as shown in 
Figure 5.5. 
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Figure 5.5. The groupings of participants in the AREDS 2 study. 
Participants were either men or women aged 50 to 85 years at the qualification (initial) visit. 
They had to have bilateral large drusen (≥ 125 microns) or large drusen in one eye and 
advanced AMD in the fellow eye. A study eye (eye without advanced AMD) may have had 
definite geographic atrophy not involving the centre of the macula without evidence of drusen. 
Based on these inclusion criteria, if a patient is over 50 years old, has bilateral large drusen or 
drusen in one and advanced AMD/ definite geographic atrophy in the fellow eye, it can be said 
that they could benefit from the AREDS 2 formulation. (The study encompassed L&Z 
(carotenoids) to the original AREDS supplement formulation, and the study results show that 
substituting L&Z for beta-carotene reduced risk of progression by an additional 18% on top of 
the original 25% risk reduction found in AREDS 1 – see section 1.7). 
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Construction  
The flowchart was initially drafted in Microsoft Word using the shapes function, as seen in 
Figure 5.6. The top of the flowchart started with the findings on ophthalmoscopy – as unusual 
macula appearance. If a patient had a normal macula, but had a family history of AMD, a 
branch of decisions was created to determine whether they would benefit from dietary 
modification. If the patient did have a non-normal macula, the branches following determined 
whether the patient fitted into the AREDS 2 inclusion criteria,  or whether they would benefit 
from dietary modification only. If the findings were not related to AMD, referral for an 
ophthalmological opinion was advised. The final outcomes were split into either dietary 
modification (advice one), or supplementation (advice two). 
Once the design had been decided upon, the chart was then created in flowchart software 
Lucidchart (Lucid Software Inc., 282 East 12000 South Suite 200, Draper, UT 84020, US), with 
‘yes’ and ‘no’ decision lines, as seen in Figure 5.7. (A full size copy is in Appendix 9) 
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.          
Figure 5.6 Initial design of the flow chart using Microsoft Word. 
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Figure 5.7. Design of the flow chart using software Lucidchart. 
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6.4 Pilot 
As a preliminary measure, the flowchart was sent to 25 optometrists who worked in hospital, 
independent, multiple and university practices by email, asking for their input into the usability 
of such an aid. The optometrists were asked to comment on any aspect of the aid if they 
wished. All 25 were enthusiastic about it, and some provided useful comments about how to 
amend the aid to make it more user-friendly or for greater clarity. Some of the comments are 
shown below: 
“I've had a look at the flow chart and it's pretty clear in an academic sense. If this is meant for optometrists on the 
high street, I think it would need a change in language to simplify it to make it more accessible as I am not 
convinced the average optom would understand about inclusion criteria and how studies work. Also I think it would 
benefit from some accompanying photos to illustrate what 'definite geographic atrophy involving the centre of the 
macula' etc looks like. I think the word 'definite' would also induce a sense of panic among optoms who aren't really 
sure and their default response may then be just to give no advice! Also when I read advice 1 quickly, it seemed to 
indicate a supplement plus the food. It was only on a second read that I realised it was in the food. Maybe it could 
be rephrased to say 'modify diet adding a cup of spinach/kale or two eggs which would provide  the required 10mg 
lutein and zeaxanthin' or something similar?” 
“The flow chart seems to be designed for patients who are not presently taking supplementation – a number of 
patients may be taking supplementation but, having heard about the AREDS2 study, would like advice on whether 
they should change.  
  
I didn’t quite follow the ‘Advice 1’ box as the wording implies that both the supplement and dietary elements are to 
be taken – does ‘either with a’ mean ‘in the form of either a’?” 
“Thanks for your email, it was really interesting. I do have a few queries regarding nutritional 
supplementation…Would it be a good idea to include an FAQ document along with the flow chart to help clinicians 
answer these?” 
“Instead of stating that the patient falls out of AREDS evidence either state no current research to suggest a nutrition 
benefit unless there are other sources. Perhaps link people to advice 1& 2 with picture symbols” 
 
The flowchart was then amended using the recommendations given by the 25 optometrists 
who piloted it (please see Appendix 9 for the flowchart). 
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6.5 Evaluation surveys 
 
The clinical decision-making aid was then evaluated using two surveys. Psychologist Albert 
Bandura proposed that behavioural change is linked to perceived self-efficacy - a person who 
believes in their capabilities to produce a given attainment is much more likely to accomplish 
the task198, 199. Evaluating self-efficacy using scales gives researchers a real idea of whether a 
subject is likely to accomplish a task in the future. Self-efficacy scales have been used in many 
surveys of medical practitioners’ confidence in performing certain procedures, or giving advice 
to patients200-202. Bandura stresses the need to accurately reflect the construct when 
developing scales, as there is no all-purpose measure of perceived self-efficacy. The items 
must be phrased with ‘can do’ (a judgement of capability) rather than ‘will do’ (a judgement of 
intent), and distinguished from self-esteem 198, 199. Using this information, a survey was created 
that asked participants to rate their confidence and self-efficacy out of 100 (in 10 increment 
steps) when performing certain tasks  such as giving nutritional advice to patients, or 
classifying the type of AMD seen in a patient. This survey was created using the software 
Bristol Online Surveys (University of Bristol, 8-10 Berkeley Square, Bristol BS8 1HH, UK) 
(please see the survey in Appendix 10). 
 
The seven item statements included in the survey were: 
 
• I am confident that I could classify the type of AMD a patient has based on retinal signs                         
• I am confident that I can advise a patient with AMD on the relationship between AMD 
and nutrition                          
• I am confident that I can advise a patient with AMD on what foods to eat that might be 
beneficial for their condition                         
• I am confident that I can advise a patient with AMD on the quantities of foods that might 
be beneficial for their eye health                         
• I am confident that I can advise a patient with AMD on when nutritional supplementation 
may be beneficial                         
• I am confident that I can advise a patient with AMD on what supplements to take and 
what dosage to recommend                         
• I am confident with talking about nutrition to those at risk of AMD   
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These items were chosen because they cover all decisions that need to be contemplated when 
determining when and what nutritional advice should be given to a patient based on the 
AREDS 2 criteria, i.e. determining that a patient had drusen and geographic atrophy, advising 
a patient that AMD and nutrition are linked, determining what foods are beneficial and how 
much, knowing which patients require supplementation, which supplements to take (and how 
much), and advising those that have a family history of AMD or are at risk. 
 
Demographic information was also elicited by questions on age, gender, number of years 
practising (as an eye care practitioner), the country practising in (as nutritional advice has been 
shown to vary in other countries 203) , and the number of AMD patients seen each week. 
 
A second survey was created to be filled in two weeks after receiving the clinical decision-
making aid. This survey was the same as the initial survey and used the same items to rate the 
participant’s confidence and self-efficacy out of 0 to 100 in 10 increment steps. Participants 
filled in the same identifying code (first three letters of the mother’s maiden name, and last 
three digits from the postcode) in both surveys, so the surveys could be correlated.  
 
6.6 Conclusion 
This chapter has discussed the background and methods employed in the construction of a 
clinical decision-making aid (a flowchart) and two evaluation surveys to be used in an 
intervention study with qualified and student optometrists. The subsequent chapters will 
describe the methods used to carry out the study and the results obtained. 
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Chapter Seven 
Qualified Practitioner Evaluation of the Flowchart 
 
The previous chapter described the background and methods used to create a clinical 
decision-making aid in the form of a flowchart, and two surveys that can be used in an 
intervention study with optometry practitioners. For the first part of the study, qualified 
practitioners were used as participants. This chapter discusses the methods employed for this 
part of the study, and the results acquired. 
 
7.1 Recruitment 
 
The optometry professional magazines Optometry Today and Optician both agreed to run a 
200 word feature of the study in their October issues. Readers were advised to email their 
interest in the study to RS, and they would receive a document with the study information.  
7.2 Ethics 
The procedures followed were in accordance with the ethical standards of the Aston University 
Ethics Committee on human experimentation that conform to the Declaration of Helsinki 1975, 
revised Hong Kong 1989; application number 717. 
 
7.3 Participants 
 
The inclusion criteria for the qualified practitioner study were that the participant was a qualified 
optometrist or ophthalmologist that had completed their pre-registration period. A total of 72 
practitioners completed the first survey, and 46 participants from the 72 completed the second 
survey. 
 
7.4 Delivery protocol  
 
If they wished to participate in the study, they were sent a URL to the initial survey on Bristol 
Online Surveys where they could enter their demographic details and answer how confident 
they felt about the seven items prior to using the clinical decision-making aid. 
90 
 
 
 
 At the end of the survey, a further link sent them to an Aston University website which 
provided them study information, with the flowchart and a list of frequently-asked-questions 
(see Appendix 11, 12) (http://www.aston.ac.uk/lhs/research/health/org/amdnutrition/). 
Participants entered an email address that we could send the follow-up survey to, two weeks 
later. Participants were sent a URL to the final survey, where they answered again how 
confident they felt with the seven items after using the flowchart. If they had any other 
questions, they could email the researcher (three participants wanted extra clarification 
regarding supplements). As mentioned in Chapter 6, the seven item statements were: 
• A. I am confident that I could classify the type of AMD a patient has based on retinal 
signs                         
• B. I am confident that I can advise a patient with AMD on the relationship between AMD 
and nutrition                          
• C. I am confident that I can advise a patient with AMD on what foods to eat that might 
be beneficial for their condition                         
• D. I am confident that I can advise a patient with AMD on the quantities of foods that 
might be beneficial for their eye health                         
• E. I am confident that I can advise a patient with AMD on when nutritional 
supplementation may be beneficial                         
• F. I am confident that I can advise a patient with AMD on what supplements to take and 
what dosage to recommend                         
• G. I am confident with talking about nutrition to those at risk of AMD   
 
7.5 Analysis 
 
Microsoft Excel was used to perform initial analysis; quantitative data (confidence scores out of 
0-100%) was summarised using percentages and graphs. Data from Excel was then used in 
statistical software IBM SPSS to compare the self-efficacy between the two surveys, using 
paired t-tests. Chi-squared analysis was used to compare categorical data such as gender and 
ethnicity. An independent t-test was used to compare the ages of participants in each group, 
and the number of years practising. 
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7.6 Results 
Reliability of the survey 
Reliability of the scale items in the surveys were shown to be reliable: Cronbach’s alpha 
coefficient (a measure of internal consistency, i.e. how closely related a set of items are as a 
group. It is a coefficient of reliability or consistency) = 0.898 for the first survey, Cronbach’s 
alpha coefficient = 0.903 for the second survey. The mean score for the items in the first 
survey strongly correlated with the mean score for the items in the second score (r=0.702, 
p<0.001) also showing a reliable set of items. 
Sample characteristics 
Table 6.1 shows the number of participants completing the surveys, and the average 
confidence scores (derived from the scores for the seven statements). There were no 
differences found in the age of participants, gender or the number of years practising as an 
optometrist, and their mean scores of the two surveys, so these variables did not appear to 
influence confidence levels. Age and practising years unsurprisingly, strongly correlated with 
each other. 
There were no demographic differences between the participants that did not complete second 
survey compared with the participants that did complete the second survey. The cohort of 
participants that ‘dropped out’ comprised 13 males and 12 females with an average age of 
48.08 years ±11.99. The average number of years practising in these participants was 23.6 ± 
12.68 years. 
 
 
 
 
 
Table 6.1 Number of participants completing the surveys, and the average confidence scores. 
 
 Males Females 
First survey participants 38 33 
Second survey participants 25 21 
Confidence for first survey (0-100) 69.0 ± 18.8 70.6 ± 12.8 
Confidence for second survey (0-
100) 
80 ± 14 84.6 ± 7.3 
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Of the participants that completed the second survey, the average age was 45.22 ±11.52 
years. The average number of years practising was 21.96 ± 11.73 years. Chi square tests 
showed no significant differences between those that completed the two surveys and gender, 
ethnicity, age and number of years practising. 
A Shapiro-Wilk’s test for normality (where p>0.05), and a visual inspection of the data’s 
histograms, normal Q-Q and box plots showed that the male survey data was normally 
distributed, the female data, however, was not. The skewness and Kurtosis values for females 
were also outside of the +1.96 to -1.96 normal range.  
Differences between surveys 
Table 6.2 displays the mean confidence scores for the participants that completed both the first 
and second survey for each item (labelled A – G; please see item statements in Chapter 6, 
section 5.5). Both a paired samples t-test and a Spearman’s rank-order correlation showed that 
there was a significant increase in confidence scores from the initial survey (M = 69.7%, SD = 
16.2%), to the second survey after a two week usage of the flowchart (M = 82.1%, SD = 
11.6%); t(45)=7.33, p=0.00), (rs = 0.609, p = 0.00). The effect size was found to be large 
according to Cohen’s (1992) categorisation scheme (Cohen’s d = 0.88). 
Confidence 
Statement 
First Survey 
(n = 46) 
Second Survey 
(n = 46)   
A 72.7 80.2 
B 73.9 83.2 
C 76.8 84.8 
D 51.3 77.7 
E 66.3 83.6 
F 59.3 79.8 
G 70.8 86.4 
 
Table 6.2 Mean confidence scores (0-100) for the 46 participants that completed both surveys. Confidence 
statements are labelled A – G (see chapter five, section 5.5). 
Verbal feedback 
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At the end of the second survey, participants were able to write comments on the flowchart if 
they so wished. Of the comments that were received, the majority were very positive: 
“Really useful tool particularly in conjunction with the supporting document.” 
“A great tool and the FAQs were useful too.” 
“Very simple to use and practical. Good to have a clear guide to follow. Although I knew about kale, spinach etc, I 
wouldn't have suggested eggs in the past.Thank you.” 
“nice to have clear guidelines about amounts and frequency” 
“Very useful summary. Have put it up on the wall in the consulting room.” 
“I found this very clear, beneficial and easy to use.” 
Two participants included comments where the flowchart could be improved: 
“Advice 1: I presume that the quantities given are to eat per day. This is not specified.” 
“the smallest font's too small (though my VA's fine)” 
The flowchart was amended to add the wording ‘per day’ in the Advice One box, and the font 
size was increased. 
7.7 Discussion 
The results obtained show that eye care practitioners felt much more confident giving nutrition 
advice after using the flowchart for two weeks. This trend appears to be regardless of the 
gender or age of the participant, or number of years practising. The participants gave positive 
feedback about the flowchart and felt that it had enhanced their clinical practise skills. 
Some participants did drop out from completing the second survey, despite having three email 
reminders. This could be because once they had access to the flowchart, they felt unwilling to 
help any further. Eye care professionals are extremely busy, and it may have simply been 
forgotten.  
This was an opportunistic sample – we did not know how many participants would respond to 
the two advertisements, so we set restrictions on the time period that a potential participant 
could respond with interest. Funds were limited, which meant that continuous advertising was 
not possible. Overall, the sample size that completed both surveys was small. To recruit a 
larger cohort, advertisements would need to be run in a variety of professional journals 
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continually for a longer period of time, with larger captions (a full page spread, if funds allowed) 
to allow maximum exposure to potential participants.  
A future step in this study would be to investigate the flowchart in action – a cohort of eye care 
practitioners could use the flowchart for a set period, and the patients that they see in this time 
could be monitored to see if they were given the correct nutrition advice, and if they put any of 
the advice into action. 
Overall, the flowchart has proved to be a useful tool in a qualified eye care practitioner 
population, and by using this aid, the cohort are much more likely to be giving correct and 
consistent advice to their patients. 
7.8 Conclusion 
This chapter has discussed the methods, protocols and results obtained from an intervention 
study using a flowchart for qualified practitioners. The results show that practitioners appear 
much more confident after using the flowchart for two weeks, and are very positive about 
including the flowchart into their clinical practise. The following chapter will discuss the 
methods, protocols and results that were obtained from a study using a cohort of student 
optometric participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
 
 
Chapter Eight 
Student Practitioner Evaluation of the Flowchart 
Aids to clinical decision making can help practitioners arrive at the correct clinical decision for 
patients much more efficiently. They can boost practitioner’s confidence and self-efficacy in 
decision making, and make it much more likely that practitioners will complete a certain task. 
Earlier chapters have described the design and construction of an aid (a flowchart) to help eye-
care practitioners decide when and what nutrition advice to give to patients with, or at risk of, 
AMD. The previous two chapters specifically discussed the methods and results obtained for 
an evaluation of the flowchart using qualified practitioners as participants. This chapter 
discusses the methods employed and the results acquired for an evaluation of the flowchart 
using a student optometric practitioner cohort. 
 
8.1 Sample size 
It was important that only students that had reached a sufficient level of knowledge about AMD 
were included in the study. Final year students have reached an appropriate level in their 
retinal knowledge to make clinic management decisions, based on the curriculum they will 
have covered. Aston University currently has one of the largest optometry schools in the UK, 
with an intake of approximately 140 students in the first year. The number of students in the 
final year in 2015 was 130 and as many as possible were recruited on an opportunity basis, as 
not all would be able to participate due to other commitments.  
8.2 Ethics 
The procedures followed were in accordance with the ethical standards of the Aston University 
Ethics Committee on human experimentation that conform to the Declaration of Helsinki 1975, 
revised Hong Kong 1989; application number 717. 
8.3 Recruitment 
 
Final year students at Aston University were informed about the study via email and 
announcements in lectures. If they wished to participate, they needed to come to the data 
collection session. The data was all collected in one tutorial session.  
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8.4 Participants 
 
The inclusion criteria for the student practitioner study were that the participant was a 
registered third year student optometrist enrolled at Aston University in 2015. A total of 51 
students participated in the study, 8 males and 43 females with a mean age of 21.7 ± 2.9 
years. 
8.5 Delivery protocol  
 
If a student wished to participate, they attended a one-off tutorial session on the 12th March 
2015. Participants were allocated to group ‘1’ or ‘2’ by numbering them alternatively. 
Students from both groups were asked to view five pairs of retinal photos depicting 
hypothetical clinical scenarios of patients in various stages of AMD (see Appendix 13) – This 
type of task is similar to questions that the students will have encountered in their summer 
examinations. Information about the patient’s age, the type of AMD they had, and if there was 
any family history of AMD was given underneath the photographs. The students had to then 
pick the most appropriate nutritional advice to give to each patient from a list of 10 possibilities:  
 
1) No action required 
2) Consider dietary modification by eating either a large cup (150g) of cooked spinach OR kale, 
OR two eggs every day 
3) Consider dietary modification by eating either a large cup (150g) of uncooked spinach OR 
kale, OR two eggs every day 
4) Consider dietary modification by eating either a small cup (75g) of cooked spinach OR kale 
every day 
5) Consider dietary modification by eating 2 bananas or 2 mangos every day 
6) Consider taking supplementation of vitamin C 500mg, vitamin E 400IU, lutein 10mg, 
xeaxanthin 2mg, zinc 25mg, copper 2mg every day. Consult GP if taking prescribed 
medication. 
7) Consider taking vitamin C 250mg, vitamin E 800IU, lutein 1mg, xeaxanthin 5mg, zinc 
250mg, copper 20mg every day. Consult GP if taking prescribed medication. 
8) Consider taking supplementation of lutein 10mg and xeaxanthin 2mg every day. 
9) Consider taking supplementation of gingko biloba and cod liver oil every day. 
10) Refer immediately for wet AMD treatment. 
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For each scenario there was only one correct answer, however some of the possibilities were 
very close to the correct answer, while others were not. After this exercise, the participants 
were given a hard copy of the survey used in the qualified practitioner study (see chapter six) 
to fill in and measure their self-efficacy about making their decisions. 
 
After the students had picked and marked their answers on the given sheet (which were then 
taken away), the groups were separated into opposite sides of the lecture hall. Group 1 were 
given a pack of written material about AMD – an article from Optician magazine commenting 
on AREDS 2 (see Appendix 14). Group 2 were given the flowchart developed and used in the 
qualified practitioner study and FAQs (see Appendix 11). The participants were then asked to 
look at the same five clinical scenarios and again pick the most appropriate advice for the 
patient. Once again, afterwards, the survey was administered to measure self-efficacy. 
 
After the exercise, students from both groups were given the correct answers and both packs 
of information for their own studies. 
 
8.6 Analysis 
 
Microsoft Excel was used to perform initial analysis; quantitative data was summarised using 
percentages and graphs. Data from Excel was then used in statistical software IBM SPSS to 
firstly find the reliability of the survey using Cronbach’s alpha and Pearson’s correlation. 
Comparisons between self-efficacy levels were next performed using paired t-tests. 
Differences between scenario answers were found using independent t-tests. Tables were 
used to summarise the data and for cross-tabulation.  
 
8.7 Results 
Reliability of the survey 
Cronbach’s alpha coefficient was used to assess the internal consistency of the confidence 
scale items in the surveys. Cronbach’s alpha = 0.841 for the first survey. Cronbach’s alpha = 
0.915 for the second survey. The mean score for the items in the first survey strongly 
correlated with the mean score for the items in the second score (r = 0.503, p=0.012). 
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Sample characteristics 
Of the 51 participants, 25 were allocated in the AREDS information only group (group 1) and 
26 participants were placed in the flowchart information group (group 2). Table 7.1 shows the 
ethnicity of the participants. Please note, ethnicity was an open question and participants were 
able to write freely what they felt their ethnicity was in their own words. 
 
Ethnicity Participants (%) 
White 17.6 
Indian 15.7 
Pakistani 7.8 
Sri Lankan 1.9 
Bangladeshi 1.9 
Arab 1.9 
Palestine 1.9 
Asian         11.7 
                                       
                                       Table 7.1. Ethnicity information for the participants. 
A Shapiro-Wilk’s test for normality (where p>0.05), and a visual inspection of the data’s 
histograms, normal Q-Q and box plots showed that the student survey data was normally 
distributed.  
Confidence scores 
Table 7.2 below shows the percentage confidence scores for each statement in both the first 
survey and the second survey, split into the two groups. Please see chapter five (section 5.5)  
for the specific statement items. A paired t-test showed there was a significant increase in 
confidence scores from the initial survey, to the second survey after receiving educational 
materials : Group AREDS ((M of first survey = 42.5, SD = 15.7, M of second survey = 64.8, SD 
= 12.3); t (24)=7.84,d = 0.67, p=0.01), Group Flowchart ((M of first survey = 41.7 , SD = 14.6. 
M of second survey = 69.1, SD = 1.7); t (25)=7.92, d = 0.81, p<0.00).  There was not a 
statistically significant difference in second survey’s confidence scores between the two 
groups, although Group Flowchart’s scores were higher than Group AREDS’. 
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Confidence 
Statement 
First Survey 
Group AREDS 
Second Survey  
Group AREDS 
First Survey 
Group Flowchart 
Second Survey  
Group Flowchart 
A 60.0 64.0 54.0 66.9 
B 46.8 53.6 46.0 68.1 
C 54.8 71.2 55.4 72.2 
D 27.6 63.2 31.7 71.2 
E 40.0 63.6 36.8 68.3 
F 31.3 61.6 26.2 68.5 
G 37.0 66.8 41.9 68.7 
 
Table 7.2 Mean confidence levels (0-100) for the seven statements (see chapter five/ chapter six). Group AREDS 
had AREDS information only, Group Flowchart had the flowchart and FAQs. 
Scenario questions 
Tables 7.3-7.6 depict the answers given to the five clinical scenarios in the initial survey and 
then in the second survey according to each group. For statistical analysis, a correct answer 
was given a value of ‘1’ and incorrect answers were given a value of ‘0’. The final value was 
the sum of the answers, out of a possible 5. An independent t-test showed both groups 
significantly increased the number of correct answers given from the initial survey to the 
second survey – Group AREDS t(24)= 6.53, p < 0.001, Group Flowchart t(25)= 6.67, p < 0.001. 
An independent t-test also showed that there was a significant difference between the two 
group’s answers in the second survey – Group Flowchart answered significantly more correctly 
than Group AREDS t(24) = 2.21, p = 0.03.  
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Answer option Scenario One 
(Correct 
answer f) 
Scenario Two 
(Correct 
answer b) 
Scenario Three 
(Correct 
answer a) 
Scenario Four 
(Correct 
answer j) 
Scenario Five 
(Correct 
answer b) 
A 4% 8% 4% 0% 8% 
B 4% 4% 0% 0% 4% 
C 8% 20% 4% 0% 16% 
D 8% 24% 12% 4% 16% 
E 0% 4% 0% 0% 0% 
F 44% 16% 36% 0% 28% 
G 0% 4% 8% 4% 8% 
H 8% 16% 20% 4% 16% 
I 0% 4% 0% 0% 4% 
J 24% 0% 16% 88% 0% 
 
Table 7.3 Answers given to five clinical scenarios in the first survey for Group AREDS. Highlighted numbers are the 
correct answers. 
Answer option Scenario One 
(Correct 
answer f) 
Scenario Two 
(Correct 
answer b) 
Scenario Three 
(Correct 
answer a) 
Scenario Four 
(Correct 
answer j) 
Scenario Five 
(Correct 
answer b) 
A 7.7% 11.5% 0% 3.8% 0% 
B 3.8% 23.1% 7.7% 0% 19.2% 
C 0% 11.5% 3.8% 0% 7.7% 
D 0% 30.8% 7.7% 3.8% 23.1% 
E 0% 0% 0% 0% 0% 
F 61.5% 0% 46.2% 3.8% 15.4% 
G 7.7% 7.7% 11.5% 0% 7.7% 
H 19.2% 11.5% 7.7% 0% 19.2% 
I 0% 3.8% 0% 0% 7.7% 
J 11.5% 0% 15.4% 88.4% 0% 
 
Table 7.4 Answers given to five clinical scenarios in the first survey for Group Flowchart. Highlighted numbers are 
the correct answers. 
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Answer option Scenario One 
(Correct 
answer f) 
Scenario Two 
(Correct 
answer b) 
Scenario Three 
(Correct 
answer a) 
Scenario Four 
(Correct 
answer j) 
Scenario Five 
(Correct 
answer b) 
A 0% 4% 8% 0% 8% 
B 0% 24% 4% 0% 8% 
C 0% 0% 0% 0% 8% 
D 4% 40% 4% 0% 12% 
E 0% 0% 0% 0% 0% 
F 92% 12% 72% 12% 56% 
G 0% 4% 0% 4% 0% 
H 4% 16% 4% 4% 8% 
I 0% 0% 0% 0% 0% 
J 0% 0% 8% 80% 0% 
 
Table 7.5 Answers given to five clinical scenarios in the second survey by Group AREDS. Highlighted numbers are 
the correct answer. 
. 
Answer option Scenario One 
(Correct 
answer f) 
Scenario Two 
(Correct 
answer b) 
Scenario Three 
(Correct 
answer a) 
Scenario Four 
(Correct 
answer j) 
Scenario Five 
(Correct 
answer b) 
A 0% 7.6% 57.7% 11.5% 11.5% 
B 7.7% 76.2% 3.8% 23.1% 73.1% 
C 3.8% 11.5% 0% 3.8% 3.8% 
D 0% 3.8% 7.7% 0% 3.8% 
E 0% 0% 0% 0% 0% 
F 80.8% 0% 7.7% 0% 7.7% 
G 3.8% 0% 0% 0% 0% 
H 3.8% 0% 0% 0% 0% 
I 0% 0% 0% 0% 0% 
J 0% 0% 23.1% 50% 0% 
 
Table 7.6 Answers given to five clinical scenarios in the second survey by Group Flowchart. Highlighted numbers 
are the correct answers 
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Verbal feedback 
After the session, a few of the participants gave verbal feedback about using the flow chart and 
FAQs. The feedback was all positive: 
“This is such a useful tool. I wish we had more flowcharts like this to help with other conditions we are likely to see in 
practice”. 
“I would not have known where to start in giving nutritional advice, but this has made it very clear”. 
“We had a lecture on giving nutrition advice, but I wouldn’t have known which patients to give it to - now I do”. 
“I like that it is small and simple”. 
One student pointed out that it would be useful to add in the word ‘dry’ to the box “Are there 
any other signs of AMD?” to clarify this a little more. This has since been added. 
8.7 Discussion 
The results obtained show that student optometric practitioners feel more confident giving 
nutrition advice after having specific AREDS information and after using the clinical decision-
making tool on five clinical scenarios. Those that used the flowchart were more confident than 
those that had the AREDS information. After using the flowchart for a period of time, it would 
be expected that confidence levels would increase to be statistically higher than the group with 
just AREDS information. 
The results also show that all participants chose more of the correct advice options after 
receiving specific information. Those that used the flowchart chose statistically more correct 
advice options when compared to those that had the AREDS information. It was apparent that 
the clinical scenario tasks appeared to vary in difficulty – scenario three had much fewer 
correct answers in the first survey overall (2%) when compared to scenario four (88.2%). Once 
the participants had received their specific educational materials, Group AREDS increased the 
correct responses in scenario three to 8%, but Group Flowchart increased the correct 
responses to 57.7% - this is a 25-fold increase. Group Flowchart appeared to have performed 
best at the tasks which were the hardest. 
The clinical scenarios were a good method for determining increased knowledge at a specific 
time, and were useful as it was only possible to get the participants together once. However, it 
would be even more useful to see how real-life use of the flow chart would affect confidence 
levels – much like the qualified practitioner study.  
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The sample size is relatively small, as it was an opportunistic sample. In an ideal world, it 
would have been good to get the entire year group together, but logistically this would have 
been impossible as students have a varied timetable. 
Overall, the flowchart has proved to be a useful tool in a student practitioner population, and 
students are much more likely to be giving correct and consistent advice to their patients. 
8.8 Conclusion 
This chapter has displayed the methods and results obtained in an evaluation study of the 
clinical decision-making aid using student optometric practitioners as participants. The 
following chapter will discuss the overall conclusions to the entire project, and discuss any 
future work that may be carried out. 
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Chapter Nine 
Discussion 
9.1 Main outcomes 
This project sought to uncover the beliefs and opinions that AMD patients had about nutrition 
and AMD, and to see how these beliefs influenced their nutritional behaviour. Nutritional 
behaviour was contrasted and compared with a cohort of people without AMD. It was intended 
that a new measure of these parameters, in the form of a survey, would be designed and 
evaluated and could be used again in the future. The last aim of the project was to act on 
whatever information was gleaned from the survey in the form of an intervention - either patient 
centred, or a practitioner/organisation/care centred, dependant on the results found from the 
survey. 
The nutritional awareness and behaviour survey 
The survey generated some interesting data. All 158 participants could be considered an 
‘informed’ population as they had actively sought the services and membership of the Macular 
Society, but all felt that they needed more information and guidance from eye care 
professionals, especially in the area of nutrition. Although the majority of participants were able 
to identify nutrient-rich foods, they were unable to verbalise why the foods were valuable for 
eye health, and were unsure over quantities to eat. Some 75% of the participants were taking a 
nutritional supplement for AMD, but were taking a variety of formulations and doses with little 
understanding about how supplements work. Of those that didn’t take a supplement, the 
majority felt that supplements were not effective in slowing the progression of AMD and did not 
take them for this reason. 
Included in the survey was a 24 hour food diary, which would provide an insight on how the 
beliefs and opinions of the participants manifested in their nutritional behaviour. These findings 
were very interesting – participants with AMD consumed an average of 1.4mg of lutein and 
zeaxanthin, much less than the recommended 10mg per day. Those that were not able to cook 
a hot meal by themselves ate significantly less lutein and zeaxanthin than those that could 
cook a hot meal alone. A lack of knowledge of lutein and zeaxanthin had led to a lack of 
consumption of these nutrients. 
Participants with AMD were not consuming enough calories (average 1515 kcal) or nutrients in 
general – many nutrients did not reach even half the recommended daily allowance. The food 
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that AMD participants were eating was limited in variety, and many were not eating the lutein 
and zeaxanthin rich foods at all. An age-matched cohort without AMD ate an average of 1.5mg 
of lutein and zeaxanthin per day, and matched or exceeded the majority of the RDAs for all 
nutrients and calories (average 2162 kcal). Their diet was more varied, and the volume of food 
consumed was higher than the AMD cohort. 
The reasons behind this dietary difference are likely to be multi-factorial, such as dislike for the 
certain foods, lack of knowledge of how to cook or prepare them, misjudging the amount 
required per day, or lack of control (family or caregivers cook food). Most importantly, dietary 
habits are difficult to change and can be quite ingrained in older adults 204. Visual impairment 
itself may impact strongly on appetite, as humans enjoy the sensory experience of viewing our 
food before we actually consume it 179. Visual impairment may also cause frustration when 
eating, and some individuals may then give up. There is very little research on the impact that 
visual impairment has on appetite and eating; further investigation in this area is warranted. 
The Intervention 
The results from the survey showed that patients with AMD would respond to more explicit 
guidance from eye care practitioners. Research has shown that there is variability in the advice 
that practitioners currently give to their patients 164, as current guidelines are vague and 
unhelpful. An intervention to help practitioners give consistent advice would therefore prevent 
patients from becoming confused, and would encourage them to take positive action to change 
behaviours. 
A clinical decision-making aid in the form of a flowchart was created that gives practitioners 
clear direction as to whether supplementation or dietary modification would be appropriate for a 
patient, based on the inclusion and exclusion criteria of the AREDS 2 study. This aid was then 
evaluated using both a qualified practitioner and a student practitioner cohort, using confidence 
and self-efficacy scales.  
The qualified practitioner cohort significantly increased their confidence scores after two weeks 
use of the flow chart in practice (mean = 69.9 ± 15.8% initially, mean = 82.3 ±10.7% after two 
weeks use), and feedback from the participants was positive. The student practitioner cohort 
also significantly increased their confidence scores when completing five clinical scenarios 
(mean = 43.4 ±10.4% initially, mean = 69.1 ± 1.7% after receiving the flow chart), and they also 
significantly increased the number of correct answers to each of the scenarios after using the 
flow chart. Feedback from the students was also very positive. 
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9.2 Limitations 
The main limitation with the project was the number of participants recruited in each study. The 
number of participants in the AMD cohort was good, but it would have been more powerful to 
have the same number of participants in the non-AMD cohort. Many contacts in optometric 
practice were used to recruit, and given enough time it would have been possible – but time 
constraints meant that only 50 participants were recruited. To combat this limitation, a sub-
group of participants with AMD were extracted that matched the age and the number in the 
non-AMD cohort. Their data was then used to compare and contrast with the non-AMD data.  
The number of participants in the flow chart studies was lower than expected, but were still 
within the range calculated to show a significant effect. The recruitment for the qualified 
practitioner study was via two mainstream optometrist magazines with a fairly wide readership, 
but the adverts were quite small and could have been easily missed by many readers. Again, 
time constraints meant that recruitment had to be halted after three months. It was surprising 
that there was a number of ‘drop-outs’ (those that completed the initial survey but not the 
second) despite three follow-up emails reminding the participant to complete the second 
survey. This may have been due to participants only wishing to get access to the flow chart 
with little interest in the evaluation process. It would have been useful to recruit 
ophthalmologists into this cohort, and it is hoped that this group could be recruited in the future. 
The number of participants in the student practitioner cohort was also lower than anticipated, 
but as the third year students are extremely busy in the final part of their studies, this was not 
too surprising. Many students expressed regret in not being able to help due to timetabling 
issues, and would have happily attended another tutorial session if it was set-up - the results 
gained from this second group, however, would not be reliable as the participants may have 
been already exposed to the flow chart and scenarios by the first group. As we did not know 
how many students would attend, and which students would attend, we were unable to 
randomly allocate participants to groups. 
9.3 Confounding variables 
Survey study 
The survey was performed over the telephone thereby giving participants very little time to 
think about their answers, and viewpoints would therefore be less practised. As can be seen 
from the focus group transcription (see Appendix 6) however, participants seemed to be 
dissatisfied with their care and services available to them, which is why they were seeking the 
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Macular Society. To get a rounded viewpoint, patients from other organisations such as the 
RNIB could be included. 
There were more females than males in both the AMD and non-AMD cohorts, which may be 
considered a confounding variable. One of the aims of the survey, however, was to reflect 
which patients are likely to seek the assistance of the Macular Society, and this gender 
difference is a finding. When viewed in this light, the gender inequality in the cohort becomes a 
positive aspect rather than a negative. 
There is known variability when self-reporting health and visual ability 205, so it cannot be relied 
upon that many participants had poor vision. Information about their visual acuity would have 
been a useful parameter to record, but impossible due to the physical location of all of the 
participants. Co-morbidities may have played a role in diet behaviour, and it would have been 
useful to note down physical parameters such as weight, height and how physically able the 
participants were. 
Although care was taken to note down size of portions, and participants were asked to be very 
specific, there will be differences in the amount and type of food recorded. The well 
documented under-reporting of food occurs in every age group 206, 207 , and must be taken into 
consideration. For future studies, we may implement a visual recording of food, such as a 
photo, to get a more accurate idea of portions.   
Qualified practitioner and student practitioner evaluations 
Confidence and self-efficacy reporting is subjective. It was felt, however, that despite the 
variations, self-efficacy is a more useful quality to evaluate than knowledge, as an individual 
may have a large amount of knowledge but poor confidence to implement it. As shown by the 
student practitioner study, as soon as information about a topic is read (no matter what form), 
confidence will increase, and this needs to be taken into account. 
Confounding variables in the qualified practitioner study might have been present without the 
investigators realising, since the participants were taking part from across the UK with only 
email contact. It is feasible that participants decided to research the topic in the two-week time 
frame which increased their confidence. There are no guarantees that participants actually 
used the flow chart at all, and completed the second survey out of a sense of obligation.  
The groups in the student practitioner cohort were assigned on the day, and the participants 
were physically spaced out so that conferring could not take place – however, there is always a 
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possibility that this still occurred. There is a learning effect to completing the same task again, 
and students may have felt more confident simply by carrying out the scenarios a second time. 
Since there were a lot more females in the student cohort, and confidence levels between 
genders can be different, it would be wise to think of gender as a possible confounding variable 
in this study. The clinical scenario tasks differed in difficulty – students appeared to find the 
third scenario much more difficult, and the fourth scenario much easier. Ideally, to get a more 
accurate representation of the student’s decision making, the difficulty between the tasks 
should vary minimally. 
9.4 Improvements 
A longer food diary will show if the trend for AMD patients to eat less, continues. Since in this 
project the survey was implemented over the phone, it would have been unreliable to make 
participants remember what they had eaten two or more days prior to the interview. If the 
survey is to be carried out in the future, a longer food diary with visual recordings (such as 
photos) will help to investigate this trend. 
Measurement of visual acuity, co-morbidities, weight, height and physical ability all may have 
enhanced the results obtained.  
9.5 Conclusions 
This project has shown that AMD patients want and need improved nutrition and diet advice 
from eye care practitioners. AMD patients are not consuming the beneficial nutrients to help 
their condition, and are at risk of damaging their general health by not eating enough food in 
general. 
Eye care practitioners respond well to clear-cut nutrition advice guidelines, and report more 
confidence in giving nutrition advice when they have access to a clinical decision-making aid. 
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Appendices 
Appendix 1 .Good food sources of vitamin C provided by the American Optometric Association  
: http://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional. 
 
 
Appendix 2. Recommended dietary allowances for vitamin E, as taken from the National Institute for Health, USA 
Government website: http://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional. 
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Appendix 3. Good food sources of vitamin E provided by the American Optometric Association 
Appendix 4. Recommended dietary allowances for vitamin C, as taken from the National Institute for Health, USA 
Government website: http://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional. 
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Appendix 5.  Lutein and Zeaxanthin content in various foods in mole %. Mole percent, or molar percent of a 
substance is the ratio of the moles of a substance in a mixture to the moles of the mixture. It represents the number 
of moles of a substance in a mixture as a percentage of the total number of moles in the mixture. Mole % = (mol 
substance in a mixture) / (mol mixture) * 100 151 
 
 
Lutein and 
zeaxanthin 
Lutein Zeaxanthin 
α 
carotene 
β 
carotene  
Egg yolk 89 54 35 0 0 
Maize (corn) 86 60 25 0 0 
Kiwi 54 54 0 0 8  
Red seedless 
grapes 
53 43 10 3 16  
Zucchini squash 52 47 5 0 5 
Pumpkin 49 49 0 0 21 
Spinach 47 47 0 0 16  
Orange pepper 45 8 37 8 21  
Yellow squash 44 44 0 28 9 
Cucumber 42 38 4 0 4 
Pea 41 41 0 0 5  
Green pepper 39 36 3 0 12  
Red grape 37 33 4 1 6  
Butternut squash 37 37 0 5 0  
Orange juice 35 15 20 3 8 
Honeydew 35 17 18 0 48  
Celery (stalks, 
leaves) 
34 32 2 13 0  
Green grapes 31 25 7 0 7  
Brussels sprouts 29 27 2 0 11 
Scallions 29 27 3 0 0  
Green beans 25 22 3 1 5 
Orange 22 7 15 8 11 
Broccoli 22 22 0 0 27  
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Lutein and 
zeaxanthin 
Lutein Zeaxanthin 
α 
carotene 
β 
carotene  
Apple (red 
delicious) 
20 19 1 5 17 
Mango 18 2 16 0 20  
Green lettuce 15 15 0 16 0  
Tomato juice 13 11 2 12 16 
Peach 13 5 8 10 50  
Yellow pepper 12 12 0 1 0 
Nectarine 11 6 6 0 48  
Red pepper 7 7 0 24 3  
Tomato (fruit) 6 6 0 0 12 
Carrots 2 2 0 43 55 
Cantaloupe 1 1 0 0 87  
Dried apricots 1 1 0 0 87  
Green kidney 
beans 
0 0 0 0 0 
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Appendix 6 
Transcription for the survey focus group teleconference. 
 
The reason why we have got you all together to give up your time very kindly is because any 
type of questionnaire based research needs some kind of validation and part of the validation 
process is to get a focus group of people who took part in the pilot just to find out their thoughts 
really. So we’re just looking at how useable acceptable you found it and your general or 
specific feelings. Now anything that you tell me I’m not going to note down who said it so it’s 
kind of anonymous in that way, I’m literally just going to write down and record what you are 
saying. Don’t feel like you have to hold back in any way you can literally say whatever comes 
to mind even if you think it’s terrible just say it, it’s really important for us so then we can amend 
thing accordingly. Does that make sense? By the way if you need to go please do so, I’m 
hoping this won’t take very long at all, fingers crossed it should only take a few minutes, alright 
that would be grand.  
OK so first of all when you  were approached to take part in the questionnaire did any of you 
feel under pressure or… 
-No, no, no, no not at all 
So were you asked to do it as a favour for the MDS or for Aston research group… 
-I don’t really remember, yes it was for the macula group and Aston society so yes anything 
that will help I like to do for them, for us all really. 
-That’s how I feel too. 
Fabulous.  Sorry for the delay I’m writing as you are talking, ok brilliant. So did any of you worry 
about your answers being anonymous or your details being known to any other party? 
-No, no, no, no 
Would you change any way, anything about how you were approached at all, could it have 
been done in a better way? 
-No, no, no it was fine, I don’t see how any other way is possible you know 
I think how it will be done is probably via the help line people will be asked if they would like to 
take part in the research and if so we’ll take their details and call them back at a later date, the 
option is that we could complete it there and then but I think it’s better to go back to it when the 
patient has had time to think about it which is what happened with yourselves, if you wanted to 
opt out then you could have done at that point. 
-I preferred someone to come back to me. 
-When you say via the helpline what do you mean? If someone rings the helpline up they might 
be asked if they want to take part? 
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Yes, what do you think about that? 
-Well if they ring the helpline they’re probably in need of help rather than being asked to do 
some research. I thought you meant the helpline would ring people that belonged to the 
society. 
Well I think that’s going to happen as well. 
-Could you not put something on the website? 
We can yeah. 
-Everybody doesn’t have a computer.  
-No but they only need a few people. 
-But still yes you need a cross section 
-How many people are you thinking of? 
-In my MD group the majority don’t have computers but I’m sure they’d be very good to do 
research on about whether they’re getting the nutrition they should be getting. 
-Or you could actually send out a letter to all the groups. 
-Yes that might help 
-Then they could do their own survey within their group 
-But then I could have a problem with the York group because they’re not really affiliated to the 
macular society, the York blind and partially sighted society who started this group about 30 
years ago I think but they don’t get letters unless the chairman is a member of the macular 
disease society, a lot of them aren’t members we try and get them to but they won’t. 
-That’s the same with Barnet’s in London, The Barnet’s Sight and care group, whereas we do 
get the literature only a handful of us belong to the society. I’m sure they’d be willing to take 
part. 
-I think they would yes but they don’t need to be part of the society to take part. 
-No they don’t but I was just getting the information across. 
-I know yeah. 
-I suppose it would have to be someone like me who goes to the society or group to tell them. 
But I’m not sure I like the idea of if someone has a problem, rings the helpline being asked if 
they would do something. 
-Yes I agree. 
-Thinking of what I was like when I first had it. 
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OK 
-I think from my point of view my own support group would be very happy to have a phone 
number and if they wanted to take part to give someone a ring and put their name down as it 
were and get someone to ring them back. 
Righty ho. 
-That’s an idea we could always do that with any of the groups couldn’t we. 
Brilliant, good, thank you. So did the questionnaire take up as much time as you expected or 
did you expect it to be longer or shorter, I know I chatted a bit. 
-I’ve no idea I was recovering from a shoulder operation. 
-About 20 minutes was it? 
-Yes it was 
-Yeah it was long enough 
-Anything longer too long 
Now were you happy to chat or would you have preferred the questions to more succinctly put? 
-I’m always happy to chat 
It’s not a general consensus, I’ll note down what everybody says 
-I was quite happy the way it was 
-As long as we didn’t take too much of your time I suppose 
It’s my job. 
-Could I ask about the point where you are contacting other people about their nutrition 
etcetera are you always going to do it on the telephone? Or is there any other way you are 
going to contact people? 
Do you mean when we contact them to take part? 
-Yes 
When we’re actually doing it, it will have to be consistent so it will have to be telephone. So 
what we’re planning to do is the survey itself will be uploaded to a website but the subject isn’t 
actually going to do that themselves, we are going to have a volunteer, I think it’s possibly Tom 
who is listening in at the moment who will be filling in that survey for them via the phone. 
-Aha yes makes sense I was just wondering how people were going to get the stuff down. 
Yeah it’s difficult because you have to vary your questionnaire according to the method in 
which you are deploying it. 
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-Yes I know, I’ve done this before. 
So if we can keep it consistent I think that’s the general idea. OK, so the initial questions were 
what we would class as demographic questions finding out a little bit about you, did any of you 
find them intrusive at all? 
-No, no, I can’t remember what they were 
Things like your age, who you live with, what type of accommodation you are in and what your 
occupation is essentially 
-No didn’t worry me, just wondering why it was relevant what type of accommodation you were 
living in, I thought it was going off the point a little. 
-I thought it was if we needed help, how we managed in the house 
It is about trying to link in certain questions, if somebody was living in sheltered 
accommodation they might be having their meals sorted for them and we would be asking that 
later on, so what they answered earlier would change what I asked later on.  It’s for that 
reason, also when we try to do the statistical analysis it’s to put people into different groups, 
but we don’t want it to be intrusive. 
-Could you say a little bit at the time why you are asking that question? 
We could do yeah 
-I thought you were just asking about the welfare of the person you were speaking to, I 
remember saying I’d just had this operation and I had all the food in the freezer and I was fine. 
It is partially that as well 
-There are some people who aren’t able to do that. 
Yes absolutely 
-I trusted it because it was the macular society and you were from Aston University and it was 
a good thing.  But I get a bit annoyed when its people who are cold calling and they ask what 
sort of accommodation you are in, those times it can be intrusive. This was only OK because of 
the background. 
-I tell them I live in a tent 
It would be better to have an explanation bit in there 
-But it’s not cold calling 
So the next bit of the questionnaire was about the type of AMD or macular issue you had. Did 
any of you mind answering that? 
-No, no, no.  Taking part in a survey you’ve got to expect to answer questions. 
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Would any of you think that the general public might not know the types of AMD, they might 
just have been told they have AMD. 
-Yes that happens 
-I had it all explained to me, depends who your consultant is and what the nurse tells you I 
suppose. 
-I’m a group leader and I know people often don’t know what type they’ve got 
-It’s becoming rarer because opticians are much more aware of MD and they’ve got the stuff in 
their consulting rooms, but I’ve been doing this a few years now and I see more and more 
people coming and they know whether they have wet or dry, but there’s just the odd person 
-Sometimes they don’t know because they haven’t taken it in 
-Sometimes it takes time to diagnose, it took 10 years for myself, and someone I was talking to 
the other day, he’s not been diagnosed and he’s in his 50s 
-It’s because they don’t expect you to have it 
-Yes, it can be very rare 
-And it can be combined with other things 
Good to know 
-We’re getting better I find, at hospital they answer questions but not everybody likes to ask. 
They’re in shock at the time I think.  They can’t formulate a question. 
-At our hospital there isn’t room for carers to sit with them, they do about 60 a day and they 
come out a little bit bewildered some of them at times, that’s when I trot up and down the line, 
but I only go once a month. 
What did you think about us asking about the visually impaired register? Was that something 
any of you minded being asked? 
-No, I think it’s important to know who’s actually registered 
-A lot don’t want to register, I find there’s a lot who don’t want to register 
-You know why don’t you? 
-They can’t drive, that’s why they hang on until the last minute 
I had a whole section which I think some of you didn’t actually answer because you answered 
differently early on about cooking and preparing food.  I did have some options about who 
mostly cooks and who mostly prepares food and the options were yourselves, your partners, 
your family members and your care givers.  Is there anybody else I could have included? 
-Meals on wheels, you might have to include where the meals come from. 
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-I get Wiltshire farm foods.  There’s another firm but I don’t remember the name. I only do that 
because of my shoulders, not because of my eyes. 
-Could you include an open question? 
I was just checking I hadn’t missed a major category 
-I live out in the country and there’s a lot of young people who like to cook and freeze things 
and they pop round and say “We’re cooking do you want anything?” 
-That’s lovely, but what do you call them? Preparers or helpers? 
-We pay for it 
-Don’t think you’d get that in our area 
-Nor mine 
-What would you call them, that’s what I was meaning 
Paid assistance maybe? I’ll put some thought into that. 
Now I’ve got a list of reasons for people not being able to cook or prepare food, and I’d got 
visual impairment, physical impairment or other.  Anything else I should have put in there? 
-No, physical and eyes are about the only things 
I then asked you all about what you ate yesterday, did any of you find that difficult to do? 
-No, sometimes I have to think, but if I really concentrate then no. 
Now we found a huge variation on the amount of detail you provided, would it be useful for you 
to just say whatever you wanted or should I have been a little more explicit with what I said? 
-I just wondered what was the point of the survey.  Was it in general to find if people of a 
certain age aren’t able to care for themselves therefore their nutrition isn’t adequate at this time 
in their life or is it in their history, what was their diet like as a child, any absorption problems or 
have they avoided any food because of allergies or they didn’t like them.  In a way I didn’t think 
it was specific enough with foods that may be good for you you have avoided throughout your 
life for whatever reason and have a common link or you have macular disease because you’ve 
had a bad diet from fifty onwards. I’m in my fifties and I’ve had this since my forties so it’s my 
diet in my twenties or as a child that has affected it now.  In a way I thought it was too general, 
the questions. 
So this timeframe is too small? 
-Yes I wish you had gone back to childhood.  The only complaint I had is that the society did a 
survey looking at diet, absorption and ulcerative colitis, it would be good if someone went 
through all the foods we are avoiding, for example I never ate any eggs and I am wondering if 
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eggs are very good for you then that’s probably why my eyes are very bad.  That’s just one 
example and in a way I’d like it more specific. 
-I think so, if they’re really going to go into the nutrition bit a lot of us who are in our eighties 
can go back to what we had during the war. It’s a very big subject. 
-On the other hand you can’t say if you were deprived of certain things during the war maybe 
that’s a reason for macular degeneration.  I used to smoke in my student years and some lady 
said to me that’s why you’ve got macular degeneration. That might be but as regards our 
condition there are all sorts of things that might come in that will cause it not necessarily lack of 
certain foods. 
-And also you didn’t ask whether it was in the family either. 
-But you wouldn’t have known way back because it wasn’t diagnosed. 
So asking about AMD in the family. 
-If that’s what you want as regards your nutrition survey.  You may not want to know that. 
It’s all up in the air really, its trying to work out what’s going to give us the best unbiased view 
and what to leave in and what to take out, but we don’t want it to be too longwinded, bit of a 
toss up really. 
-Everyone thinks they have a good diet until things are pointed out to them. 
-It’s just AMD you are surveying not the dystrophies? 
No technically it’s just AMD, I know we bent the rules just for yourselves but for the official 
survey it will just be AMD. 
-Might be useful then to ask what their diet was like or had they had any illnesses as well like 
ulcerative colitis or Crohn’s disease where you are not having full absorption. 
So it would be useful to pop in a general health question. 
-Can you just say quickly what is the point of it? What is it about? I know it’s about nutrition but 
what are you trying to do? 
We are trying to find out if people are being given enough information about nutrition from the 
practitioners point of view but also whether there’s a case to show patients with AMD find doing 
that nutritional advice difficult.  So if people are told to eat kale but have difficulty preparing it 
should we be doing something else. 
-Like supplements 
-Really then what they’ve had in their past life is irrelevant. 
Sort of yes, but it is important to know the type of subject we are dealing with.  So someone 
who is in their fifties and suddenly develops AMD and someone in their eighties who has had 
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AMD for some time that goes wet, we would want to see the differences between the two, so 
putting in a general health question would probably be quite good. 
-When people get older sometimes they can’t be bothered to eat properly 
Yeah we’ve got to find that out, is it their eyes or is it other factors 
-You want to see how different is their diet, whether they are taking all this stuff the kale and 
egg yolks are you wanting to know if they are doing that is it making a difference 
-You wouldn’t be able to tell that 
You couldn’t do that on a questionnaire, its more about how patients are feeling themselves, 
are they being given advice and then are they able to put that advice into practice or is that 
advice redundant because of their condition, its almost like a chicken and egg situation 
-I don’t think they’re given advice through the hospital are they? 
That’s the thing we need to find out 
-Well I was but I think my consultant was a bit of an exception 
I asked everybody about a list of foods, carrots, spinach, ice cream and whether it affected eye 
health and we were thinking of asking why you thought it affected eye health.  Do you think that 
would be a good idea or would it be too hard for some people? 
-Why do we eat these foods? Probably because we’ve been told at a conference that these 
foods are beneficial for people with AMD.  I wouldn’t have had kale unless I had been told 
specifically because it wasn’t available at one time.  Now it’s much more available. Whether 
that’s through the macular disease society I don’t know. I think people who have been to the 
conference and listened to people talking about nutrition and bought a cookbook, I don’t think 
other people would be aware of these foods. 
-But we have the macular booklet A51 which is good and feel we have it drummed into us and 
if you are part of a group you probably know these things. 
-There are those who want to hear and when I chat to people they don’t even know there is a 
macular disease society. The problem is there is a table but everyone has drops in their eyes 
so they don’t read it. There’s not enough room for carers so they are in the wrong place. A lot I 
talk to don’t even know there’s a group. 
-My consultant has help cards with a number on, he gives those out. 
I talked about nutritional supplements and it occurred to me that someone in the general public 
might not know what a supplement was.  Is that something you’ve come across in your 
groups? 
-No, but it is possible I suppose. 
-I think it would be good to put something about lutein and antioxidants in it. 
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Define it a little better then? 
-Maybe they could have a questionnaire handed to them by whoever is looking after them in 
the department just to say do you eat this and do you take that supplement. Would that be any 
good? 
-It’s very difficult there’s lots of bits of paper on the chairs but everybody sits on them. They 
don’t pick them up because they’ve got the drops in. 
I also asked at the end how much money people would be willing to spend on a nutritional 
supplement that would be useful for them, and why they would be willing to spend it. Is that a 
good idea? 
-Yes. 
We added the why so we could find out if it was their personal income or the nutritional 
supplement. 
-If they’re going to work I probably would but there’s no guarantees. 
-Surely there’s one supplement you can get on the national health. 
-My doctor won’t give me mine now. 
It’s very variable. I think everyone is waiting for the AREDs study. 
Would you have liked a section about AMD to express your thoughts about how much 
information is given and we jotted down your thoughts, would that be a good idea? Or would 
you prefer to say how you feel about certain statements? 
-Is that really relevant to your study about nutrition? 
-It would make your questionnaire far too long because some people have issues and would 
go off on a tangent. 
-How would that be useful to you? 
It’s all part of qualitative analysis which lets the subject tell you exactly what’s on their mind and 
sometimes gives you a better idea of their thoughts rather than try to restrict them into a certain 
category. It’s harder for the person collecting the data but at the end it can be more useful. 
-If it’s useful give people an opportunity if they wish. 
-Can you record it? 
We don’t know yet, we have to fill in ethical applications. 
-I think you’ll get a lot of response because there’s a big gap from when they’re first diagnosed 
and what happens to them. There’s no continuity, it’s just here you go, goodbye and they leave 
the consulting room shocked, angry and thinking now what happens, and they are turned out 
on the street and sort yourself out. There’s a lot of anger and this will all come out. 
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-If the social worker is not at the hospital at the time they’re not guided to ask her any 
questions. I think that would be a good idea but then you’ve got to get up to the staff and 
consultants and get them a leaflet to take home for them or their carer to read. 
That was all the questions I had for you, I would just like to know if there’s anything else you 
would like to change in the questionnaire or point out any flaws or anything else you can think 
of and I will make a note of them. 
-When you’ve done this questionnaire and got it all assimilated do you send it to the 
ophthalmologists? 
No it’s probably going to form part of other research and may branch into something else.  
Eventually though it will get published and ophthalmologists and opticians will be able to see it. 
We were thinking of doing an advertising campaign of what we are doing but it’s all up in the air 
until we know what our data is. 
-I think an advertising campaign would be useful as people don’t realise what you can see and 
what you cannot see and why, and people think oh you’re blind.  Make people aware that eye 
problems exist and because you can see something you’re not fine, and correlating some of 
your information to the healthcare workers but there’s big gaps in how they work because it’s 
not in their job description, pointing out where they can help. 
-Everybody’s different in what they can see with AMD. 
-People who can see might then be aware of what it’s like with AMD, and even having a bit 
more understanding when somebody stands next to you and asks you to read something they 
don’t give you a double take “Woah that’s big enough can’t you see that”. Some people have 
sight problems and don’t have a sign on top of their heads saying I have a sight problem. 
-I have to say I can read but I can’t see it. 
-You have to justify everything and that’s what annoys me.-The badges we wear, people don’t 
like wearing badges. A lot of people who can see don’t know what it is anyway. 
Any other thoughts with regard to the questionnaire? 
-Why did you ask about ice-cream? 
A lot of people will correlate carrots with eyes because that’s what they’ve been taught. Putting 
a bit of a curve ball in like cheese and ice-cream it’s to filter out people who would just say yes 
to anything. 
-But with the ice-cream and the cheese I think fats are good with the anti-oxidants because 
they absorb better, I thought that’s why you put the cheese question in. 
Not necessarily, but we want to know why people say yes to why they affect the eye. 
-So are you going to say anything about the needs for fats with anti-oxidants? 
We are not going to comment in any way. 
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-Not even at the end of it? Things like the omega oils are good. 
With regards to nutrition that is good for AMD it is literally just the antioxidants. Lutein and the 
things that you would find in kale and chard and that sort of thing, I put mango down and that is 
not particularly useful although people assume it is. There’s a lot of variability and we wouldn’t 
even comment at all even at the end of the questionnaire, we would refer the patient back to 
the MDS for the information. 
-I’ve taken antioxidants for ten years and I’ve still got it. 
-With all these things there really is no proof. 
Everyone’s waiting for the AREDS study for guidelines. 
-I think it’s been proved about the lutein though hasn’t it. 
That’s why lutein injections are given. 
-Ooh do they do lutein injections? 
Yes the issue is capturing at a certain stage of the AMD before treatment can be done. 
-I was talking about lutein not lucentis! 
Oh sorry. 
-Lutein spray, capsules, by mouth. 
It’s about trying to do as much as you can, for some people it’s good and for some people it’s 
not so good. It’s kind of luck of the draw. It’s worth a go for many people. 
-Anything’s worth a go. 
-Then there’s sunlight as well isn’t there 
Well that’s it at the end of the questionnaire I asked about smoking. I think what we will do is 
not give the categories out at all just ask them what behavioural or conditional factors affect. 
Anything else ladies? 
-Sorry I have to go, is that it? 
Yes, that’s it. I’m really really grateful. Is there anything that Tom or Andy or Pete want to add 
at all 
-No 
-I don’t think so Rebekah 
Fabulous, thank you very much. 
-There is one thing, I wondered if your sample gets the opportunity to get your research 
results? 
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Tentatively yes everyone gets the chance, I’m not sure how that will be distributed. We will 
definitely make the results known to MDS, but whether we get everyone who took part and give 
it them might be a different matter.  What we might have to do is provide a contact number or 
email for them to come in themselves. 
-Webpage? 
-Publish in the magazine? 
Yeah that’s the other thing the MDS magazine would be useful. 
-Even a more in depth one in digest. 
-Yes 
-I think that’s a good idea and I’m sure that will be done. 
Thank you I’m really grateful. This is an important part of the validation process. This focus 
group has made it more valid. Hopefully we won’t have to bother you again. 
-Bye 
-Bye 
-Bye everybody 
51.53, focus group have left conference 
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Appendix 7. Final survey. 
 
Questions Options 
How old are you?   
Would you describe yourself as… Male 
  Female 
Do you live… Alone 
  With partner 
  With family 
  With friends 
  Other (please specify) 
Do you live… In own residence 
  In family/ friend's residence 
  In sheltered 
accommodation 
  In nursing home 
  Other (please specify) 
What is, or was your main occupation   
How would you describe your general health today? How would you describe your vision today? Extremely good 
  Good 
  Satisfactory 
  Poor 
  Extremely poor 
Do you have the eye condition age-related macular degeneration Yes 
  No  
  Have not heard of this 
condition 
If Yes, how many years have you had it in total?   
What type of age-related macular degeneration do you have?   
Are you on any visually impaired register? Sight impaired (partially 
sighted) 
  Severely sight impaired 
(blind) 
  Neither 
Who MOSTLY prepares your food? You 
  Partner 
  Family member 
  Care giver 
  Other (please specify) 
Who MOSTLY cooks your food? You 
  Partner 
  Family member 
  Care giver 
  Do not eat cooked food 
145 
 
 
 
  Other (please specify) 
What prevents you from preparing food (select all that apply) Visual impairment 
  Physical impairment 
  Nothing 
  Other (please specify) 
Are you able to cook a hot meal on your own? Yes 
  No 
What prevents you from cooking food (select all that apply) Visual impairment 
  Physical impairment 
  Nothing 
  Other (please specify) 
Who MOSTLY does your food shopping? You 
  Friend 
  Family member 
  Care giver 
  Other (please specify) 
Where do you get your food from? (select all that apply) Supermarket 
  Local grocers/ corner shop 
  Internet 
  Meals on wheels 
  Market 
  Grow own food 
  Other (please specify) 
What is the most important factor that dictates what you eat? Cost 
  Preference 
  Habit 
  Ability to cook or prepare it 
  Ability to acquire it 
  How it affects your health 
  Other (please specify) 
Would you like to change your diet in any way? Yes 
  No 
What prevents you from changing your diet? Visual impairment 
  Physical impairment 
  Nothing 
  Other (please specify) 
  Do not want to change diet 
Please could you describe what you ate yesterday (Breakfast, Lunch, Dinner, Snacks - your 
interviewer will describe portions). 
  
Were the vegetables eaten yesterday (if any)… Mostly cooked 
 
  
Mostly raw 
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  No vegetables eaten 
yesterday 
Please state how strongly you agree or disagree with the following statement:  Strongly agree 
There are specific foods that can affect your health. Agree 
  Neither 
  Disagree 
  Strongly disagree 
Please state how strongly you agree or disagree with the following statement: Strongly agree 
 There are specific foods that can affect your EYE health. Agree 
  Neither 
  Disagree 
  Strongly disagree 
Do you think any of the following foods are beneficial for eye health… and why Carrots 
  Ice-cream 
  Spinach 
  Cabbage 
  Kale 
  Bilberries 
  Cheese 
  Peppers 
  Mango 
Which, if any, of the following vegetables did you eat last week? (select all that apply) Carrots 
  Peas 
  Spinach 
  Cabbage 
  Broccoli 
  Kale 
  None of the above 
Have you ever discussed taking a nutritional supplement with a health specialist or advisor? Yes 
  No 
If yes, who? Ophthalmologist 
  GP 
  Optician 
  Specialist doctor 
  Nurse 
  Herbalist 
  Pharmacist 
  Dietician 
  Helpline worker 
  Other (please specify) 
Do you Currently take any nutritional supplements? Yes 
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  No 
If yes, what supplements do you take?   
How often do you take the supplements listed above? More than twice per day 
  Twice per day 
  Once per day 
  Once per week 
  Other (please specify) 
If you answered No, Can you give a reason for not taking a nutritional supplement Too expensive 
  Not sure if effective 
  Fear/ experience of side-
effects 
  worry about interaction with 
other drugs 
  Too much trouble 
  Other (please specify) 
How much money would you be willing to spend on a monthly basis on a nutritional supplement 
which promised good results? 
No money 
  £1-5 
  £6-10 
  £11-15 
  £16-20 
  £20+ 
Please state how strongly you agree or disagree with the following statement: Strongly agree 
 Age-related macular degeneration patients are given enough information on how nutrition 
affects their eye health. 
Agree 
  Neither 
  Disagree 
  Strongly disagree 
Where have you received information on age-related macular degeneration from? (select all that 
apply) 
Opthalmologist 
  Optician 
  Internet 
  Newspapers 
  TV 
  Organisations such as the 
Macular Society 
  Other (please specify) 
Do you believe that age-related macular degeneration can be prevented by lifestyle choices such 
as nutrition? 
Strongly agree 
  Agree 
  Neither 
  Disagree 
  Strongly disagree 
Which changes to the way that you live do you think could affect age-related macular generation?   
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Appendix 8 –Example of a flowchart used in optometry is the US to help aid diagnosis 
with low vision patients from http://www.odcareer.com/bad-vision/ 
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Appendix 9. Final flowchart. 
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Appendix 10. Qualified Practitioner Survey 
 
1. I confirm that I have read and have understood the information for the above study and have 
had the opportunity to ask questions via email.  
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my legal rights being affected.  
3. I agree to take part in the above study.  
4. Please tell us the first three letters of your Mother's maiden name  
4.a. Please tell us the last three digits (one number and two letters) of your postcode  
5. Please provide a valid email address below. This will be used to send a link to a follow-on 
survey. 
6. How old are you?  
7. Would you describe yourself as... Male or Female 
8. How many years have you been practising as an eye care clinician?  
9. On average, how many patients with AMD do you see per week?  
10. Which country do you currently practise in?  
11. Please state your ethnic background 
12. Please select an option for each row of the table to indicate the degree of confidence you 
feel for each of the following statements: 
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    Select you level of confidence from 0 - no confidence, to 100 - highly 
confident   
   0    10    20    30    40    50    60    70    80    90    100   
 a. I am confident that 
I could classify the 
type of AMD a patient 
has based on retinal 
signs  
           
 b. I am confident that 
I can advise a patient 
with AMD on the 
relationship between 
AMD and nutrition  
           
 c. I am confident that 
I can advise a patient 
with AMD on what 
foods to eat that might 
be beneficial for their 
condition  
           
 d. I am confident that 
I can advise a patient 
with AMD on the 
quantities of foods 
that might be 
beneficial for their eye 
health  
           
 e. I am confident that 
I can advise a patient 
with AMD on when 
nutritional 
supplementation may 
be beneficial  
           
 f. I am confident that I 
can advise a patient 
with AMD on what 
supplements to take 
and what dosage to 
recommend  
           
 g. I am confident with 
talking about nutrition 
to those at risk of 
AMD  
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Appendix 11 - Clinical decision-making aid FAQs. 
 
 
 
 
Nutrition Advice for people with or at risk of AMD 
 
Frequently Asked Questions 
 
 
 
 
Why is AMD research important? 
 
Age-related macular degeneration (AMD) is the leading cause of visual impairment in older adults in 
the developed world (1). As the population increases and people continue to live longer, finding 
ways to reduce the risk of onset and progression of the condition is imperative. 
 
What risk factors are associated with developing AMD? 
 
There have been many studies into risk factors associated with AMD. These include age, gender, 
genetics, UV light, smoking, light coloured irises, hyperopia, race, BMI and obesity, alcohol, cardio- 
vascular disease, statins and some hypertensive medication (2). Many studies have been concerned 
with investigating the density of macular pigment at the macula. Macular pigment is made up of 
lutein, zeaxanthin and meso-zeaxanthin, and these carotenoids collectively protect the macula from 
oxidation and blue light which are thought to be involved in the development of AMD. Macular 
pigment is acquired purely from our diet. Some studies have shown that the density of macular 
pigment is lower in those with AMD. 
 
Which foods contain lutein and zeaxanthin? 
 
The largest amount of lutein and zeaxanthin can be found in kale, spinach, eggs and goji berries. 
Other leafy green vegetables, peppers and some fruits also contain the carotenoids, but with lesser 
amounts. To impact on the macula pigment, 10mg of lutein and 2 mg of zeaxanthin ingested per day 
has been found to be beneficial (3). This can be obtained by eating only two eggs OR a large cup 
(150g) full of cooked spinach OR kale per day (4). 
 
A patient might feel that these foods are not to their taste and would rather have a nutritional 
supplement instead. There is positive research to support supplementation in patients with 
intermediate to advanced AMD – the clinical decision making aid will enable you to decide whether 
a patient falls into this criteria. There are currently many eye supplements available, and there have 
been many studies into various formulations of supplementation – the largest trial of recent years is 
the Age-Related Eye Disease Study (AREDS) based in the US. 
 
What is the Age-Related Eye Disease Study (AREDS)? 
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The world’s largest clinical trial into dietary supplementation for AMD was first conducted in 2001. 
The follow up trial study (AREDS 2) released their results in 2013. The team initially investigated a 
combination of high dose nutrient supplementation on AMD and cataracts over a period of 6 years. 
The AREDS formulation of vitamin C 500 mg, vitamin E 400 IU, b-carotene 15 mg, and zinc (zinc oxide 
80mg and cupric oxide 2 mg) showed a 25% risk reduction in progression to advanced AMD over 5 
years in patients with intermediate AMD (extensive intermediate drusen in one or both eyes, one or 
more large drusen in at least one eye, or nonsubfoveal geographic atrophy in one eye) or advanced 
AMD (subfoveal geographic atrophy or choroidal neovascular membrane) in one eye (5). The risk of 
losing vision of three or more lines also was reduced by 19% with this combination treatment. 
Because of the high dosage of zinc, and the inclusion of beta-carotene, some ophthalmologists and 
other eye professionals became concerned with the safety of the formulation and were reluctant to 
advise patients to use it. 
 
A further study (AREDS 2), which encompassed lutein and zeaxanthin to the original AREDS 
supplement formulation, found that using lutein and zeaxanthin instead of beta-carotene further 
reduced the risk of progression to advanced AMD by 18%. The dose of zinc was reduced in this new 
formulation (3). 
 
What advice can practitioners provide for patients who have, or are at risk of, AMD? 
 
Currently, the advice that practitioners provide patients can be vague. The College of Optometrist’s 
guidelines state that patients should “eat leafy green vegetables”. A recent study into AMD patient’s 
nutritional behaviour showed that the majority of AMD patients felt confused by the information 
given to them, and many reported that they needed much more guidance (6). Patients are also 
overwhelmed by the number of eye supplements on the market – many of which have no clinical 
evidence to support them. 
 
By using the AREDS 2 study as a guideline, practitioners can be more unified in giving nutritional 
advice to patients with the confidence that the advice has been rigorously investigated. The clinical 
decision-making aid is designed to help decide which advice to give – supplementation and/or diet 
modification, labelled as ‘Advice 1’ and ‘Advice 2’. 
 
Advice one refers to dietary modification – the patient can incorporate 150g (one cup or one large 
handful) cooked spinach or kale, or two cooked eggs into their diet. These can be eaten either alone 
or part of a recipe. Advice two refers to supplementation - the supplement type can be narrowed 
down to the AREDS2 formulation, the details of which ones are shown below. 
 
Can a simple balanced diet provide 10mg of lutein and 2mg of zeaxanthin? 
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Incorporating some leafy green vegetables such as cabbage and broccoli will provide the body with 
some carotenoids. However, standard portions of many vegetables and fruits will not provide the 
recommended 10 mg lutein. Examples of the amounts of lutein available in different foods can be 
found in the table below. Please note that lutein and zeaxanthin are extracted from foods together, 
so a small amount of zeaxanthin will be incorporated with each 10 mg portion of lutein. 
Are two eggs per day safe? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Up until recently, eggs have been linked to increased cholesterol and the Food Standards Agency’s 
advice was to limit consumption. However, this advice has now been altered and now consumption 
is unlimited. The guidance for older adults is to make sure the egg yolks are fully cooked to avoid risk 
of salmonella poisoning (7). 
 
 
 
 
What is geographic atrophy? 
 
Geographic atrophy can be defined as a demarcated circular shape at the central macula, with 
reduced retinal pigment epithelium. Please see the diagram. 
 
Diagram available from www.myvisiontest.com Why do the drusen 
need to be larger than the central retinal artery? 
 
As we are only able to give advice based on the exact AREDS2 inclusion criteria, supplementation can 
only be recommended if the drusen are larger than 125µm. Since this is a difficult size to evaluate, 
we have used a retinal marker to help gauge the size. The average central retinal artery can vary 
between 140 - 170µm, and so underestimation of drusen is unlikely by using this retinal marker. 
 
FOOD SERVING SIZE LUTEIN  (mg) 
Kale, cooked 1 cup 20.5 
Collard greens, cooked 1 cup 15.4 
Spinach, cooked 1 cup 12.6 
Turnip greens, cooked 1 cup 12.1 
Broccoli, cooked ½ cup 4 
Spinach, raw 1 cup 3.6 
Aubergine, raw 1 cup 2.6 
Peas, cooked 1 cup 2.2 
Broccoli, raw 1 cup 2.1 
Corn, cooked ½ cup 1.5 
Lettuce, cos or romaine 1 cup 1.5 
Brussels sprouts, cooked ½ cup 1.1 
Papaya 1 papaya 0.3 
Peaches 1 peach 0.2 
Apple 1 apple 0.04 
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Where can a patient get an AREDS2 supplement? 
 
To date, there are few supplements that are ‘pure’ AREDS 2 formulations, and contain nothing but 
the following ingredients: 
 
Lutein = 10mg  Zinc = 25 mg 
Zeaxanthin = 2mg Copper = 2 mg 
Vitamin C = 500mg Vitamin E = 400IU 
Viteyes® by Butterfly Healthcare is a pure AREDS 2 formula – please look around for other brands 
that might emerge in the next few months. There are other supplements that are very near to the 
AREDS2 formulation that you might also wish to consider, such as EyeBar®, MacuLEH® and 
Macushield Gold® - these contain the necessary AREDS 2 ingredients, but they might also contain 
extra carotenoids or ingredients such as omega3 or meso-zeaxanthin, and reduced amounts of 
copper. 
 
What are the risks associated with taking the AREDS2 supplement? 
 
There are currently no known risks with taking an AREDS2 supplement. Having the correct dose is 
very important, as some AMD patients do not realise that there is no increased effect by double or 
triple-dosing. Please refer to the specific supplement for dosing information, as they can vary 
between brands. It would be wise to advise a patient to inform their GP when taking supplements as 
there may be interactions with prescribed medication. 
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Appendix 12. Qualified Practitioner Study Information 
 
STUDY INFORMATION  
Nutrition Advice for people with or at risk of AMD 
 
Purpose of the study  
Age-related macular degeneration (AMD) is the leading cause of visual impairment in the 
western developed world. Marketing of nutritional supplements towards people with, or at 
risk of, AMD has made it very difficult for patients and eye care practitioners to determine 
what nutritional advice to follow. Despite the wealth of supplements that are available, only 
two formulations are backed by large-scale clinical intervention trials. These are the AREDS 
1 and AREDS 2 formulations (we have focused on the more recently developed AREDS 2 
formulation). Even armed with this information, patients and practitioners need to know 
which patients meet the AREDS inclusion criteria, and so could benefit from this specific 
formulation. 
We have designed a clinical decision making aid in the form of a flow chart to help eye care 
practitioners to choose appropriate nutritional advice for their patients. The aim of this study 
is to validate this clinical decision making aid. 
 
Why have I been chosen? 
This study is open to any eye care practitioner (optometrist or ophthalmologist) in the UK 
who is currently practicing.  
 
Do I have to take part? 
No. Participation is entirely voluntary. If you decide to take part and later wish to withdraw, 
please note the study will close on 1st March 2015. 
 
What will I have to do if I take part? 
Firstly, there is a short survey to complete that takes approximately five minutes and will 
assess your feelings on giving nutritional advice to patients with, and at risk of, AMD. The 
survey will mainly involve answering questions on a scale of 0 -100. An example question is:  
• “How confident are you in providing nutritional advice to patients with AMD?” 
The survey is accessed online using a link that we will make available to you. Once this 
survey has been completed, you will be provided with a link to the clinical decision making 
aid that you can print out. We would like you to use the aid for two weeks, and then we will 
email you to ask you to complete a follow up survey that will take approximately five minutes 
again, and is very similar to the first survey. 
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What are the benefits of taking part? 
The clinical decision making aid will be yours to keep. There will be a ‘Frequently Asked 
Questions’ leaflet accompanying it, that will provide you with information regarding current 
research in nutrition for AMD.   
 
Are there any risks of disadvantages of taking part? 
There is very little risk of disadvantages in taking part. Some practitioners may lack 
confidence in the area of nutrition for AMD, but participation is anonymous and their 
confidence has the potential to improve after using the clinical decision making aid. 
 
What will happen to the results of the study? 
The results are anonymous and will be used to validate the clinical decision making aid. The 
data is kept on a survey database that only the researchers have access to, and all other 
data is kept on one password protected computer in a locked room.  
 
Who has reviewed the study? 
The study has been reviewed by the School of Life and Health Sciences Ethics Committee, 
Aston University as well as members of the Aston University Ophthalmic Research Group. 
  
Researchers 
Rebekah Stevens  
Optometrist, Clinical Demonstrator, PhD student. Vision Sciences department, Aston 
University. Contact: r.stevens3@aston.ac.uk 
 
Hannah Bartlett 
Optometrist. Senior Lecturer. Vision Sciences department, Aston University. 
Contact: h.e.bartlett@aston.ac.uk 
 
Richard Cooke 
Psychologist. Senior Lecturer. Psychology department, Aston University. 
Contact: r.cooke@aston.ac.uk 
  
Where can I get more information? 
Please contact Rebekah Stevens (r.stevens3@aston.ac.uk) if you would like any more 
information about the study. 
What if there is a problem? 
If you have any concerns about the way in which the study has been conducted, then you 
should contact the Secretary of the University Research Ethics Committee, Mr John Walter, 
at j.g.walter@aston.ac.uk or telephone 0121 204 4665 
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Appendix 13. Student clinical scenarios 
 
 
                                                       
1)       Large drusen in one eye, and geographic atrophy in fellow eye with male patient aged 78 
 
                                          
2) Normal healthy retinas of female aged 65, with family history of AMD. 
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3) Large drusen in one eye, and geographic atrophy in fellow eye with female patient aged 48 
 
                        
4) Large haemorrhage in one eye, and a normal fellow eye in female aged 80. 
 
                        
 
5) Small drusen in one eye, and a normal fellow eye in male aged 60 
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Appendix 14 – Optician article given to participants as AREDS 2 information. 
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Appendix 15 – Age-related macular degeneration patients’ awareness of nutritional factors.
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Appendix 16 – Dietary Analysis and nutritional behaviour in people with and without age-
related macular disease 
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